ANNUAL REPORT

FY 2024 — Annual report (ARS)

FY 2024PDF · 86 pages14.8 MB
Abbott
2 0 2 4 A N N U A L R E P O R T

-- 1 of 86 --

FRONT COVER:
Her mother knew early in her life that something
in Trinity’s body wasn’t working right. When
Trinity was diagnosed with Type 1 diabetes, it
started a journey to a better understanding of the
impact of food and exercise on her health.
TABLE OF CONTENTS
1 Letter to Shareholders
5 The Abbott we have built
6 Delivering now
8 Designing what’s next
10 Neuromodulation
12 Structural Heart
14 Electrophysiology
16 Vascular
18 Cardiac Rhythm Management
20 Heart Failure Management
22 Diabetes Care
24 Biowearables
26 Nutrition
28 Medicines
30 Rapid Diagnostics
32 Laboratory Diagnostics
34 Passion and purpose
36 Financial Report
Abbott is a global healthcare leader, with
114,000 employees serving people in more than
160 countries. We have balanced leadership
across diverse markets and geographies — with
businesses and products in medical devices,
diagnostics, nutritionals, and medicines — giving
us more ways to succeed and greater resilience
as markets and economies evolve.
Our unwavering focus on helping people get
healthy and stay that way, at all stages of life, has
helped us deliver consistent, sustainable growth
and shareholder returns.
Trinity Lindblade
WALKERSVILLE, MARYLAND, USA
FREESTYLE LIBRE 3 SYSTEM
FreeStyle Libre 3 system

-- 2 of 86 --

Few companies can demonstrate the full range
of benefits that business brings to society as
powerfully as Abbott. Our performance in
2024 embodied that broad value and the many
strengths that make it possible.
DEAR FELLOW SHAREHOLDER:
ROBERT FORD
Chairman of the Board and
Chief Executive Officer

-- 3 of 86 --

2
A B B O T T 2 0 2 4 A N N U A L R E P O R T
CONTINUED, CONSIS TENT GROW TH IN 2024
9.6%†
ORGANIC SALES
GROWTH, UNDERLYING
BASE BUSINESS
$4.67 ‡
ADJUSTED
DILUTED EPS
$42B
WORLDWIDE
SALES
A HEALTHY BAL ANCE
One of the best-known axioms in politics is, “It’s the
economy, stupid.” It’s a pragmatic reminder to focus on
what matters most to people and to society. And if the
key to politics comes down to the economy, the economy
itself comes down to business, which represents the great
majority of all human economic activity. Business accounts
for more than 70 percent of GDP and a similar percentage
of employment, and more than two-thirds of all research
and development spending, in the U.S. and other OECD
countries. And the prosperity it creates flows into all sectors
of the economy and every aspect of our society.
Companies help form the bedrock of our communities by
providing employment, healthcare, taxes, philanthropic
support, growth and sustainability. They not only create and
supply the vital products and services that people rely on to
live their lives, but they also drive the innovation that leads
to continual improvement in the human standard of living.
In healthcare, business takes the advances forged by science,
fashions them into solutions, and brings them to the world.
That’s Abbott’s purpose: helping people live fuller lives
through our healthcare products and technologies. Our
company has thrived for 137 years because it has done this
consistently and with a rare degree of success. As a result,
Abbott improves the lives of not only our own large direct
community — our 114,000 employees around the world and
their families, our retirees, our investors — but the larger
communities of which they’re part and, most importantly,
the vast community of people we serve in more than 160
countries around the world.
To keep advancing human health, Abbott must first
maintain our success as a company — specifically, a public
company with obligations to the shareholders who own
it. We work to continuously balance this equation,
providing public goods through private enterprise.
If Abbott doesn’t succeed as a business, it cannot succeed
as an agent of progress.
To ensure that we can successfully balance this equation,
we’ve rethought the reward for innovation. Traditionally,
healthcare has delivered high innovation, but at a cost
that has resulted in lower access to the breakthroughs it’s
created. We believe that the leading healthcare companies of
the future will be those that can help the most people solve
not only the medical problem, but the access problem, as
well. Our strategy is to innovate for access, designing every
stage of the product process — first in conception, then by
bending the cost curve through advanced manufacturing,
AI, and digitization — to maximize the number of people
around the world who can benefit from our advancements.
Because of the broad and rapid expansion of our innovations,
over the past five years, Abbott’s sales have grown by
$10 billion, or almost one-third, and pre-tax profits by
almost $3 billion, or 43 percent.* Over the same period,
we’ve returned more than $25 billion to shareholders
through dividends and share repurchase. In 2024 Abbott
again successfully achieved this balance, serving both its
purpose and its shareholders, delivering the products people
need as well as strong returns as a business.
OUR MODEL IN ACTION
It was, in many ways, a model year for Abbott. All of our
major businesses delivered strong results. Our business
diversity can provide defensive advantages against
challenges in specific markets; but 2024 was all offense, with
robust and well-balanced growth across the board.
And balance is the keynote to our performance and our
outlook, as we maintain a dynamic equilibrium of delivering
results and rewarding our shareholders in the present, with
investing for the future to maintain our growth and success
for the long term.
* On a non-GAAP basis † On a GAAP basis, full-year Abbott sales increased 4.6% ‡ Full-year 2024 GAAP diluted EPS was $7.64
For full financial data and reconciliation of non-GAAP measures, please see Abbott’s 2024 earnings releases at www.abbottinvestor.com

-- 4 of 86 --

A B B O T T 2 0 2 4 A N N U A L R E P O R T
3
BROADER BUSINESS , BRIGHTER FUTURE
Strong Financial Performance
Abbott’s global sales in the year were $42 billion, which
reflects an increase of 9.6%† on an organic basis for the base
business. Adjusted earnings per share were $4.67.‡ All four
of our major businesses contributed to our year-over-year
growth, and each of them delivered accelerated quarter-
to-quarter growth to close out the year, positioning our
company very well for a successful 2025.
In the year, Abbott completed a full century of
uninterrupted returns to investors when it paid its 400th
consecutive quarterly dividend. And our dividends
have risen in each of the last 53 years, earning Abbott
membership in the exclusive ranks of Dividend Kings.
Continuing this legacy, in December we announced a
dividend increase of 7.3 percent for 2025.
We are sharply focused on raising our gross margin levels.
Thanks to the outstanding execution of the teams we’ve
dedicated to this effort across the company, we succeeded
in raising our profile by 70 basis points on an adjusted basis
in 2024, § despite the headwinds of inflation and foreign
exchange. We intend to deliver a similar increase this year.
Investing for the Future
While delivering those strong returns, since 2019 we’ve
simultaneously raised investment in research and
development by more than 20 percent, to $2.7 billion,# and
capital investment by 35 percent to fuel sustained growth
and impact.
Innovation
With R&D centers around the world, we are better able
to tailor our products to the needs of local markets. And
we augment our strong internal pipeline through our
Ventures group, which has invested more than $200 million
in a promising portfolio of new growth opportunities.
Together, these efforts have produced a strong long-term
pipeline that delivered more than 150 new approvals,
launches, line extensions, and treatment indications in 2024.
Among the most notable were:
• Advisor HD Grid X Mapping Catheter, Sensor Enabled, to
further support mapping of both pulsed field ablation and
radiofrequency ablation cases
• Assert IQ, our Bluetooth®-enabled insertable cardiac
monitor that provides physicians a new option for
diagnostic evaluation and long-term monitoring of people
experiencing abnormal heartbeats
• AVEIR DR, the world’s first dual-chamber leadless
pacemaker system, received CE Mark in Europe
• Esprit BTK, our first-of-its-kind resorbable scaffold for
people with chronic limb-threatening ischemia below
the knee
• Femoston Mini, a hormonal replacement therapy to treat
postmenopausal symptoms and help prevent osteoporosis,
launched in China
• Liberta RC, the world’s smallest rechargeable deep brain
stimulation system with remote programming to treat
movement disorders
• Lingo, our biowearable device for consumers who are
looking to improve their overall health and wellness
• PROTALITY, our new nutrition shake to support the
growing number of adults interested in pursuing weight
loss while maintaining muscle mass and good nutrition
• TriClip, our first-of-its kind device to repair leaky
tricuspid heart valves
Last year, newly launched products contributed more than
$1 billion to our sales; we expect to double that performance
in 2025 and to maintain this level of pipeline productivity
over the next five years.
DIVERSITY
by payer
• Consumers
• Insurers
• Governments
DIVERSITY
by technology
• Cardiovascular
• Diabetes Care
• Diagnostics
• Medicines
• Neuromodulation
• Nutrition
DIVERSITY
by regions
• Africa
• Asia-Pacific
• Europe
• North America
• South America
§ Full-year gross margin as a percent of sales improved 60 basis points on a GAAP basis # Full-year R&D Expense on a GAAP basis for 2024 was $2.8 billion

-- 5 of 86 --

, '	v /a
4
VALUES BUILD VALUE
pioneering
INNOVATING
IN ALL WE DO
caring
FOCUSING ALWAYS
ON OUR CUSTOMERS’
NEEDS
achieving
DELIVERING
FOR OUR
STAKEHOLDERS
enduring
LEADING FOR MORE
THAN 135 YEARS
Infrastructure
We’re ensuring our ability to meet the future demand for
these products with capital investments of $2.2 billion in
2024 around the world. In addition to opening our new
Diabetes Care manufacturing facility in Kilkenny, Ireland, to
support the robust growth of our world-leading continuous
glucose monitoring business, we’re building, expanding, and
adding capacity in Mexico for electrophysiology products, in
Colombia for biosimilars, in Ohio for nutrition products,
and in Illinois and Texas for diagnostics.
We’re also investing to strengthen our IT and digital
infrastructure to ensure our ability to keep up with the
fast-evolving technology landscape.
Community
The primary way Abbott helps to improve human and
societal health is by creating new and better healthcare
products and bringing them to people around the world.
Our success in doing so also allows us to pursue the
same goals in other ways. To offer just a few examples:
We donated over $53 million in cash and products to
support humanitarian efforts in more than 50 countries.
We partnered with the Big Ten collegiate athletics
conference to create and conduct The We Give Blood Drive to
increase blood donation. In its first year, the drive generated
almost 20,000 donations, enough to save nearly 60,000 lives.
We continued working to expand healthcare infrastructure
and access in Tanzania. Our 25-year partnership with
the Tanzanian government has created the country’s first
emergency medicine department, built a nationwide
network of diagnostic labs, and helped to build
livelihoods and advance education, among other efforts
to strengthen communities.
We launched HeartMates, a program to provide support
and community to people living with heart disease across
the U.S.
And we invested more than $1 billion in healthcare and other
employee benefits, helping ensure that our colleagues can be
at their best, not only to fulfill Abbott’s mission, but also to
contribute to the life of their communities.
WHAT WE’RE HERE FOR
Abbott began as one physician hand-making better
medicines for his own patients. From that noble inspiration
grew a tradition — an organization, a business — that spread
around the world and has helped make it a better place by
decreasing human suffering and enriching human life.
Each year, some 2 billion lives are improved through Abbott
products and technologies, and more still by the broader
activity of our company and the ever-widening circle of
benefits created by its success. And we aim to expand access
to healthcare further still by making it easier to use, more
available, and more affordable.
As a result, more people than ever before will be able
to enjoy the benefits of the incredible advances that are
revolutionizing human health, demonstrating the promise
and the power of companies to change the world for the
better. And Abbott will remain at the forefront, representing
business at its public-spirited best, and helping people
everywhere live fuller, healthier lives.
Abbott Proud,
ROBERT B. FORD
Chairman of the Board and Chief Executive Officer
March 3, 2025

-- 6 of 86 --

Our diversified business model proved
its power again in 2024. We grew organically
across our businesses, meeting important
healthcare needs and delivering for our
stakeholders today, while positioning the
company for long-term impact and success.
The
Abbott
we have
built
5

-- 7 of 86 --

1
Delivering
now
$32B	$32B
2019 SALES
$42B	$42B
2024 SALES
Abbott’s business breadth and
market leadership have powered
consistent growth and financial
results year after year.
A B B O T T 2 0 2 4 A N N U A L R E P O R T
6

-- 8 of 86 --

I
A B B O T T 2 0 2 4 A N N U A L R E P O R T
77
CONSECUTIVE
DIVIDENDS PAID
>	>400400COMP OUNDED ORG ANIC
GROW TH , 2019–2024
~8%*	~8%*
T H R O U G H B U Y B AC K S/D I V I D E N D S 2019–2024
RE TURNED TO
SHAREHOLDERS
>	>$25B	$25B
7*On a GAAP basis, 2019-2024 annual growth rate of 6%. For full financial data and reconciliation of non-GAAP measures, please see Abbott’s earnings releases at www.abbottinvestor.com
77
CONSECUTIVE
DIVIDENDS PAID
>	>400400COMP OUNDED ORG ANIC
GROW TH , 2019–2024
~8%	~8%*	*
T H R O U G H B U Y B AC K S/D I V I D E N D S 2019–2024
RE TURNED TO
SHAREHOLDERS
>	>$25B	$25B
A B B O T T 2 0 2 4 A N N U A L R E P O R T
7	*On a GAAP basis, 2019-2024 annual growth rate of 6%. For full financial data and reconciliation of non-GAAP measures, please see Abbott’s earnings releases at www.abbottinvestor.com

-- 9 of 86 --

1
Designing
what’s 	next
8
A B B O T T 2 0 2 4 A N N U A L R E P O R T
R&D INVES TMENT
$2.2B
2019
 	$2.7B
2024
I N V E S TM E NT S I N N E W PRO D U C T
D E V E LO PM E NT
C APITAL INVES TMENT
$1.6B
2019
 	→ 	→	$2.2B
2024
I N V E S TM E NT S I N M A N U FAC T U R I N G C A PACIT Y,
S U PPLY CH A I N , TECH A DVA N CE M E NT S
Designing
what’s 	next
R&D INVES TMENT
$2.2B*2019 $2.7B*2024
I N V E S TM E NT S I N N E W PRO D U C T
D E V E LO PM E NT
C APITAL INVES TMENT
$1.6B
2019
 	→ 	→	$2.2B
2024
A B B O T T 2 0 2 4 A N N U A L R E P O R T
I N V E S TM E NT S I N M A N U FAC T U R I N G C A PACIT Y,
S U PPLY CH A I N , TECH A DVA N CE M E NT S
*Full-year R&D Expense on a GAAP basis for 2019 and 2024 was $2.4 billion and $2.8 billion, respectively
For full financial data and reconciliation of non-GAAP measures, please see Abbott’s earnings releases at www.abbottinvestor.com	
8

-- 10 of 86 --

I
w
A B B O T T 2 0 2 4 A N N U A L R E P O R T
9
We’ve been building our
infrastructure and R&D pipeline
to sustain global leadership,
organic growth, and positive
impact on the health of billions
of people around the world.
Abbott’s first continuous glucose
monitoring system available
without a prescription for people
without diabetes.
Lingo
NEW PRODUC T
CONTRIBUTION
~25%	~25%
P R OJ E C T E D S A L E S I N
FI R S T 2 Y E A R S A F T E R
L AU N C H , T H R O U G H 2029
OF SALES FROM
RECENTLY
L AUNCHED
PRODUC T S
>	>$	$1	1B	B
I N 2024

-- 11 of 86 --

-ENZMIN141	. . ..........
10
Lasting relief
with our smallest
spinal cord
stimulation (SCS)
system yet. 8
Eterna SCS
Advanced technologies
to improve care for
movement disorders and
chronic pain.
A B B O T T N O W
NEUROMODULATION
A B B O T T N E X T
NeuroSphere:
An Integrated, Digital Future
Our digital-health ecosystem
empowers patients with on-demand
educational resources, real-time
outcomes, and extended care beyond
the walls of the clinic.
Actual size.

-- 12 of 86 --

Margaret Kohn
MAITLAND, FLORIDA, USA
LIBERTA RC DBS
Our Liberta RC deep
brain stimulation (DBS)
system helps keep the
disruptive signals from
Parkinson's disease at
bay so Margaret can stay
ready to return serve.
*Formerly called NeuroSp
ABBOTT 2024 ANNUAL REPORT
Abbott's chronic-pain and movement-disorder therapy
solutions include radiofrequency ablation (RFA),
spinal cord stimulation (SCS), dorsal root ganglion
(DRG) stimulation and deep brain stimulation (DBS).
At the start of 2024, Abbott launched the Liberta RC
DBS System, the smallest rechargeable DBS generator
on the market to treat movement disorders.L2
For Parkinson's disease and essential tremor, Liberta
RC offers the longest time between charges of any
DBS technology on the market, allowing people
with movement disorders to recharge the device
only 10 times a year.3A5 Like Liberta RC, our Infinity
DBS system also employs a directional lead that's
capable of sending energy toward major therapeutic
targets while reducing stimulation to areas that may
create side effects. Both devices work with Abbott's
proprietary NeuroSphere Virtual Clinic, which lets
doctors remotely reprogram a patient's implant. Abbott
has the only DBS IPGs capable of remote programming.6
And our NeuroSphere Digital Health App* helps people
evaluate SCS or DRG therapy as they experience a
new device and offers educational tools for DBS patients,
helping doctors and patients have better-informed
discussions.
Our SCS technologies for pain management include
the Eterna spinal cord stimulation system, the world's
smallest implantable, rechargeable SCS system.78,9 Eterna,
which is designed to reduce the need for recharging,
requires as few as five recharges per year.10,11,12,13
A B B O T T 2 0 2 4 A N N U A L R E P O R T
Margaret Kohn
MAITLAND, FLORIDA, USA
LIBERTA RC DBS
Our Liberta RC deep
brain stimulation (DBS)
system helps keep the
disruptive signals from
Parkinson’s disease at
bay so Margaret can stay
ready to return serve.
Abbott’s chronic-pain and movement-disorder therapy
solutions include radiofrequency ablation (RFA),
spinal cord stimulation (SCS), dorsal root ganglion
(DRG) stimulation and deep brain stimulation (DBS).
At the start of 2024, Abbott launched the Liberta RC
DBS System, the smallest rechargeable DBS generator
on the market to treat movement disorders.1,2
For Parkinson’s disease and essential tremor, Liberta
RC offers the longest time between charges of any
DBS technology on the market, allowing people
with movement disorders to recharge the device
only 10 times a year. 3,4,5 Like Liberta RC, our Infinity
DBS system also employs a directional lead that’s
capable of sending energy toward major therapeutic
targets while reducing stimulation to areas that may
create side effects. Both devices work with Abbott’s
proprietary NeuroSphere Virtual Clinic, which lets
doctors remotely reprogram a patient’s implant. Abbott
has the only DBS IPGs capable of remote programming. 6
And our NeuroSphere Digital Health App* helps people
evaluate SCS or DRG therapy as they experience a
new device and offers educational tools for DBS patients,
helping doctors and patients have better-informed
discussions.
Our SCS technologies for pain management include
the Eterna spinal cord stimulation system, the world’s
smallest implantable, rechargeable SCS system.7,8,9 Eterna,
which is designed to reduce the need for recharging,
requires as few as five recharges per year.10,11,12,13
11	*Formerly called NeuroSphere myPath

-- 13 of 86 --

12
STRUCTURAL
HEART
Navitor Vision
From transcatheter and surgical valves to structural
interventions, Abbott’s Structural Heart device
portfolio is the most comprehensive in the industry.
In April, Abbott received U.S. FDA approval for
TriClip, the first-of-its-kind transcatheter edge-to-
edge repair (TEER) device to repair leaky tricuspid
heart valves. More than 1.6 million people in the U.S.
are affected by tricuspid regurgitation. TriClip is now
approved in more than 50 countries.
MitraClip is the world’s first minimally invasive
TEER therapy for primary and secondary mitral
regurgitation.
Our transcatheter aortic valve implantation (TAVI)
and surgical valve portfolios are designed to maximize
key clinical outcomes and the possibilities for patient
lifetime management of their heart-valve disease.
In November, Abbott announced its first step toward
a software-guided balloon-expandable TAVI system.
The investigational system will complement our
Navitor TAVI system for aortic stenosis.
Approximately 9 percent of older Americans have
aortic stenosis.
Navitor Vision, the latest addition to the Navitor
TAVI system, recently launched in the U.S. It features
advancements to reduce the risk of blood leakage
around the implant.
A B B O T T N O W
Transcatheter Aortic Valve
Implantation System
The most comprehensive
portfolio of devices
designed to keep
blood flowing.
A B B O T T 2 0 2 4 A N N U A L R E P O R T

-- 14 of 86 --

I
I
•
I
13
Knud Kjeldgaard
GRAESTED,
HOVEDSTADEN, DENMARK
NAVITOR VISION
After having his Navitor
Vision transcatheter
aortic valve implantation
(TAVI) device inserted at
Rigshospitalet Copenhagen,
Knud has remained active
and engaged, including
with his kayak club.
A B B O T T N E X T
Advancing Innovation
Abbott continues to
innovate in stroke
prevention with its next-
generation left atrial
appendage occluder
for patients with atrial
fibrillation, which
is being studied in the
VERITAS trial.
The Amplatzer Amulet offers immediate
closure of the left atrial appendage in people
with atrial fibrillation at risk of stroke without
requiring blood-thinning medication.
The Epic Max aortic stented tissue valve is
designed to help patients with more complex
cases of aortic regurgitation or stenosis who
cannot take blood-thinning medications.
TriClip
Tricuspid Valve
Repair Device
A B B O T T N E X T

-- 15 of 86 --

A B B O T T 2 0 2 4 A N N U A L R E P O R T
14
With innovative additions to our portfolio and new
trials for next-gen rhythm disorder technologies,
Abbott’s Electrophysiology business continues to deliver
strong growth.
Atrial fibrillation (AFib) — the most common type of
arrhythmia, or irregular heartbeat — impacts more than
37 million people worldwide. That number is expected to
grow to more than 60 million by 2050.
From implantable monitors to sophisticated mapping
systems, Abbott devices generate complex data sets that
help doctors treat this condition more effectively.
In September, we completed enrollment for our VOLT-
AF IDE trial to evaluate our pulsed field ablation (PFA)
system for treating patients with heart rhythm disorders
such as AFib. PFA uses high-energy electrical pulses for
ablation procedures. Our Volt PFA System is designed to
overcome limitations of first-generation PFA systems by
providing a clearer indication of contact between the Volt
PFA Catheter and targeted tissue.
Our Advisor HD Mapping Catheter uses a first-of-its-kind
electrode configuration to create more-highly detailed
maps of the heart.
Our best-in-class cardiac-mapping system, EnSite X,
allows doctors to diagnose a wide range of arrhythmias.
EnSite X features a screen that displays 3D images of the
heart and its activity in real time, helping a doctor find the
specific tissue that’s causing the heart to beat irregularly.
Our TactiFlex ablation catheter, Sensor Enabled, is the
world’s first ablation catheter designed with a unique
flexible electrode tip and contact-force sensing.
ELECTROPHYSIOLOGY
A growing portfolio of cutting-edge
technologies for the treatment
of atrial fibrillation.
A B B O T T N O W

-- 16 of 86 --

ernisat
v 04 age 10812 total
is4p liii roxp eit;:pairri ii iii i iiiiip11111111111 1 1111
2500 9000 3500
15
Dr. Jun Kishihara
and Ryo
AIKAWA, KANAGAWA
PREFECTURE, JAPAN
ENSITE X
As the Director of Medicine
in the Department of
Cardiology and Vascular
Medicine at Kitasato
University Hospital, Dr.
Kishihara depends on
Abbott’s EnSite X mapping
system when he’s treating his
patients’ atrial fibrillation.
And when he needed help
getting his own heart back
in rhythm, his doctors
counted on EnSite X, too.
A B B O T T N E X T
Volt: Advancing Pulsed
Field Ablation Solutions
The Volt PFA System uses
high-energy electrical pulses
to destroy cells causing
abnormal heart rhythms, while
reducing the risk of damaging
adjacent tissue.
A B B O T T 2 0 2 4 A N N U A L R E P O R T
Next-generation
3D mapping platform
EnSite X System

-- 17 of 86 --

16	16
VASCULAR
Expanding our
comprehensive portfolio
of devices to optimize
vascular interventions.
The only below-
the-knee device
that delivers its
drug, provides
support, and leaves
nothing behind. 1
Esprit BTK
A B B O T T N O W
A B B O T T N E X T
Leveraging Abbott Leadership
Abbott will continue to expand its
portfolio of market-leading stents,
diagnostic and imaging devices,
cutting-edge atherectomy systems,
and vascular-closure devices.
OPTIS Next
Imaging Systems

-- 18 of 86 --

A B B O T T 2 0 2 4 A N N U A L R E P O R T
17
More than 20 million people in the U.S. are living with
peripheral artery disease (PAD). Until 2024, there had
been limited treatment options. That changed with the
U.S. FDA approval of Abbott’s breakthrough, first-of-its-
kind Esprit BTK drug-eluting resorbable scaffold, which
dissolves over time and leaves nothing behind 1 after it
has opened blocked arteries below the knee, offering a
clear advantage in limb preservation. 2
Our Vascular Care portfolio also includes drug-eluting
stents like our next-generation XIENCE Skypoint,
which allows treatment of larger blood vessels and
longer lesions.
With more than 20 million implants and studies in 120-
plus clinical trials, XIENCE stents provide consistent
long-term safety data, allowing interventional
cardiologists to achieve positive results.
Our OPTIS Next Imaging Systems use optical
coherence tomography (OCT) to capture hundreds
of micron-level resolution images on the inside of the
artery. These images are then analyzed by our AI-
powered Ultreon 2.0 imaging and physiology software,
providing automatic insights to optimize treatment for
every patient.
Our Perclose family of vascular closure systems includes
our latest generation Perclose ProStyle, which delivers
a surgical suture to femoral access sites enabling rapid
repair of blood vessels, early return to movement, and
same-day discharge of patients after procedures.
Our leading atherectomy system, Diamondback 360,
prepares vessels for angioplasty or stenting to restore
blood flow.
Paul Kolbe
TITUSVILLE, FLORIDA, USA
ESPRIT BTK
The Esprit BTK
bioresorbable scaffold
system helps treat chronic
limb-threatening ischemia
for people like Paul, and
clinical trial data show
long-term effectiveness
for people with the
most severe form of
peripheral artery disease
(PAD) below the knee
(BTK), with fewer repeat
procedures at two years.

-- 19 of 86 --

A B B O T T 2 0 2 4 A N N U A L R E P O R T
18
Building on our
leadership with
innovative solutions
for managing
abnormal heart
rhythms.
CARDIAC RHYTHM
MANAGEMENT
A B B O T T N O W
With enhanced connectivity and expanded approvals,
our life-changing leadless and transvenous pacemaker
technologies deliver personalized care from diagnosis
to ongoing care, giving Abbott’s Cardiac Rhythm
Management portfolio the capability to help millions
more around the world.
Our first-of-its-kind AVEIR DR Dual Chamber Leadless
Pacemaker (LP) System received CE Mark in June,
expanding treatment options for people in Europe
living with abnormal heart rhythms. AVEIR DR LP
System is composed of two unique devices: One that
paces the right ventricle (AVEIR VR) and one that paces
the right atrium (AVEIR AR). They’re roughly one-
tenth the size of a traditional pacemaker and smaller
than a AAA battery. The devices communicate through
our proprietary i2i system. The AVEIR system is also
designed to be easily retrievable, should a patient’s
therapy needs change.
Our implantable cardioverter defibrillators (ICD)
are designed to continuously monitor patients’ heart
rhythms and detect irregular heartbeats, delivering
electrical signals and controlled shocks to restore a
normal heart rhythm when necessary.
These devices are setting the standard for patient care
through new algorithms and technology intended to
improve patient safety and therapy assurance. This
portfolio includes the Entrant ICD, which offers non-
invasive programming options and wireless remote
monitoring with our Merlin@home transmitter; and
Gallant ICD, which combines built-in smartphone
connectivity with intuitive programming to help
doctors meet patients’ changing needs.
A B B O T T 2 0 2 4 A N N U A L R E P O R T
18
Building on our
leadership with
innovative solutions
for managing
abnormal heart
rhythms.
CARDIAC RHYTHM
MANAGEMENT
A B B O T T N O W
With enhanced connectivity and expanded approvals,
our life-changing leadless and transvenous pacemaker
technologies deliver personalized care from diagnosis
to ongoing care, giving Abbott’s Cardiac Rhythm
Management portfolio the capability to help millions
more around the world.
Our first-of-its-kind AVEIR DR Dual Chamber Leadless
Pacemaker (LP) System received CE Mark in June,
expanding treatment options for people in Europe
living with abnormal heart rhythms. AVEIR DR LP
System is composed of two unique devices: One that
paces the right ventricle (AVEIR VR) and one that paces
the right atrium (AVEIR AR). They’re roughly one-
tenth the size of a traditional pacemaker and smaller
than a AAA battery. The devices communicate through
our proprietary i2i system. The AVEIR system is also
designed to be easily retrievable, should a patient’s
therapy needs change.
Our implantable cardioverter defibrillators (ICD)
are designed to continuously monitor patients’ heart
rhythms and detect irregular heartbeats, delivering
electrical signals and controlled shocks to restore a
normal heart rhythm when necessary.
These devices are setting the standard for patient care
through new algorithms and technology intended to
improve patient safety and therapy assurance. This
portfolio includes the Entrant ICD, which offers non-
invasive programming options and wireless remote
monitoring with our Merlin@home transmitter; and
Gallant ICD, which combines built-in smartphone
connectivity with intuitive programming to help
doctors meet patients’ changing needs.

-- 20 of 86 --

I
-Bit._
19
Karen Pekowitz
WELLESLEY, MASSACHUSETTS, USA
AVEIR DR DUAL CHAMBER
LEADLESS PACEMAKER (LP) SYSTEM
Karen, a teacher near Boston,
relies on her AVEIR DR dual-
chamber leadless pacemaker to
keep her heart functioning as
it should so she can be there for
her students.
A B B O T T N E X T
Upgradable and Connected,
as You Need
Designed to be upgradable from
single- to dual-chamber therapy,
the AVEIR system removes
pocket- and lead-related complications,
and visible scarring. It can also be
retrieved at the end of service.
Our Dual Chamber
Leadless Pacemaker
(LP) System is the first
of its kind to provide
beat-to-beat synchrony
between the chambers
of the heart.
AVEIR DR

-- 21 of 86 --

20	20
Solutions for every stage of heart failure,
from the earliest to the most advanced.
HEART FAILURE
MANAGEMENT
A B B O T T N O W
Kurt-Josef
Müller
FULDA, HESSE, GERMANY
HEARTMATE 3
Our HeartMate 3
LVAD (left ventricular
assist device) has been
Kurt-Josef’s companion
for a decade, helping
his heart do its job
and enabling him to
continue his cross-
continent adventures.

-- 22 of 86 --

A B B O T T 2 0 2 4 A N N U A L R E P O R T
21
A B B O T T N E X T
HeartMate 3
LVAD
There are not enough donor hearts for the nearly
26 million people around the world who suffer
from heart failure. Our industry-leading portfolio
increases patients’ quality and length of life until
a new heart is available.
In October, Abbott announced a first-of-its-kind
clinical trial designed to identify high-risk heart failure
patients who could benefit from receiving a life-saving
HeartMate 3 left ventricular assist device (LVAD, or
heart pump) earlier, lowering mortality rates and
raising quality of life.
Our various cardiac resynchronization therapy (CRT)
devices are proven clinical treatments for heart failure
management that can be tailored to patients’ needs in
all stages of therapy.
These devices can communicate with Abbott’s
Merlin@home system to facilitate efficient remote care
management of patients, complementing or replacing
in-clinic visits with remote patient transmissions.
In addition to helping people with chronic heart
disease, our CentriMag circulatory support system was
a life-saving option during the COVID-19 pandemic for
thousands of patients who required respiratory
and circulatory support as they battled the disease.
CentriMag is approved by the FDA for longer-term
life support.
TEAM-HF Trial — Saving Lives Sooner
The TEAM-HF trial will help identify objective
criteria among people who are earlier in
their heart failure progression, when treatment
can be more effective.
Our proprietary
Full MagLev flow
technology reduces
trauma to the blood
as it passes through
the pump.

-- 23 of 86 --

A B B O T T 2 0 2 4 A N N U A L R E P O R T
22
Helping people live life
with diabetes — on their
own terms.
Abbott’s world-leading 1,2 FreeStyle Libre technology has
revolutionized the way nearly 7 million people across
more than 60 countries manage their diabetes.1
Our commitment to innovation has made Abbott the
global leader in continuous glucose monitoring (CGM). 1
We designed our FreeStyle Libre portfolio with access
and affordability in mind from the start to make it
widely available to all people living with diabetes who
could benefit from using this life-changing technology.
Our FreeStyle Libre systems let people see their glucose
levels in real time so they can make more confident
choices 3,4 , and lower their hemoglobin A1C (a measure
of glucose levels) over time. 3,5
Our commitment to innovation led to the introduction
of two new sensors in 2024: the FreeStyle Libre 2
Plus and the FreeStyle Libre 3 Plus. These sensors are
indicated for use by people 2 years and older, can be
worn for up to 15 days, and can work with automated
insulin delivery (AID) systems.
Over the past two years, Abbott has entered into
partnerships that enable consumers to connect our
FreeStyle Libre 2 Plus or FreeStyle Libre 3 Plus sensors
to four different AID systems worldwide.
DIABETES
CARE
A B B O T T N O W

-- 24 of 86 --

I FreeStyleLibre 3
GLUCOSE GOING LOW
4• mmol/L
au t• • m-411
23
Trinity Lindblade
WALKERSVILLE, MARYLAND, USA
FREESTYLE LIBRE 3 SYSTEM
As a college student
and basketball player,
Trinity depends on her
FreeStyle Libre 3 system
to keep her ready to go.
It’s the world’s smallest,
thinnest, and most
discreet sensor. 1,6
Lets people see
their glucose
levels in real
time to make
more confident
choices. 3,4
FreeStyle
Libre 3 system
A B B O T T N E X T
Dual Glucose-Ketone Sensor
Combining glucose- and ketone-
sensing capabilities into a single sensor
can be especially important for people
with diabetes who are at higher risk
of developing diabetic ketoacidosis, a
potentially life-threatening condition.
For illustrative
purposes only.
Not actual
patient data.

-- 25 of 86 --

24
Serena Williams
and Alexis Ohanian
LOS ANGELES,
CALIFORNIA, USA
LINGO
The power couple – an
all-time tennis great and
a tech entrepreneur –
count on Lingo to track
their individual glucose
responses, gaining insights
and learning as they eat
their favorite meals.
Lingo: The future of
wearable health tech
for a deeper connection
to your body.
BIOWEARABLES
A B B O T T N O W

-- 26 of 86 --

3:58
Today -
0 ®0I
Bern leant ea al 2,091 9am
142me/d1. at 12:02
Breakfast
Smoked salmon, bagel C011ae w. max
Croissant Fru,
0 1:17
0,0am mej
411111.,
1. 1
Your Lingo Count
increased most in the
afternoon
om9e9199
eae
•
A B B O T T 2 0 2 4 A N N U A L R E P O R T
25
The biosensor tracks
glucose and the app
gives a real-time view,
with insights and
education.
Lingo
The technology that powers our FreeStyle Libre portfolio
of continuous glucose monitors — the best-selling
medical device in history — became available in 2024
to U.S. consumers without diabetes through Lingo, an
over-the-counter CGM system. Lingo is Abbott’s first
biowearable cleared by the FDA for consumers 18 years
and older, not on insulin, and looking to improve their
overall health and wellness.
Lingo, which is available without a prescription, tracks
glucose and provides real-time insights, based on the
user’s body’s reaction to nutrition, exercise and life’s
daily stressors.
The Lingo system includes a biosensor and a mobile
app that work together to help users understand their
unique glucose responses.
Lingo employs science to help users discover which
foods work for their bodies, and which ones don’t.
Lingo’s coaching program helps people see the
connections between their food choices and glucose
data, and create healthier habits over time.
By better understanding glucose trends, users can build
healthy habits to manage weight, improve sleep and
energy, and retrain their metabolism over time.
A B B O T T N E X T
Metabolic Health in Your Hands
Metabolic health is a lot to unpack. Lingo
streamlines the science, so you not only
learn what works for you, but why.
For illustrative
purposes
only. Not actual
patient data.
Not actual size.

-- 27 of 86 --

26
Caili and Evie
Elwell
GRAY, MAINE , USA
ELECARE
When Evie was an infant,
food could be downright
scary given her allergies,
which included peanuts,
eggs, tree nuts, milk, and
soy, among others. Her
mother, Caili, counted
on Abbott’s EleCare
amino-acid-based infant
formula to support Evie’s
nutrition.
26
Science-based nutrition to
support the growth,
health, and wellness of people
at every stage of life.
For a century, Abbott’s science-based nutrition has been
designed to benefit people at every age and stage of life,
from infancy through adulthood.
Abbott helped create a new category of nutrition
product more than 50 years ago with the introduction
of Ensure, the No. 1 doctor-recommended oral
nutrition supplement brand, encompassing a full line
that includes pre- and post-surgery drinks specifically
formulated to support recovery. In 2024, sales of
Ensure products were more than $3 billion.
Abbott’s portfolio of specialty nutrition products
benefits people facing a variety of conditions with
nutritional needs, including:
NUTRITION
A B B O T T N O W
Caili and Evie
Elwell
GRAY, MAINE , USA
ELECARE
When Evie was an infant,
food could be downright
scary given her allergies,
which included peanuts,
eggs, tree nuts, milk,
and soy, among others.
Her mother, Caili,
counted on Abbott’s
EleCare amino-acid-based
infant formula to support
Evie’s nutrition.

-- 28 of 86 --

OVER10% MORE!
(=at,
Pe i
_ • Similac
a.' li•
, rk 360 Total Care
Iw
) .X0]
INFANT FORMAA
ElleCare
PHA !ARA
kina Acitl-Based Ns*
Infant Formula
valh Iron
- 3.1212 111.-dt-7'
#1MAR,71`,7717.1,ME
ELECTROLYTES
AND ill SUCA17
1.11fr )"	-sure 01510e Sure
0TH PLUS PLUS
Moo
H.
Q
ViEkTil;: !:
fnsur!woo— I COMPLETE	
MAX	
PROTEIN
A B B O T T 2 0 2 4 A N N U A L R E P O R T
27
• Glucerna products: Made with CARBSTEADY, a unique
blend of low-glycemic carbohydrates that helps
minimize blood-sugar spikes for people with diabetes
• Nepro: Helps replace protein lost during dialysis
• Juven: specialized nutrition to support wound healing
In August, we announced our Pure Bliss by Similac
infant formula line that includes USDA Certified
Organic options, in addition to Pure Bliss by Similac
Irish Farms, a European-made infant formula
that starts with fresh milk from cows in Ireland.
These offerings give parents additional options that
are backed by Abbott’s century of experience
providing high-quality, complete infant nutrition.
Abbott’s market-leading Similac line of infant formulas
is the foundation of our pediatric nutrition business.
Similac 360 Total Care’s exclusive blend of 5 HMO
prebiotics makes it our closest yet to breast milk.
We also offer a variety of amino-acid-based formulas
for children and adults living with food allergies,
gastrointestinal disorders, and inborn errors of
metabolism.
PediaSure’s macro- and micronutrients help children
with, or at risk for, undernutrition catch up on growth,
and has long been the market-leading nutritional
supplement for children.
Pedialyte helps people of all ages replace fluids and
electrolytes they’ve lost due to mild-to-moderate
dehydration. It’s the No. 1 doctor-recommended brand.
A B B O T T N E X T
Hydration When
You Need It
Whatever the cause of mild-
to-moderate dehydration,
Pedialyte helps you rehydrate
and feel better fast. And
we’re continuing to innovate
our Pedialyte portfolio to
meet consumers’ needs.
Innovative products designed
for every stage of life

-- 29 of 86 --

28	28
A growing array of medicines
and therapies to transform the
quality of healthcare.
Hugo Rojas
BOGOTÁ, D.C., COLOMBIA
ABXEDA (BEVACIZUMAB)
Hugo’s colon cancer
was treated with
Abbott’s biosimilar
Abxeda (Bevacizumab).
He is now cancer-free
and living his best life
with his family, including
his grandchildren.
MEDICINES
A B B O T T N O W

-- 30 of 86 --

A B B O T T 2 0 2 4 A N N U A L R E P O R T
29
Bevacizumab
Every day, more than 60 million people around the
world benefit from Abbott medicines and services.
Abbott’s understanding of the specific health challenges
and needs of local communities in emerging markets
helps us deliver insight-driven innovation that builds on
Abbott’s trusted global brand. Our portfolio is focused
in important treatment areas like:
• Gastroenterology: Including enzyme deficiencies
and digestive disorders
• Women’s health: Addressing hormonal imbalances
and other women’s health issues
• Cardiometabolic: For managing cholesterol levels
and cardiovascular health
• Primary care: General health, including antibiotics,
flu vaccines, and anti-inflammatory remedies
In 2024, we expanded our biosimilars portfolio in
oncology, women’s health, and immunology through
strategic partnerships. With launches starting in
2025, our broadened range of biosimilars will enhance
access to high-quality biologics to deliver cutting-edge
treatment options to more people.
Our patient-focused services include a:care, our digital
initiative developed with behavioral science and
technology, giving patients and healthcare providers
tools, tips, and resources to build healthier habits. These
tools can help improve how people manage their health,
improving interactions between patients and healthcare
professionals and helping reduce healthcare costs.
A B B O T T N E X T
Biosimilars: Improving
Global Access
Biosimilars — or biologic medicines —
have greatly improved treatment for
some of the hardest-to-treat diseases,
including many types of cancer, and
have reduced costs for patients and
healthcare systems.
Treatment for cancer

-- 31 of 86 --

30
A B B O T T 2 0 2 4 A N N U A L R E P O R T
Abbott is working to ensure
diagnostic testing is available
wherever people need care.
From healthcare providers in clinical settings to
consumers testing at home, Abbott’s range of rapid
testing solutions are industry leaders.
Our i-STAT TBI test using whole blood was cleared by
the FDA in 2024 to aid in the evaluation of patients 18
and older with suspected mild traumatic brain injury
at the point of care. Producing lab-quality results in 15
minutes, the test can be used by healthcare professionals
to help evaluate patients up to 24 hours after injury,
providing results bedside in the emergency room, and
allowing use in urgent-care clinics and other healthcare
settings outside the hospital.
Our ID NOW benchtop analyzer — a rapid, instrument-
based, isothermal system — has continued to accelerate
Abbott’s strategy of decentralizing testing by offering
reliable, near-patient testing that reduces overall
healthcare costs.
Our rapid diagnostics portfolio also includes Piccolo
Xpress, the only portable diagnostic analyzer to offer a
full complement of CLIA-waived blood chemistry tests
at the point of care; Afinion 2, a compact, rapid, multi-
assay analyzer; and the Cholestech LDX analyzer, which
empowers healthcare professionals and patients with
a complete lipid profile and glucose level in just five
minutes per test cassette.
For COVID-19, Abbott’s BinaxNOW (the No. 1 self-test
in the U.S.) and Panbio tests continue to be world leaders
for at-home COVID testing, having been used more
than 3 billion times around the world since their
development in 2020. Another rapid test, our Panbio
HIV Self Test, empowers people to proactively know
their HIV status and live fuller lives through earlier
diagnosis and treatment.
Measures biomarkers
associated with brain
injury in the blood
stream.
i-STAT TBI
RAPID
DIAGNOSTICS
A B B O T T N O W

-- 32 of 86 --

STREPTOCOCCUS
PNEUMONIAE
31
Charlotte Radek
CHICAGO, ILLINOIS, USA
ID NOW STREP A 2
When Charlotte came down with a
cough and fever, her mom, Stephanie,
was grateful that Charlotte’s doctor
could quickly determine exactly what
ailed her. With rapid molecular tests
on the ID NOW platform, results
are available in just minutes and in
more point-of-care locations, helping
people make health decisions sooner,
to reduce the spread of illnesses
like strep and RSV.
A B B O T T N E X T
Bringing the
Future Home
With regular testing at
home, families around
the world can know their
status so they can take
actions to help stop the
spread of illness.

-- 33 of 86 --

32
A B B O T T 2 0 2 4 A N N U A L R E P O R T
32
Abbott’s market-leading diagnostic tests, instruments,
and informatics systems deliver crucial information
to help guide decision-making for hundreds of health
conditions — from heart attacks to blood disorders to
infectious diseases and cancers.
Our customized, scalable solutions help laboratories
maximize precious space to improve throughput and
productivity in diagnostic labs.
Abbott systems and tests screen more than 50 percent of
the world’s blood and plasma supply. In 2024, we began
a partnership with the Big Ten collegiate athletics
conference to raise awareness and increase blood
donations that will help save thousands of lives.
Our Alinity portfolio of harmonized diagnostic
systems includes:
• The Alinity ci series, which integrates clinical
chemistry and immunoassay testing to help maximize
operational efficiency.
• The Alinity m family, which includes molecular
screening for the human papillomavirus, or HPV,
adding a powerful cervical-cancer screening tool.
• The AlinIQ, Abbott’s suite of digital health solutions
that help labs uncover intelligent insights and
operational productivity from the data they generate.
• And the Alinity s, our purpose-built instrument for
blood and plasma screening, which allows laboratory
staff to process more samples with less effort, greater
consistency, and increased control, leading to a more
productive blood- and plasma-screening process.
Customized,
scalable solutions
improving
throughput and
productivity in
diagnostic labs.
LABORATORY
DIAGNOSTICS
A B B O T T N O W

-- 34 of 86 --

CE :
O
O
O
O 33
A B B O T T 2 0 2 4 A N N U A L R E P O R T
EXPANDING TEST MENUS
LAUNCHING NEW SYSTEMS
INCREASING CAPACITY
A B B O T T N E X T
Alinity: Expanding Our Base
By streamlining critical interactions
among individuals, systems, and
information, Abbott is enabling
health professionals to redefine
performance in laboratories.
Maggie Schmidt
MILWAUKEE, WISCONSIN, USA
BLOOD DONATION WITH
MIXED REALITY
With the world’s blood supply
under constant pressure, it’s
important for everyone to
donate, especially younger
people like Maggie. Abbott’s
immersive mixed-reality digital
experience is designed to attract
new and younger donors.
ENHANCING EFFICIENCY
AND PRODUCTIVITY

-- 35 of 86 --

34
A B B O T T 2 0 2 4 A N N U A L R E P O R T
34
A B B O T T 2 0 2 4 A N N U A L R E P O R T
Passion
and
purpose
>$53M
THE WE GIVE BLOOD DRIVE
20,000
donations
NE ARLY
in cash and products
to support global
humanitarian efforts in
more than 50 countries
OUR PARTNERSHIP WITH THE BIG TEN
COLLEG IATE ATHLE TIC S CONFERENCE HELPED
S TRENG THEN THE U. S . BLO OD SUPPLY

-- 36 of 86 --

1
A B B O T T 2 0 2 4 A N N U A L R E P O R T
35	35
A B B O T T 2 0 2 4 A N N U A L R E P O R T
“Abbott Proud” expresses
our enthusiasm for helping
people live their best,
healthiest lives. We’re
here — all of us — to do
great things and, above
all, the 	right 	thing.
800
teammates
HE ARTM ATES
Abbott is helping
build a community of
support for people and
caregivers impacted by
heart conditions
1.3M
Patients who have received
emergency medical care
thanks to Abbott’s efforts
to help build healthcare
infrastructure in Tanzania
2024

-- 37 of 86 --

36
A B B O T T 2 0 2 4 A N N U A L R E P O R T
2024
Financial
Report
36
37 Consolidated Statement
of Earnings
38 Consolidated Statement
of Comprehensive Income
39 Consolidated Statement
of Cash Flows
40 Consolidated Balance Sheet
42 Consolidated Statement
of Shareholders’ Investment
43 Notes to Consolidated
Financial Statements
62 Management Report
on Internal Control Over
Financial Reporting
62 Report of Independent
Registered Public
Accounting Firm
64 Report of Independent
Registered Public
Accounting Firm
65 Financial Instruments and
Risk Management
66 Financial Review
79 Performance Graph
80 Summary of Selected
Financial Data
81 	Directors and
Corporate Officers
82 Shareholder and
Corporate Information

-- 38 of 86 --

37
A B B O T T 2 0 2 4 A N N U A L R E P O R T
Year Ended December 31 	2024 	2023 	2022
Net Sales 	$41,950 	$40,109 	$43,653
Cost of products sold, excluding amortization of intangible assets 	18,706 	17,975 	19,142
Amortization of intangible assets 	1,878 	1,966 	2,013
Research and development 	2,844 	2,741 	2,888
Selling, general and administrative 	11,697 	10,949 	11,248
Total Operating Cost and Expenses 	35,125 	33,631 	35,291
Operating Earnings 	6,825 	6,478 	8,362
Interest expense 	559 	637 	558
Interest income 	(344) 	(385) 	(183)
Net foreign exchange (gain) loss 	(27) 	41 	2
Other (income) expense, net 	(376) 	(479) 	(321)
Earnings before Taxes 	7,013 	6,664 	8,306
Taxes on Earnings 	(6,389) 	941 	1,373
Net Earnings 	$13,402 	$÷5,723 	$÷6,933
Basic Earnings Per Common Share 	$÷÷7.67 	$÷÷3.28 	$÷÷3.94
Diluted Earnings Per Common Share 	$÷÷7.64 	$÷÷3.26 	$÷÷3.91
Average Number of Common Shares Outstanding Used for Basic
Earnings Per Common Share 	1,740 	1,740 	1,753
Dilutive Common Stock Options 	8 	9 	11
Average Number of Common Shares Outstanding Plus Dilutive
Common Stock Options 	1,748 	1,749 	1,764
Outstanding Common Stock Options Having No Dilutive Effect 	7 	5 	3
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D S TAT E M E N T O F E A R N I N G S
(in millions except per share data)

-- 39 of 86 --

38
A B B O T T 2 0 2 4 A N N U A L R E P O R T
C O N S O L I D AT E D S TAT E M E N T O F C O M P R E H E N S I V E I N C O M E
(in millions)
Year Ended December 31 	2024 	2023 	2022
Net Earnings 	$13,402 	$«5,723 	$«6,933
Foreign currency translation gain (loss) adjustments 	(1,001) 	229 	(894)
Net actuarial gains (losses) and prior service cost and credits and amortization
of net actuarial losses and prior service cost and credits, net of taxes of $228 in
2024, $31 in 2023 and $330 in 2022 	765 	117 	1,177
Net gains (losses) on derivative instruments designated
as cash flow hedges, net of taxes of $48 in 2024, $(66) in 2023 and $11 in 2022 	169 	(134) 	40
Other Comprehensive Income (Loss) 	(67) 	212 	323
Comprehensive Income 	$13,335 	$«5,935 	$«7,256
Supplemental Accumulated Other Comprehensive Income (Loss) Information,
net of tax as of December 31:
Cumulative foreign currency translation (loss) adjustments 	$«(7,505) 	$(6,504) 	$(6,733)
Net actuarial (losses) and prior service (cost) and credits 	(611) 	(1,376) 	(1,493)
Cumulative gains (losses) on derivative instruments designated
as cash flow hedges 	210 	41 	175
Accumulated other comprehensive income (loss) 	$«(7,906) 	$(7,839) 	$(8,051)
The accompanying notes to consolidated financial statements are an integral part of this statement.

-- 40 of 86 --

39
A B B O T T 2 0 2 4 A N N U A L R E P O R T
C O N S O L I D AT E D S TAT E M E N T O F C A S H F L O W S
(in millions)
Year Ended December 31 	2024 	2023 	2022
Cash Flow From (Used in) Operating Activities:
Net earnings 	$13,402 	$«5,723 	$«6,933
Adjustments to reconcile earnings to net cash from operating activities —
Depreciation 	1,340 	1,277 	1,254
Amortization of intangible assets 	1,878 	1,966 	2,013
Share-based compensation 	673 	644 	685
Investing and financing losses, net 	482 	126 	215
Trade receivables 	(691) 	(356) 	(68)
Inventories 	(58) 	(232) 	(1,413)
Prepaid expenses and other assets 	(796) 	(542) 	(75)
Trade accounts payable and other liabilities 	356 	(760) 	420
Income taxes 	(8,028) 	(585) 	(383)
Net Cash From Operating Activities 	8,558 	7,261 	9,581
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment 	(2,207) 	(2,202) 	(1,777)
Acquisitions of businesses and technologies, net of cash acquired 	— 	(877) 	—
Proceeds from business dispositions 	1 	40 	48
Purchases of investment securities 	(169) 	(159) 	(185)
Proceeds from sales of investment securities 	28 	43 	152
Other 	9 	22 	22
Net Cash From (Used in) Investing Activities 	(2,338) 	(3,133) 	(1,740)
Cash Flow From (Used in) Financing Activities:
Proceeds from issuance of (repayments of ) short-term debt, net and other 	(100) 	21 	47
Proceeds from issuance of long-term debt and debt with maturities over 3 months 	223 	2 	7
Repayments of long-term debt and debt with maturities over 3 months 	(660) 	(2,498) 	(753)
Purchases of common shares 	(1,295) 	(1,227) 	(3,795)
Proceeds from stock options exercised 	264 	167 	167
Dividends paid 	(3,836) 	(3,556) 	(3,309)
Net Cash From (Used in) Financing Activities 	(5,404) 	(7,091) 	(7,636)
Effect of exchange rate changes on cash and cash equivalents 	(96) 	(23) 	(122)
Net Increase (Decrease) in Cash and Cash Equivalents 	720 	(2,986) 	83
Cash and Cash Equivalents, Beginning of Year 	6,896 	9,882 	9,799
Cash and Cash Equivalents, End of Year 	$7,616 	$6,896 	$«9,882
Supplemental Cash Flow Information:
Income taxes paid 	$1,723 	$1,475 	$«1,864
Interest paid 	604 	662 	563
The accompanying notes to consolidated financial statements are an integral part of this statement.

-- 41 of 86 --

40
A B B O T T 2 0 2 4 A N N U A L R E P O R T
December 31 	2024 	2023
Assets
Current assets:
Cash and cash equivalents 	$÷7,616 	$÷6,896
Investments, primarily bank time deposits and U.S. treasury bills 	351 	383
Trade receivables, less allowances of — 2024: $439; 2023: $444 	6,925 	6,565
Inventories:
Finished products 	3,700 	3,946
Work in process 	840 	807
Materials 	1,654 	1,817
Total inventories 	6,194 	6,570
Other prepaid expenses and receivables 	2,570 	2,256
Total current assets 	23,656 	22,670
Investments 	886 	799
Property and equipment, at cost:
Land 	528 	529
Buildings 	4,207 	4,161
Equipment 	15,517 	15,179
Construction in progress 	2,488 	2,064
22,740 	21,933
Less: accumulated depreciation and amortization 	12,082 	11,779
Net property and equipment 	10,658 	10,154
Intangible assets, net of amortization 	6,647 	8,815
Goodwill 	23,108 	23,679
Deferred income taxes and other assets 	16,459 	7,097
$81,414 	$73,214
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D B A L A N C E S H E E T
(dollars in millions)

-- 42 of 86 --

41
A B B O T T 2 0 2 4 A N N U A L R E P O R T
December 31 	2024 	2023
Liabilities and Shareholders’ Investment
Current liabilities:
Trade accounts payable 	$÷«4,195 	$÷«4,295
Salaries, wages and commissions 	1,701 	1,597
Other accrued liabilities 	5,143 	5,422
Dividends payable 	1,024 	955
Income taxes payable 	594 	492
Current portion of long-term debt 	1,500 	1,080
Total current liabilities 	14,157 	13,841
Long-term debt 	12,625 	13,599
Post-employment obligations and other long-term liabilities 	6,731 	6,947
Commitments and contingencies
Shareholders’ investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 	— 	—
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2024: 1,991,472,630; 2023: 1,987,883,852 	25,153 	24,869
Common shares held in treasury, at cost — Shares: 2024: 259,774,639; 2023: 253,807,494 	(16,844) 	(15,981)
Earnings employed in the business 	47,261 	37,554
Accumulated other comprehensive income (loss) 	(7,906) 	(7,839)
Total Abbott Shareholders’ Investment 	47,664 	38,603
Noncontrolling interests in subsidiaries 	237 	224
Total Shareholders’ Investment 	47,901 	38,827
$«81,414 	$«73,214
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D B A L A N C E S H E E T
(dollars in millions)

-- 43 of 86 --

42
A B B O T T 2 0 2 4 A N N U A L R E P O R T
Year Ended December 31 	2024 	2023 	2022
Common Shares:
Beginning of Year
Shares: 2024: 1,987,883,852; 2023: 1,986,519,278; 2022: 1,985,273,421 	$«24,869 	$«24,709 	$«24,470
Issued under incentive stock programs
Shares: 2024: 3,588,778; 2023: 1,364,574; 2022: 1,245,857 	173 	66 	72
Share-based compensation 	673 	646 	687
Issuance of restricted stock awards 	(562) 	(552) 	(520)
End of Year
Shares: 2024: 1,991,472,630; 2023: 1,987,883,852; 2022: 1,986,519,278 	$«25,153 	$«24,869 	$«24,709
Common Shares Held in Treasury:
Beginning of Year
Shares: 2024: 253,807,494; 2023: 248,724,257; 2022: 221,191,228 	$(15,981) 	$(15,229) 	$(11,822)
Issued under incentive stock programs
Shares: 2024: 4,423,897; 2023: 4,881,031; 2022: 4,980,202 	280 	297 	269
Purchased
Shares: 2024: 10,391,042; 2023: 9,964,268; 2022: 32,513,231 	(1,143) 	(1,049) 	(3,676)
End of Year
Shares: 2024: 259,774,639; 2023: 253,807,494; 2022: 248,724,257 	$(16,844) 	$(15,981) 	$(15,229)
Earnings Employed in the Business:
Beginning of Year 	$«37,554 	$«35,257 	$«31,528
Net earnings 	13,402 	5,723 	6,933
Cash dividends declared on common shares
(per share — 2024: $2.24; 2023: $2.08; 2022: $1.92) 	(3,904) 	(3,625) 	(3,365)
Effect of common and treasury share transactions 	209 	199 	161
End of Year 	$«47,261 	$«37,554 	$«35,257
Accumulated Other Comprehensive Income (Loss):
Beginning of Year 	$÷(7,839) 	$÷(8,051) 	$÷(8,374)
Other comprehensive income (loss) 	(67) 	212 	323
End of Year 	$÷(7,906) 	$÷(7,839) 	$÷(8,051)
Noncontrolling Interests in Subsidiaries:
Beginning of Year 	$÷÷÷224 	$÷÷÷219 	$÷÷÷222
Noncontrolling Interests’ share of income, net of distributions and
share repurchases 	13 	5 	(3)
End of Year 	$÷÷÷237 	$÷÷÷224 	$÷÷÷219
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D S TAT E M E N T O F S H A R E H O L D E R S ’ I N V E S T M E N T
(in millions except shares and per share data)

-- 44 of 86 --

43
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Business — Abbott’s principal business is the discovery,
development, manufacture and sale of a broad line of health care
products.
Basis of Consolidation — The consolidated financial statements
include the accounts of the parent company and subsidiaries, after
elimination of intercompany transactions.
Use of Estimates — The consolidated financial statements have been
prepared in accordance with generally accepted accounting princi-
ples in the United States and necessarily include amounts based on
estimates and assumptions by management. Actual results could
differ from those amounts. Significant estimates include amounts
for sales rebates, income taxes, pension and other post-employment
benefits, valuation of intangible assets, litigation, derivative financial
instruments, and inventory and accounts receivable exposures.
Foreign Currency Translation — The statements of earnings of
foreign subsidiaries whose functional currencies are other than
the U.S. dollar are translated into U.S. dollars using average
exchange rates for the period. The net assets of foreign subsidiar-
ies whose functional currencies are other than the U.S. dollar are
translated into U.S. dollars using exchange rates as of the balance
sheet date. The U.S. dollar effects that arise from translating the
net assets of these subsidiaries at changing rates are recorded in
the foreign currency translation adjustment account, which is
included in equity as a component of Accumulated other compre-
hensive income (loss). Transaction gains and losses are recorded
on the Net foreign exchange (gain) loss line of the Consolidated
Statement of Earnings.
Revenue Recognition — Revenue from product sales is recognized
upon the transfer of control, which is generally upon shipment or
delivery, depending on the delivery terms set forth in the customer
contract. Provisions for discounts, rebates and sales incentives to
customers, and returns and other adjustments are provided for
in the period the related sales are recorded. Sales incentives to
customers are not material. Historical data is readily available and
reliable, and is used for estimating the amount of the reduction in
gross sales. Revenue from the launch of a new product, from an
improved version of an existing product, or for shipments in
excess of a customer’s normal requirements are recorded when
the conditions noted above are met. In those situations, manage-
ment records a returns reserve for such revenue, if necessary. In
certain Abbott businesses, primarily within diagnostics, Abbott
participates in selling arrangements that include multiple perfor-
mance obligations (e.g., instruments, reagents, procedures, and
service agreements). The total transaction price of the contract is
allocated to each performance obligation in an amount based on
the estimated relative standalone selling prices of the promised
goods or services underlying each performance obligation.
Income Taxes — Deferred income taxes are provided for the tax
effect of differences between the tax bases of assets and liabilities
and their reported amounts in the financial statements at the
enacted statutory rate to be in effect when the taxes are paid. No
additional income taxes have been provided for any remaining
undistributed foreign earnings not subject to the transition tax
related to the U.S. Tax Cuts and Jobs Act (TCJA), or any additional
outside basis differences that exist, as these amounts continue to
be indefinitely reinvested in foreign operations. The TCJA sub-
jects taxpayers to tax on global intangible low-taxed income
(GILTI) earned by certain foreign subsidiaries. Abbott treats the
GILTI tax as a period expense and provides for the tax in the
year that the tax is incurred. Interest and penalties on income
tax obligations are included in taxes on earnings.
Earnings Per Share — Unvested restricted stock units and awards
that contain non-forfeitable rights to dividends are treated as
participating securities and are included in the computation of
earnings per share under the two-class method. Under the two-
class method, net earnings are allocated between common shares
and participating securities. Net earnings allocated to common
shares in 2024, 2023 and 2022 were $13.351 billion, $5.701 billion
and $6.905 billion, respectively.
Pension and Post-Employment Benefits — Abbott accrues for
the actuarially determined cost of pension and post-employment
benefits over the service attribution periods of the employees.
Abbott must develop long-term assumptions, the most significant
of which are the health care cost trend rates, discount rates and
the expected return on plan assets. Differences between the
expected long-term return on plan assets and the actual return
are amortized over a five-year period. Actuarial losses and gains
are amortized over the remaining service attribution periods of
the employees under the corridor method.
Fair Value Measurements — For assets and liabilities that are
measured using quoted prices in active markets, total fair value is
the published market price per unit multiplied by the number of
units held without consideration of transaction costs. Assets and
liabilities that are measured using significant other observable
inputs are valued by reference to similar assets or liabilities,
adjusted for contract restrictions and other terms specific to that
asset or liability. For these items, a significant portion of fair value
is derived by reference to quoted prices of similar assets or liabili-
ties in active markets. For all remaining assets and liabilities, fair
value is derived using a fair value model, such as a discounted cash
flow model or Black-Scholes model. Purchased intangible assets
are recorded at fair value. The fair value of significant purchased
intangible assets is based on independent appraisals. Abbott uses
a discounted cash flow model to value intangible assets. The dis-
counted cash flow model requires assumptions about the timing
and amount of future net cash flows, risk, the cost of capital, termi-
nal values and market participants. Intangible assets are reviewed
for impairment on a quarterly basis. Goodwill and indefinite-lived
intangible assets are tested for impairment at least annually.
Share-Based Compensation — The fair value of stock options
and restricted stock awards and units are amortized over their
requisite service period, which could be shorter than the vesting
period if an employee is retirement eligible, with a charge to
compensation expense.
Litigation — Abbott accounts for litigation losses in accordance
with Financial Accounting Standards Board (FASB) Accounting
Standards Codification (ASC) No. 450, “Contingencies.” Under
ASC No. 450, loss contingency provisions are recorded for proba-
ble losses at management’s best estimate of a loss, or when a best
estimate cannot be made, a minimum loss contingency amount
is recorded. Legal fees are recorded as incurred.
Cash, Cash Equivalents and Investments — Cash equivalents
consist of bank time deposits, U.S. government securities, money
market funds and U.S. treasury bills with original maturities of
three months or less. Abbott holds certain investments with a
carrying value of $139 million that are accounted for under the
equity method of accounting. Investments held in a rabbi trust

-- 45 of 86 --

44
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
and investments in publicly traded equity securities are recorded
at fair value and changes in fair value are recorded in earnings.
Investments in equity securities that are not traded on public stock
exchanges are recorded at cost minus impairment, if any, plus or
minus changes resulting from observable price changes in orderly
transactions for identical or similar investments of the same issuer.
Trade Receivable Valuations — Accounts receivable are stated
at the net amount expected to be collected. The allowance for
doubtful accounts reflects the current estimate of credit losses
expected to be incurred over the life of the accounts receivable.
Abbott considers various factors in establishing, monitoring, and
adjusting its allowance for doubtful accounts, including the aging
of the accounts and aging trends, the historical level of charge-
offs, and specific exposures related to particular customers. Abbott
also monitors other risk factors and forward-looking information,
such as country risk, when determining credit limits for customers
and establishing adequate allowances. Accounts receivable are
charged off after all reasonable means to collect the full amount
(including litigation, where appropriate) have been exhausted.
Inventories — Inventories are stated at the lower of cost (first-in,
first-out basis) or net realizable value. Cost includes material and
conversion costs.
Property and Equipment — Depreciation and amortization are
provided on a straight-line basis over the estimated useful lives
of the assets. The following table shows estimated useful lives of
property and equipment:
Classification 	Estimated Useful Lives
Buildings 	10 to 50 years
Equipment 	2 to 20 years
Product Liability — Abbott accrues for product liability claims
when it is probable that a liability has been incurred and the
amount of the liability can be reasonably estimated based on
existing information. The liabilities are adjusted quarterly as
additional information becomes available. Product liability losses
are self-insured.
Research and Development Costs — Internal research and develop-
ment costs are expensed as incurred. Clinical trial costs incurred
by third parties are expensed as the contracted work is performed.
Where contingent milestone payments are due to third parties under
research and development arrangements, the milestone payment
obligations are expensed when the milestone results are achieved.
Acquired In-Process and Collaborations Research and Development
(IPR&D) — The initial costs of rights to IPR&D projects obtained
in an asset acquisition are expensed as IPR&D unless the project
has an alternative future use. These costs include initial payments
incurred prior to regulatory approval in connection with research
and development collaboration agreements that provide rights
to develop, manufacture, market and/or sell pharmaceutical or
medical device products. The fair value of IPR&D projects
acquired in a business combination are capitalized and accounted
for as indefinite-lived intangible assets until completed and are
then amortized over the remaining useful life. Collaborations are
not significant.
Concentration Of Risk and Guarantees — Due to the nature of its
operations, Abbott is not subject to significant concentration risks
relating to customers, products or geographic locations. Product
warranties are not significant.
Abbott has no material exposures to off-balance sheet arrange-
ments; no special purpose entities; nor activities that include
non-exchange-traded contracts accounted for at fair value. Abbott
periodically acquires a business or product rights in which Abbott
agrees to pay contingent consideration based on attaining certain
thresholds or based on the occurrence of certain events.
NOTE 2 — NEW ACCOUNTING STANDARDS
RECENTLY ADOPTED ACCOUNTING STANDARDS
In November 2023, the FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment
Disclosures, which expands the breadth and frequency of
required segment disclosures. The guidance is required to be
applied retrospectively to all periods presented in the financial
statements. Abbott adopted the standard on January 1, 2024. The
new standard did not have an impact on Abbott’s consolidated
financial statements, but required additional disclosures, retro-
spectively applied to all periods presented in Note 16 — Segment
and geographic area information.
In September 2022, the FASB issued Accounting Standards
Update (ASU) 2022-04, Disclosure of Supplier Finance Program
Obligations, which requires an entity to report information about
its supplier finance program. Abbott adopted the standard on
January 1, 2023. The new standard did not have an impact on
Abbott’s consolidated financial statements.
RECENT ACCOUNTING STANDARDS NOT YET ADOPTED
In November 2024, the FASB issued ASU 2024-03, Income
Statement (Subtopic 220-40): Reporting Comprehensive Income —
Expense Disaggregation Disclosures, which requires an entity to
disclose on an annual and interim basis, disaggregated information
about specific income statement expense categories. The guidance
should be applied prospectively with the option to apply the stan-
dard retrospectively. The standard becomes effective for Abbott for
full year 2027 reporting. Abbott is currently evaluating the impact
of this new standard on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes
(Topic 740): Improvements to Income Tax Disclosures, which
requires an entity to disclose annually additional information
related to the company’s income tax rate reconciliation and
income taxes paid during the period. The guidance should be
applied prospectively with the option to apply the standard retro-
spectively. The standard becomes effective for Abbott for full year
2025 reporting. Abbott is currently evaluating the impact of this
new standard on its consolidated financial statements.
NOTE 3 — REVENUE
Abbott’s revenues are derived primarily from the sale of a
broad line of health care products under short-term receivable
arrangements. Patent protection and licenses, technological and
performance features, and inclusion of Abbott’s products under
a contract most impact which products are sold; price controls,
competition and rebates most impact the net selling prices of
products; and foreign currency translation impacts the measure-
ment of net sales and costs. Abbott’s products are generally sold
directly to retailers, wholesalers, distributors, hospitals, health
care facilities, laboratories, physicians’ offices and government
agencies throughout the world. Abbott has four reportable seg-
ments: Established Pharmaceutical Products, Diagnostic Products,
Nutritional Products, and Medical Devices.

-- 46 of 86 --

45
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following tables provide detail by sales category:
2024 	2023 	2022
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical Products —
Key Emerging Markets 	$÷÷÷÷— 	$÷3,858 	$÷3,858 	$÷÷÷÷— 	$÷3,807 	$÷3,807 	$÷÷÷÷— 	$÷3,766 	$÷3,766
Other 	— 	1,336 	1,336 	— 	1,259 	1,259 	— 	1,146 	1,146
Total 	— 	5,194 	5,194 	— 	5,066 	5,066 	— 	4,912 	4,912
Nutritional Products —
Pediatric Nutritionals 	2,208 	1,815 	4,023 	1,977 	1,957 	3,934 	1,562 	1,919 	3,481
Adult Nutritionals 	1,481 	2,909 	4,390 	1,436 	2,784 	4,220 	1,357 	2,621 	3,978
Total 	3,689 	4,724 	8,413 	3,413 	4,741 	8,154 	2,919 	4,540 	7,459
Diagnostic Products —
Core Laboratory 	1,332 	3,903 	5,235 	1,243 	3,916 	5,159 	1,137 	3,751 	4,888
Molecular 	150 	371 	521 	172 	402 	574 	370 	625 	995
Point of Care 	408 	180 	588 	396 	169 	565 	372 	153 	525
Rapid Diagnostics 	1,940 	1,057 	2,997 	2,518 	1,172 	3,690 	6,652 	3,409 	10,061
Total 	3,830 	5,511 	9,341 	4,329 	5,659 	9,988 	8,531 	7,938 	16,469
Medical Devices —
Rhythm Management 	1,154 	1,236 	2,390 	1,085 	1,170 	2,255 	1,029 	1,090 	2,119
Electrophysiology 	1,141 	1,326 	2,467 	1,008 	1,187 	2,195 	909 	1,018 	1,927
Heart Failure 	986 	293 	1,279 	888 	273 	1,161 	809 	226 	1,035
Vascular 	1,056 	1,781 	2,837 	978 	1,703 	2,681 	864 	1,619 	2,483
Structural Heart 	1,051 	1,195 	2,246 	883 	1,061 	1,944 	818 	894 	1,712
Neuromodulation 	767 	195 	962 	725 	165 	890 	619 	151 	770
Diabetes Care 	2,633 	4,172 	6,805 	2,129 	3,632 	5,761 	1,633 	3,123 	4,756
Total 	8,788 	10,198 	18,986 	7,696 	9,191 	16,887 	6,681 	8,121 	14,802
Other 	16 	— 	16 	14 	— 	14 	11 	— 	11
Total 	$16,323 	$25,627 	$41,950 	$15,452 	$24,657 	$40,109 	$18,142 	$25,511 	$43,653
Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $115 million of sales in 2022 were moved from Rapid
Diagnostics to Heart Failure.
Products sold by the Diagnostics segment include various types
of diagnostic tests to detect COVID-19. Abbott’s COVID-19
testing-related sales totaled approximately $747 million in 2024,
$1.6 billion in 2023 and $8.4 billion in 2022.
Abbott recognizes revenue from product sales upon the transfer of
control, which is generally upon shipment or delivery, depending
on the delivery terms set forth in the customer contract. For main-
tenance agreements that provide service beyond Abbott’s standard
warranty and other service agreements, revenue is recognized
ratably over the contract term. A time-based measure of progress
appropriately reflects the transfer of services to the customer.
Payment terms between Abbott and its customers vary by the type of
customer, country of sale, and the products or services offered. The
term between invoicing and the payment due date is not significant.
Management exercises judgment in estimating variable consider-
ation. Provisions for discounts, rebates and sales incentives to
customers, and returns and other adjustments are provided for
in the period the related sales are recorded. Sales incentives to
customers are not material. Historical data is readily available and
reliable, and is used for estimating the amount of the reduction in
gross sales. Abbott provides rebates to government agencies, whole-
salers, group purchasing organizations and other private entities.
Rebate amounts are usually based upon the volume of purchases
using contractual or statutory prices for a product. Factors used
in the rebate calculations include the identification of which
products have been sold subject to a rebate, which customer or
government agency price terms apply, and the estimated lag time
between sale and payment of a rebate. Using historical trends,
adjusted for current changes, Abbott estimates the amount of the
rebate that will be paid, and records the liability as a reduction of
gross sales when Abbott records its sale of the product. Settlement
of the rebate generally occurs from one to six months after sale.
Abbott regularly analyzes the historical rebate trends and makes
adjustments to reserves for changes in trends and terms of rebate
programs. Historically, adjustments to prior years’ rebate accruals
have not been material to net income.
Other allowances charged against gross sales include cash
discounts and returns, which are not significant. Cash discounts
are known within 15 to 30 days of sale, and therefore can be
reliably estimated. Returns can be reliably estimated because
Abbott’s historical returns are low, and because sales return terms
and other sales terms have remained relatively unchanged for
several periods. Product warranties are also not significant.

-- 47 of 86 --

46
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
Abbott also applies judgment in determining the timing of
revenue recognition related to contracts that include multiple
performance obligations. The total transaction price of the con-
tract is allocated to each performance obligation in an amount
based on the estimated relative standalone selling prices of the
promised goods or services underlying each performance obliga-
tion. For goods or services for which observable standalone
selling prices are not available, Abbott uses an expected cost plus
a margin approach to estimate the standalone selling price of
each performance obligation.
REMAINING PERFORMANCE OBLIGATIONS
As of December 31, 2024, the estimated revenue expected to
be recognized in the future related to performance obligations
that are unsatisfied (or partially unsatisfied) was approximately
$5.5 billion in the Diagnostic Products segment and approxi-
mately $440 million in the Medical Devices segment. Abbott
expects to recognize revenue on approximately 56 percent of
these remaining performance obligations over the next
24 months, approximately 17 percent over the subsequent
12 months and the remainder thereafter.
These performance obligations primarily reflect the future sale
of reagents/consumables in contracts with minimum purchase
obligations, extended warranty or service obligations related to
previously sold equipment, and remote monitoring services
related to previously implanted devices. Abbott has applied the
practical expedient described in ASC 606-10-50-14 and has not
included remaining performance obligations related to contracts
with original expected durations of one year or less in the
amounts above.
ASSETS RECOGNIZED FOR COSTS TO OBTAIN A
CONTRACT WITH A CUSTOMER
Abbott has applied the practical expedient in ASC 340-40-25-4
and records as an expense the incremental costs of obtaining
contracts with customers in the period of occurrence when the
amortization period of the asset that Abbott otherwise would have
recognized is one year or less. Upfront commission fees paid to
sales personnel as a result of obtaining or renewing contracts with
customers are incremental to obtaining the contract. Abbott capi-
talizes these amounts as contract costs. Capitalized commission
fees are amortized based on the contract duration to which the
assets relate which ranges from two to ten years. The amounts as
of December 31, 2024 and 2023 were not significant.
Additionally, the cost of transmitters provided to customers that
use Abbott’s remote monitoring service with respect to certain
medical devices are capitalized as contract costs. Capitalized
transmitter costs are amortized based on the timing of the transfer
of services to which the assets relate, which typically ranges from
eight to ten years. The amounts as of December 31, 2024 and 2023
were not significant.
OTHER CONTRACT ASSETS AND LIABILITIES
Abbott discloses Trade receivables separately in the Consolidated
Balance Sheet at the net amount expected to be collected. Contract
assets primarily relate to Abbott’s conditional right to consideration
for work completed but not billed at the reporting date. Contract
assets at the beginning and end of the period, as well as the
changes in the balance, were not significant.
Contract liabilities primarily relate to payments received from
customers in advance of performance under the contract.
Abbott’s contract liabilities arise primarily in the Medical Devices
reportable segment when payment is received upfront for various
multi-period extended service arrangements. Changes in the
contract liabilities during the period are as follows:
(in millions)
Contract Liabilities:
Balance at December 31, 2022 	$«500
Unearned revenue from cash received during the period 	469
Revenue recognized related to contract liability balance 	(424)
Balance at December 31, 2023 	545
Unearned revenue from cash received during the period 	483
Revenue recognized related to contract liability balance 	(460)
Balance at December 31, 2024 	$«568
NOTE 4 — SUPPLEMENTAL FINANCIAL INFORMATION
Other (income) expense, net, for 2024, 2023 and 2022 includes
approximately $542 million, $498 million and $406 million of
income, respectively, related to the non-service cost components
of the net periodic benefit costs associated with the pension and
post-retirement medical plans.
In the second quarter of 2024, Abbott sold a non-core business
related to its Established Pharmaceutical Products segment. Abbott
recorded a loss of approximately $143 million on the sale in Other
(income) expense, net in its Consolidated Statement of Earnings.
Net assets which primarily related to inventory and net property
and equipment and had a carrying value of $28 million were
included in the sale. The loss on the sale also included $116 million
of cumulative foreign currency translation adjustment previously
recorded in Accumulated other comprehensive income (loss).
The following summarizes the activity related to the allowance
for doubtful accounts:
(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2022 	$262
Provisions/charges to income 	26
Amounts charged off and other deductions 	(47)
Balance at December 31, 2023 	241
Provisions/charges to income 	61
Amounts charged off and other deductions 	(55)
Balance at December 31, 2024 	$247

-- 48 of 86 --

47
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The allowance for doubtful accounts reflects the current
estimate of credit losses expected to be incurred over the life
of the accounts receivable. Abbott considers various factors in
establishing, monitoring, and adjusting its allowance for doubtful
accounts, including the aging of the accounts and aging trends,
the historical level of charge-offs, and specific exposures related
to particular customers. Abbott also monitors other risk factors
and forward-looking information, such as country risk, when
determining credit limits for customers and establishing
adequate allowances.
The detail of various balance sheet components is as follows:
(in millions)
December 31 	2024 	2023
Long-term Investments:
Equity securities 	$553 	$555
Other 	333 	244
Total 	$886 	$799
The increase in Abbott’s long-term investments as of December 31,
2024 versus the balance as of December 31, 2023 primarily relates
to investment in long term deposits and equity method invest-
ments, partially offset by the impairment of certain securities.
Abbott’s equity securities as of December 31, 2024 and
December 31, 2023, include $313 million and $314 million, respec-
tively, of investments in mutual funds that are held in a rabbi trust.
These investments, which are specifically designated as available
for the purpose of paying benefits under a deferred compensation
plan, are not available for general corporate purposes and are
subject to creditor claims in the event of insolvency.
Abbott also holds certain investments as of December 31, 2024
with a carrying value of $139 million that are accounted for under
the equity method of accounting and other equity investments
with a carrying value of $91 million that do not have a readily
determinable fair value.
(in millions)
December 31 	2024 	2023
Other Accrued Liabilities:
Accrued rebates payable to government agencies 	$÷«621 	$÷«650
Accrued other rebates (a) 	1,098 	1,091
All other 	3,424 	3,681
Total 	$5,143 	$5,422
(a) Accrued wholesaler chargeback rebates of $262 million and $232 million at December 31, 2024
and 2023, respectively, are netted in trade receivables because Abbott’s customers are invoiced
at a higher catalog price but only remit to Abbott their contract price for the products.
(in millions)
December 31 	2024 	2023
Post-employment Obligations and
Other Long-term Liabilities:
Defined benefit pension plans and post-employment
medical and dental plans for significant plans 	$1,880 	$1,964
Deferred income taxes 	512 	568
Operating lease liabilities 	896 	949
All other (b) 	3,443 	3,466
Total 	$6,731 	$6,947
(b) Includes approximately $860 million and $650 million of net unrecognized tax benefits
and $210 million and $430 million of transition tax obligation related to the TCJA in
2024 and 2023, respectively.
NOTE 5 — ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
The components of the changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:
(in millions)
Cumulative Foreign
Currency Translation
Adjustments
Net Actuarial Gains
(Losses) and Prior
Service (Costs)
and Credits
Cumulative Gains
(Losses) on Derivative
Instruments Designated
as Cash Flow Hedges 	Total
Balance at December 31, 2022 	$(6,733) 	$(1,493) 	$«175 	$(8,051)
Other comprehensive income (loss) before reclassifications 	212 	127 	5 	344
(Income) loss amounts reclassified from accumulated other
comprehensive income (a) 	17 	(10) 	(139) 	(132)
Net current period other comprehensive income (loss) 	229 	117 	(134) 	212
Balance at December 31, 2023 	(6,504) 	(1,376) 	41 	(7,839)
Other comprehensive income (loss) before reclassifications 	(1,117) 	757 	245 	(115)
(Income) loss amounts reclassified from accumulated other
comprehensive income (a) 	116 	8 	(76) 	48
Net current period other comprehensive income (loss) 	(1,001) 	765 	169 	(67)
Balance at December 31, 2024 	$(7,505) 	$«÷(611) 	$«210 	$(7,906)
(a) The reclassification of $116 million out of Accumulated other comprehensive income (loss) in 2024 is included in the loss related to the sale of a non-core business included in Other (income)
expense. (Income) loss amounts reclassified from accumulated other comprehensive income related to cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior
service cost is included as a component of net periodic benefit cost – see Note 14 — Post-Employment Benefits for additional information.

-- 49 of 86 --

48
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
NOTE 6 — BUSINESS ACQUISITIONS
On September 22, 2023, Abbott completed the acquisition of
Bigfoot Biomedical, Inc. (Bigfoot), which furthers Abbott’s efforts
to develop connected solutions for making diabetes management
more personal and precise. The purchase price, the final allocation
of acquired assets and liabilities, and the revenue and net income
contributed by Bigfoot since the date of acquisition are not
material to Abbott’s consolidated financial statements.
On April 27, 2023, Abbott completed the acquisition of
Cardiovascular Systems, Inc. (CSI) for $20 per common share,
which equated to a purchase price of $851 million. The transaction
was funded with cash on hand and accounted for as a business
combination. CSI’s atherectomy system, which is used in treating
peripheral and coronary artery disease, adds complementary
technologies to Abbott’s portfolio of vascular device offerings.
The final allocation of the purchase price of the CSI acquisition
resulted in the recording of two non-deductible developed tech-
nology intangible assets totaling $305 million; a non-deductible
in-process research and development asset of $15 million, which
will be accounted for as an indefinite-lived intangible asset until
regulatory approval or discontinuation; non-deductible goodwill
of $369 million; net deferred tax assets of $46 million and other
net assets of $116 million. The goodwill is identifiable to the
Medical Devices reportable segment and is attributable to expected
synergies from combining operations, as well as intangible assets
that do not qualify for separate recognition. Revenues and earnings
of CSI included in Abbott’s consolidated financial statements since
the acquisition date are not material to Abbott’s consolidated
revenue and earnings.
NOTE 7 — GOODWILL AND INTANGIBLE ASSETS
The total amount of reported goodwill was $23.1 billion at
December 31, 2024 and $23.7 billion at December 31, 2023.
Foreign currency translation adjustments decreased goodwill
by $533 million in 2024 and increased goodwill by $304 million
in 2023. In 2023, business acquisitions increased goodwill by
approximately $576 million. The amount of goodwill related to
reportable segments at December 31, 2024 was $2.6 billion for
the Established Pharmaceutical Products segment, $285 million
for the Nutritional Products segment, $3.5 billion for the
Diagnostic Products segment, and $16.8 billion for the Medical
Devices segment. There were no reductions of goodwill relating
to impairments in 2024 and 2023.
The gross amount of amortizable intangible assets, primarily
product rights and technology, was $27.1 billion and $27.7 billion
as of December 31, 2024 and 2023, respectively. In 2023, the gross
amount of amortizable intangible assets increased by $305 million
due to a business acquisition. Accumulated amortization was
$21.3 billion and $19.7 billion as of December 31, 2024 and 2023,
respectively. Foreign currency translation adjustments decreased
intangible assets by $78 million in 2024 and increased intangible
assets by $44 million in 2023. In 2024, intangible assets decreased
$207 million due to impairment charges recorded on the Cost of
products sold line of the Consolidated Statement of Earnings,
primarily related to the Medical Devices reportable segment.
The estimated annual amortization expense for intangible assets
recorded at December 31, 2024 is approximately $1.7 billion in
2025, $1.5 billion in 2026, $1.2 billion in 2027, $668 million in
2028 and $605 million in 2029. Amortizable intangible assets are
amortized over 2 to 20 years.
Indefinite-lived intangible assets, which relate to IPR&D acquired
in a business combination, were approximately $784 million and
$787 million at December 31, 2024 and 2023, respectively. In 2024,
IPR&D decreased by $39 million of charges recorded on the
Research and development line of the Consolidated Statement
of Earnings for the impairment of an indefinite-lived intangible
asset related to the Medical Devices reportable segment and was
partially offset by an increase of $35 million due to the finalization
of purchase accounting related to a business acquisition. In 2023,
$100 million of impairment charges related to certain indefinite-
lived intangible assets in the Medical Devices reportable segment
were recorded on the Research and development line of the
Consolidated Statement of Earnings. In 2023, business acquisi-
tions increased IPR&D assets by $80 million.
NOTE 8 — RESTRUCTURING PLANS
In 2024, Abbott management approved plans to streamline certain
operations in order to reduce costs and improve efficiencies in its
Diagnostic, Medical Devices, Established Pharmaceutical and
Nutritional businesses, including the discontinuation of its
ZonePerfect® product line. Abbott recorded employee related
severance and other charges of $129 million, of which $62 million
was recorded in Cost of products sold, $21 million was recorded
in Research and development, and $46 million was recorded in
Selling, general and administrative expenses. Payments related
to these actions totaled $32 million in 2024 and the remaining
liability totaled $97 million at December 31, 2024. In addition,
Abbott recognized inventory related charges of $34 million and
fixed asset impairment charges of $12 million related to these
restructuring plans.

-- 50 of 86 --

49
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
In 2023, Abbott management approved plans to restructure
various operations in order to reduce costs in its Medical Devices,
Diagnostic, and Established Pharmaceutical businesses. Abbott
recorded employee related severance and other charges of
$144 million of which $56 million was recorded in Cost of products
sold, $22 million was recorded in Research and development and
$66 million was recorded in Selling, general and administrative
expenses. In addition, Abbott recognized fixed asset impairment
and inventory related charges of $31 million related to these
restructuring plans.
The following summarizes the activity related to the 2023
restructuring actions and the status of the related accruals as
of December 31, 2024:
(in millions)
Restructuring charges in 2023 	$144
Payments and other adjustments 	(65)
Accrued balance at December 31, 2023 	79
Payments and other adjustments 	(58)
Accrued balance at December 31, 2024 	$÷21
In 2022, Abbott management approved plans to streamline opera-
tions in order to reduce costs and improve efficiencies in its Medical
Devices, Nutritional, Diagnostic, and Established Pharmaceutical
businesses. Abbott recorded employee related severance and other
charges of $234 million of which $59 million was recorded in
Cost of products sold, $36 million was recorded in Research and
development and $139 million was recorded in Selling, general and
administrative expenses. In addition, Abbott recognized inventory
related charges of $23 million and fixed asset impairment charges
of $4 million related to these restructuring plans.
The following summarizes the activity related to the 2022
restructuring actions and the status of the related accruals as
of December 31, 2024:
(in millions)
Restructuring charges in 2022 	$«234
Payments and other adjustments 	(6)
Accrued balance at December 31, 2022 	228
Payments and other adjustments 	(170)
Accrued balance at December 31, 2023 	$58
Payments and other adjustments 	(49)
Accrued balance at December 31, 2024 	$÷÷«9
NOTE 9 — INCENTIVE STOCK PROGRAM
The 2017 Incentive Stock Program authorizes the granting of non-
qualified stock options, restricted stock awards, restricted stock units,
performance awards, foreign benefits and other share-based awards.
Stock options and restricted stock awards and units comprise the
majority of benefits that have been granted and are currently out-
standing under this program and a prior program. In 2024, Abbott
granted 1,683,097 stock options, 404,597 restricted stock awards
and 5,341,050 restricted stock units under this program.
Under Abbott’s stock incentive programs, the purchase price of
shares under option must be at least equal to the fair market value
of the common stock on the date of grant, and the maximum term
of an option is 10 years. Options generally vest equally over three
years. Restricted stock awards generally vest over three years, with
no more than one-third of the award vesting in any one year upon
Abbott reaching a minimum return on equity target. Restricted
stock units vest over three years and upon vesting, the recipient
receives one share of Abbott stock for each vested restricted stock
unit. The aggregate fair market value of options and restricted
stock awards and units is recognized as expense over the requisite
service period, which may be shorter than the vesting period if an
employee is retirement eligible. Forfeitures are estimated at the
time of grant. Restricted stock awards and settlement of vested
restricted stock units are issued out of treasury shares. Abbott
generally issues new shares for exercises of stock options. As a
policy, Abbott does not purchase its shares relating to its share-
based programs.
In April 2017, Abbott’s shareholders authorized the 2017 Incentive
Stock Program under which a maximum of 170 million shares
were available for issuance. At December 31, 2024, approximately
61 million shares remained available for future issuance.

-- 51 of 86 --

50
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following table summarizes restricted stock awards and units
activity for the year ended December 31, 2024.
Share Units
Weighted
Average
Grant-Date
Fair Value
Outstanding at December 31, 2023 	10,278,286 	$112.51
Granted 	5,745,647 	116.78
Vested 	(4,978,325) 	115.35
Forfeited 	(536,036) 	112.82
Outstanding at December 31, 2024 	10,509,572 	$113.48
The fair market value of restricted stock awards and units vested
in 2024, 2023 and 2022 was $570 million, $536 million and
$639 million, respectively.
The total intrinsic value of options exercised in 2024, 2023 and
2022 was $238 million, $102 million and $85 million, respectively.
The total unrecognized compensation cost related to all share-
based compensation plans at December 31, 2024 amounted to
approximately $462 million, which is expected to be recognized
over the next three years.
Total non-cash stock compensation expense charged against
income in 2024, 2023 and 2022 for share-based plans totaled
approximately $673 million, $644 million and $685 million,
respectively, and the tax benefit recognized was approximately
$181 million, $144 million and $170 million, respectively.
Stock compensation cost capitalized as part of inventory is
not significant.
The table below summarizes the fair value of an option granted in
2024, 2023 and 2022 and the assumptions included in the Black-
Scholes option-pricing model used to estimate the fair value:
2024 	2023 	2022
Fair value 	$31.10 	$26.87 	$25.26
Risk-free interest rate 	4.3% 	4.0% 	1.9%
Average life of options (years) 	6.0 	6.0 	6.0
Volatility 	25.2% 	24.4% 	23.8%
Dividend yield 	1.9% 	1.9% 	1.6%
The risk-free interest rate is based on the rates available at the
time of the grant for zero-coupon U.S. government issues with a
remaining term equal to the option’s expected life. The average life
of an option is based on both historical and projected exercise and
lapsing data. Expected volatility is based on implied volatilities
from traded options on Abbott’s stock and historical volatility of
Abbott’s stock over the expected life of the option. Dividend yield
is based on the option’s exercise price and annual dividend rate
at the time of grant.
NOTE 10 — DEBT AND LINES OF CREDIT
The following is a summary of long-term debt at December 31:
(in millions) 	2024 	2023
0.10% Notes, due 2024 	— 	655
2.95% Notes, due 2025 	1,000 	1,000
3.875% Notes, due 2025 	500 	500
1.50% Notes, due 2026 	1,188 	1,266
3.75% Notes, due 2026 	1,700 	1,700
0.375% Notes, due 2027 	615 	655
1.15% Notes, due 2028 	650 	650
5-year term loan due 2029 	583 	419
1.40% Notes, due 2030 	650 	650
4.75% Notes, due 2036 	1,650 	1,650
6.15% Notes, due 2037 	547 	547
6.00% Notes, due 2039 	515 	515
5.30% Notes, due 2040 	694 	694
4.75% Notes, due 2043 	700 	700
4.90% Notes, due 2046 	3,250 	3,250
Unamortized debt issuance costs 	(53) 	(56)
Other, including fair value adjustments
relating to interest rate hedge contracts
designated as fair value hedges 	(64) 	(116)
Total carrying amount of long-term debt 	14,125 	14,679
Less: Current portion 	1,500 	1,080
Total long-term portion 	$12,625 	$13,599
On November 19, 2024, Abbott repaid the €590 million out-
standing principal amount of its 0.10% Notes upon maturity.
The repayment equated to approximately $640 million. On
November 30, 2023, Abbott repaid the $1.05 billion outstanding
principal amount of its 3.40% Notes upon maturity. On
September 27, 2023, Abbott repaid the €1.14 billion outstanding
principal amount of its 0.875% Notes upon maturity. The repay-
ment equated to approximately $1.2 billion. In September 2023,
Abbott repaid approximately $197 million of debt assumed as
part of a recent business acquisition.
The following table summarizes stock option activity for the year ended December 31, 2024 and the outstanding stock options as of
December 31, 2024.
(intrinsic values in millions) 	Options
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Life (Years)
Aggregate
Intrinsic Value
Outstanding at December 31, 2023 	28,569,075 	$÷74.52 	4.8 	$1,073
Granted 	1,683,097 	116.88
Exercised 	(3,593,503) 	47.26
Lapsed 	(111,920) 	119.40
Outstanding at December 31, 2024 	26,546,749 	$÷80.70 	4.6 	$÷«906
Exercisable at December 31, 2024 	22,712,676 	$÷75.20 	3.9 	$÷«897

-- 52 of 86 --

51
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
On June 26, 2024, Abbott modified its existing, yen-denominated
5-year term loan scheduled to mature in November 2024. The
amended terms include a net increase in principal debt from
¥59.8 billion to ¥92.0 billion, with a new maturity date in June
2029. The modified, 5-year term loan bears interest at the Tokyo
Interbank Offered Rate (TIBOR) plus a fixed spread, and the
interest rate is reset quarterly. The net proceeds equated to
approximately $201 million.
Abbott has readily available financial resources, including
unused lines of credit that support commercial paper borrowing
arrangements and provide Abbott with the ability to borrow up to
$5 billion on an unsecured basis. On January 29, 2024, Abbott
terminated its 2020 Five Year Credit Agreement (2020 Agreement)
and entered into a new Five Year Credit Agreement (Revolving
Credit Agreement). There were no outstanding borrowings under
the 2020 Agreement at the time of its termination. Any borrowings
under the Revolving Credit Agreement will mature and be payable
on January 29, 2029 and will bear interest, at Abbott’s option, based
on either a base rate or Secured Overnight Financing Rate (SOFR),
plus an applicable margin based on Abbott’s credit ratings.
Principal payments required on long-term debt outstanding at
December 31, 2024 are $1.5 billion in 2025, $2.9 billion in 2026,
$617 million in 2027, $650 million in 2028, $583 million in 2029
and $8.0 billion in 2030 and thereafter.
At December 31, 2024, Abbott’s long-term debt rating was AA-
by S&P Global Ratings and Aa3 by Moody’s Investors Service.
Abbott expects to maintain an investment grade rating.
NOTE 11 — LEASES
LEASES WHERE ABBOTT IS THE LESSEE
Abbott has entered into operating leases as the lessee for office
space, manufacturing facilities, R&D laboratories, warehouses,
vehicles and equipment. Finance leases are not significant.
Abbott’s operating leases generally have remaining lease terms
of 1 to 10 years. Some leases include options to extend beyond the
original lease term, generally up to 10 years and some include
options to terminate early. These options have been included in
the determination of the lease liability when it is reasonably
certain that the option will be exercised.
For all of its asset classes, Abbott elected the practical expedient
allowed under FASB ASC No. 842, “Leases” to account for each
lease component (e.g., the right to use office space) and the
associated non-lease components (e.g., maintenance services)
as a single lease component. Abbott also elected the short-term
lease accounting policy for all asset classes; therefore, Abbott is
not recognizing a lease liability or right of use (ROU) asset for
any lease that, at the commencement date, has a lease term of
12 months or less and does not include an option to purchase the
underlying asset that Abbott is reasonably certain to exercise.
As Abbott’s leases typically do not provide an implicit rate, the
interest rate used to determine the present value of the pay-
ments under each lease typically reflects Abbott’s incremental
borrowing rate based on information available at the lease
commencement date.
The following table provides information related to Abbott’s
operating leases:
(in millions, except weighted averages) 	2024 	2023 	2022
Operating lease cost (a) 	$366 	$356 	$355
Cash paid for amounts included in the
measurement of operating lease liabilities 	300 	276 	274
ROU assets arising from entering into new
operating lease obligations 	253 	253 	263
Weighted average remaining lease term at
December 31 (in years) 	7 	7 	8
Weighted average discount rate at December 31 	3.6% 	3.4% 	2.9%
(a) Includes short-term lease expense and variable lease costs, which were immaterial in the
years ended December 31, 2024, 2023 and 2022.
Future minimum lease payments under non-cancellable operating
leases as of December 31, 2024 were as follows:
(in millions)
2025 	$÷«290
2026 	252
2027 	183
2028 	134
2029 	103
Thereafter 	356
Total future minimum lease payments – undiscounted 	1,318
Less: imputed interest 	(168)
Present value of lease liabilities 	$1,150
The following table summarizes the amounts and location of
operating lease ROU assets and lease liabilities:
(in millions)
December 31 	2024 	2023 	Balance Sheet Caption
Operating Lease –
ROU Asset
$1,075 	$1,122 	Deferred income taxes
and other assets
Operating Lease Liability:
Current 	$÷«254 	$÷«245 	Other accrued liabilities
Non-current 	896 	949 	Post-employment
obligations and other
long-term liabilities
Total Liability 	$1,150 	$1,194
LEASES WHERE ABBOTT IS THE LESSOR
Certain assets, primarily diagnostics instruments, are leased to cus-
tomers under contractual arrangements that typically include an
operating or sales-type lease as well as performance obligations for
reagents and other consumables. Sales-type leases are not signifi-
cant. Contract terms vary by customer and may include options to
terminate the contract or options to extend the contract. Where
instruments are provided under operating lease arrangements,
some portion or the entire lease revenue may be variable and sub-
ject to subsequent non-lease component (e.g., reagent) sales. The
allocation of revenue between the lease and non-lease components
is based on standalone selling prices. Operating lease revenue
represented less than 3 percent of Abbott’s total net sales in the
years ended December 31, 2024, 2023 and 2022.

-- 53 of 86 --

52
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
Assets related to operating leases are reported within Net property
and equipment on the Consolidated Balance Sheet. The original cost
and the net book value of such assets were $3.9 billion and $1.8 billion,
respectively, as of December 31, 2024 and December 31, 2023.
NOTE 12 — FINANCIAL INSTRUMENTS, DERIVATIVES AND
FAIR VALUE MEASURES
Certain Abbott foreign subsidiaries enter into foreign currency
forward exchange contracts to manage exposures to changes in
foreign exchange rates primarily for anticipated intercompany
purchases by those subsidiaries whose functional currencies are
not the U.S. dollar. These contracts, with gross notional amounts
totaling $7.0 billion at December 31, 2024, and $7.3 billion at
December 31, 2023, are designated as cash flow hedges of the
variability of the cash flows due to changes in foreign exchange
rates and are recorded at fair value. Accumulated gains and losses
as of December 31, 2024 will be included in Cost of products sold
at the time the products are sold, generally through the next
twelve to eighteen months.
Abbott enters into foreign currency forward exchange contracts
to manage currency exposures for foreign currency denominated
third-party trade payables and receivables, and for intercompany
loans and trade accounts payable where the receivable or payable
is denominated in a currency other than the functional currency
of the entity. For intercompany loans, the contracts require Abbott
to sell or buy foreign currencies, primarily European currencies,
in exchange for primarily U.S. dollars and European currencies.
For intercompany and trade payables and receivables, the currency
exposures are primarily the U.S. dollar and European currencies.
At December 31, 2024 and 2023, Abbott held gross notional
amounts of $16.2 billion and $13.8 billion, respectively, of such
foreign currency forward exchange contracts.
Abbott has designated a yen-denominated, 5-year term loan of
approximately $583 million and $419 million as of December 31,
2024 and December 31, 2023, respectively, as a hedge of the net
investment in certain foreign subsidiaries. The change in the value
of the debt is due to the net incremental borrowing of $201 million
discussed in Note 10 — Debt and Lines of Credit, as well as
changes in foreign exchange rates, recorded in Accumulated
other comprehensive income (loss), net of tax.
Abbott is a party to interest rate hedge contracts to manage its
exposure to changes in the fair value of fixed-rate debt. These
contracts are designated as fair value hedges of the variability of
the fair value of fixed-rate debt due to changes in the long-term
benchmark interest rates. The effect of the hedge is to change a
fixed-rate interest obligation to a variable rate for that portion
of the debt. Abbott records the contracts at fair value and adjusts
the carrying amount of the fixed-rate debt by an offsetting amount.
Abbott had interest rate contracts totaling approximately
$2.2 billion at December 31, 2024 and 2023.
The following table summarizes the amounts and location of certain derivative financial instruments as of December 31:
(in millions)
Fair Value—Assets 	Fair Value—Liabilities
2024 	2023 	Balance Sheet Caption 	2024 	2023 	Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current 	$÷«— 	$÷«— 	Deferred income taxes
and other assets
$÷51 	$÷95 	Post-employment
obligations and other
long-term liabilities
Current 	1 	— 	Prepaid expenses
and other receivables
— 	— 	Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments 	243 	88 	Prepaid expenses
and other receivables
19 	134 	Other accrued liabilities
Others not designated as hedges 	147 	81 	Prepaid expenses
and other receivables
112 	97 	Other accrued liabilities
Debt designated as a hedge of net investment in a
foreign subsidiary
— 	— 	n/a 	583 	419 	Long-term debt
(Current portion of
long-term debt in 2023)
$391 	$169 	$765 	$745
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges,
debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as
the amounts and location of income (expense) and gain (loss) reclassified into income.
(in millions)
Gain (loss) Recognized in Other
Comprehensive Income (loss)
Income (expense) and Gain (loss)
Reclassified into Income
Income Statement Caption	2024 	2023 	2022 	2024 	2023 	2022
Foreign currency forward exchange contracts
designated as cash flow hedges
$347 	$(22) 	$281 	$103 	$187 	$234 	Cost of products sold
Debt designated as a hedge of net investment in a
foreign subsidiary
37 	27 	75 	n/a 	n/a 	n/a 	n/a
Interest rate swaps designated as fair value hedges 	n/a 	n/a 	n/a 	44 	61 	(243) 	Interest expense

-- 54 of 86 --

53
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
A gain of $131 million, a loss of $44 million and a gain of
$70 million were recognized in 2024, 2023 and 2022, respectively,
related to foreign currency forward exchange contracts not desig-
nated as hedges. These amounts are reported in the Consolidated
Statement of Earnings on the Net foreign exchange (gain) loss line.
The interest rate swaps are designated as fair value hedges of the
variability of the fair value of fixed-rate debt due to changes in
the long-term benchmark interest rates. The hedged debt is
marked to market, offsetting the effect of marking the interest
rate swaps to market.
The carrying values and fair values of certain financial instruments
as of December 31 are shown in the table below. The carrying values
of all other financial instruments approximate their estimated fair
values. The counterparties to financial instruments consist of select
major international financial institutions. Abbott does not expect
any losses from nonperformance by these counterparties.
(in millions)
2024 	2023
Carrying Value 	Fair Value 	Carrying Value 	Fair Value
Long-term Investment Securities:
Equity securities 	$÷÷÷553 	$÷÷÷553 	$÷÷÷555 	$÷÷÷555
Other 	333 	333 	244 	244
Total long-term debt 	(14,125) 	(13,710) 	(14,679) 	(14,769)
Foreign Currency Forward Exchange Contracts:
Receivable position 	390 	390 	169 	169
(Payable) position 	(131) 	(131) 	(231) 	(231)
Interest Rate Hedge Contracts:
Receivable position 	1 	1 	— 	—
(Payable) position 	(51) 	(51) 	(95) 	(95)
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:
(in millions)
Outstanding
Balances
Basis of Fair Value Measurement
Quoted Prices in
Active Markets
Significant Other
Observable
Inputs
Significant
Unobservable
Inputs
December 31, 2024:
Equity securities 	$÷«323 	$323 	$÷÷÷— 	$÷«—
Interest rate swap derivative financial instruments 	1 	— 	1 	—
Foreign currency forward exchange contracts 	390 	— 	390 	—
Total Assets 	$÷«714 	$323 	$÷«391 	$÷«—
Fair value of hedged long-term debt 	$2,096 	$÷«— 	$2,096 	$÷«—
Interest rate swap derivative financial instruments 	51 	— 	51 	—
Foreign currency forward exchange contracts 	131 	— 	131 	—
Contingent consideration related to business combinations 	38 	— 	— 	38
Total Liabilities 	$2,316 	$÷«— 	$2,278 	$÷38
December 31, 2023:
Equity securities 	$326 	$326 	$— 	$÷«—
Foreign currency forward exchange contracts 	169 	— 	169 	—
Total Assets 	$÷«495 	$326 	$÷«169 	$÷«—
Fair value of hedged long-term debt 	$2,052 	$÷«— 	$2,052 	$÷«—
Interest rate swap derivative financial instruments 	95 	— 	95 	—
Foreign currency forward exchange contracts 	231 	— 	231 	—
Contingent consideration related to business combinations 	112 	— 	— 	112
Total Liabilities 	$2,490 	$÷«— 	$2,378 	$112

-- 55 of 86 --

54
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The fair value of foreign currency forward exchange contracts is
determined using a market approach, which utilizes values for
comparable derivative instruments. The fair value of the debt was
determined based on the face value of the debt adjusted for the fair
value of the interest rate swaps, which is based on a discounted
cash flow analysis using significant other observable inputs.
Contingent consideration relates to businesses acquired by Abbott.
The fair value of the contingent consideration was determined based
on independent appraisals at the time of acquisition, adjusted for the
time value of money and other changes in fair value. The decrease in
the amount of contingent consideration from December 31, 2023
reflects a payment of $40 million and a $34 million change in the
fair value of the remaining contingent consideration. The maximum
amount for certain contingent consideration is not determinable as
it is based on a percent of certain sales. Excluding such contingent
consideration, the maximum amount that may be due under the
other contingent consideration arrangements was estimated at
December 31, 2024 to be approximately $65 million, which is depen-
dent upon attaining certain sales thresholds or upon the occurrence
of certain events, such as regulatory approvals.
NOTE 13 — LITIGATION AND ENVIRONMENTAL MATTERS
Abbott has been identified as a potentially responsible party for
investigation and cleanup costs at a number of locations in the
United States and Puerto Rico under federal and state remediation
laws and is investigating potential contamination at a number of
company-owned locations. Abbott has recorded an estimated
cleanup cost for each site for which management believes Abbott
has a probable loss exposure. No individual site cleanup exposure
is expected to exceed $4 million, and the aggregate cleanup expo-
sure is not expected to exceed $10 million.
Abbott has been named as a defendant in a number of lawsuits
alleging that its preterm infant formula and human milk fortifier
products that contain cow’s milk cause an intestinal disease known
as necrotizing enterocolitis (NEC) and inadequately warn about the
risk of NEC. These lawsuits claim that certain preterm infants suf-
fered injury or death as a result of contracting NEC. In a trial held in
July 2024, a jury in a Missouri state court awarded a plaintiff
$495 million in damages. Abbott stands by its products and the
information it provided about them, and it appealed this jury’s ver-
dict with the Missouri Court of Appeals in December 2024. In a trial
held in October 2024 involving Abbott and another infant formula
manufacturer and the treating hospital as co-defendants, a jury in a
Missouri state court returned a unanimous verdict in favor of Abbott
and co-defendants. In December 2024, the plaintiff filed a motion for
a new trial. Abbott does not believe that it is probable that a material
loss will be incurred related to these lawsuits and therefore, no
reserves have been recorded. Given the uncertainty as to the possible
outcome in each of these lawsuits, Abbott is unable to reasonably
estimate a range of possible loss related to these lawsuits.
Abbott is involved in various claims and legal proceedings,
and Abbott estimates the range of possible loss for its legal
proceedings and environmental exposures to be from approxi-
mately $25 million to $35 million. The recorded accrual balance
at December 31, 2024 for these proceedings and exposures was
approximately $30 million. This accrual represents management’s
best estimate of probable loss, as defined by FASB ASC No. 450,
“Contingencies.” Within the next year, legal proceedings may
occur that may result in a change in the estimated loss accrued by
Abbott. While it is not feasible to predict the outcome of all such
proceedings and exposures with certainty, management believes
that their ultimate disposition should not have a material adverse
effect on Abbott’s financial position, cash flows, or results of oper-
ations, except for the cases discussed in the second paragraph of
this note, the resolution of which could be material to Abbott’s
financial position, cash flows, or results of operations.
NOTE 14 — POST-EMPLOYMENT BENEFITS
Retirement plans consist of defined benefit, defined contribution
and medical and dental plans. Information for Abbott’s major
defined benefit plans and post-employment medical and dental
benefit plans is as follows:
(in millions)
Defined Benefit Plans
Medical and
Dental Plans
2024 	2023 	2024 	2023
Projected benefit
obligations, January 1 	$10,030 	$÷9,167 	$1,181 	$1,126
Service cost — benefits
earned during the year 	242 	230 	39 	38
Interest cost on projected
benefit obligations 	469 	455 	54 	59
(Gains) losses, primarily
changes in discount rates,
plan design changes, law
changes and differences
between actual and
estimated health care costs 	(763) 	458 	(33) 	35
Benefits paid 	(398) 	(377) 	(73) 	(77)
Other, including foreign
currency translation 	(130) 	97 	(2) 	—
Projected benefit
obligations, December 31 	$÷9,450 	$10,030 	$1,166 	$1,181
Plan assets at fair value,
January 1 	$13,085 	$11,373 	$÷«288 	$÷«302
Actual return (loss)
on plan assets 	1,259 	1,611 	26 	26
Company contributions 	349 	349 	36 	37
Benefits paid 	(398) 	(377) 	(73) 	(77)
Other, including foreign
currency translation 	(152) 	129 	— 	—
Plan assets at fair value,
December 31 	$14,143 	$13,085 	$÷«277 	$÷«288
Projected benefit obligations
less (greater) than plan
assets, December 31 	$÷4,693 	$÷3,055 	$÷(889) 	$÷(893)
Long-term assets 	$÷5,724 	$÷4,164 	$÷÷÷— 	$÷÷÷—
Short-term liabilities 	(38) 	(36) 	(2) 	(2)
Long-term liabilities 	(993) 	(1,073) 	(887) 	(891)
Net asset (liability) 	$÷4,693 	$÷3,055 	$÷(889) 	$÷(893)
Amounts Recognized
in Accumulated
Other Comprehensive
Income (loss):
Actuarial losses, net 	$÷÷«772 	$÷1,751 	$÷÷«29 	$÷÷«62
Prior service costs (credits) 	5 	6 	(8) 	(22)
Total 	$÷÷«777 	$÷1,757 	$÷÷«21 	$÷÷«40

-- 56 of 86 --

55
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The $763 million of defined benefit plan gains and $33 million
of medical and dental plan gains in 2024 that decreased the
projected benefit obligations primarily reflect the year-over-year
increase in the discount rates used to measure the obligations.
The $458 million of defined benefit plan losses and $35 million
of medical and dental plan losses in 2023 that increased the
projected benefit obligations primarily reflect the year-over-year
decline in the discount rates used to measure the obligations.
The projected benefit obligations for non-U.S. defined benefit
plans were $2.3 billion and $2.6 billion at December 31, 2024
and 2023, respectively. The accumulated benefit obligations for
all defined benefit plans were $8.7 billion and $9.2 billion at
December 31, 2024 and 2023, respectively.
For plans where the projected benefit obligations exceeded
plan assets at December 31, 2024 and 2023, the projected benefit
obligations and the aggregate plan assets were as follows:
(in millions) 	2024 	2023
Projected benefit obligation 	$1,180 	$1,314
Fair value of plan assets 	149 	205
For plans where the accumulated benefit obligations exceeded
plan assets at December 31, 2024 and 2023, the aggregate accumu-
lated benefit obligations, the projected benefit obligations and the
aggregate plan assets were as follows:
(in millions) 	2024 	2023
Accumulated benefit obligation 	$1,112 	$1,175
Projected benefit obligation 	1,180 	1,248
Fair value of plan assets 	149 	144
Retirement plans consist of defined benefit, defined contribution,
and medical and dental plans. Net periodic benefit costs, other
than service costs, are recognized in the Other (income) expense,
net line of the Condensed Consolidated Statement of Earnings.
The components of the net periodic benefit cost as of December 31
were as follows:
(in millions)
Defined
Benefit Plans
Medical and
Dental Plans
2024 	2023 	2022 	2024 	2023 	2022
Service cost — benefits
earned during the year 	$÷÷242 	$«230 	$«374 	$«39 	$«38 	$«50
Interest cost on projected
benefit obligations 	469 	455 	300 	54 	59 	36
Expected return on
plans’ assets 	$(1,050) 	(971) 	(931) 	(24) 	(23) 	(30)
Amortization of actuarial
losses (gains) 	24 	11 	231 	(2) 	(2) 	11
Amortization of prior
service costs (credits) 	1 	1 	1 	(13) 	(13) 	(24)
Total net cost (income) 	$÷«(314) 	$(274) 	$÷(25) 	$«54 	$«59 	$«43
In addition, approximately $15 million of income was recognized in
2023 related to the curtailment of a non-U.S. defined benefit plan.
Other comprehensive income (loss) for each respective year
includes the amortization of actuarial losses and prior service
costs (credits) as noted in the previous table. Other comprehensive
income (loss) for each respective year also includes: net actuarial
gains of $971 million for defined benefit plans and a gain of
$36 million for medical and dental plans in 2024; net actuarial
gains of $182 million for defined benefit plans and a loss of
$33 million for medical and dental plans in 2023, and net actuarial
gains of $858 million for defined benefit plans and a gain of
$374 million for medical and dental plans in 2022. The net actuarial
gains in 2024 related to defined benefit plans are primarily due to
the favorable impact of actual asset returns in excess of expected
returns and the year-over-year increase in discount rates. The net
actuarial gain in 2024 related to medical and dental plans is pri-
marily due to the year-over-year increase in discount rates. The net
actuarial gains in 2023 related to defined benefit plans are primarily
due to the favorable impact of actual asset returns in excess of
expected returns, partially offset by the year-over-year decrease in
discount rates. The net actuarial losses in 2023 related to medical
and dental plans are primarily due to the year-over-year decrease
in discount rates. The net actuarial gains in 2022 were primarily
due to the year-over-year increase in discount rates, partially offset
by the impact of 2022 actual asset returns being less than
expected returns.
The weighted average assumptions used to determine benefit
obligations for defined benefit plans and medical and dental plans
are as follows:
2024 	2023 	2022
Discount rate 	5.4% 	4.8% 	5.0%
Expected aggregate average long-
term change in compensation 	4.6% 	4.6% 	4.5%
The weighted average assumptions used to determine the net
cost for defined benefit plans and medical and dental plans are
as follows:
2024 	2023 	2022
Discount rate 	4.8% 	5.0% 	2.7%
Expected return on plan assets 	7.6% 	7.6% 	7.5%
Expected aggregate average long-
term change in compensation 	4.6% 	4.5% 	4.4%
The assumed health care cost trend rates for medical and dental
plans at December 31 were as follows:
2024 	2023 	2022
Health care cost trend rate
assumed for the next year 	8% 	8% 	7%
Rate that the cost trend rate
gradually declines to 	5% 	5% 	5%
Year that rate reaches the
assumed ultimate rate 	2031 	2029 	2027
The discount rates used to measure liabilities were determined
based on high-quality fixed income securities that match the
duration of the expected retiree benefits. The health care cost
trend rates represent Abbott’s expected annual rates of change in
the cost of health care benefits and are forward projections of
health care costs as of the measurement date.

-- 57 of 86 --

56
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following table summarizes the bases used to measure the defined benefit and medical and dental plan assets at fair value:
(in millions)
Outstanding
Balances
Basis of Fair Value Measurement
Quoted
Prices in
Active Markets
Significant
Other Observable
Inputs
Significant
Unobservable
Inputs
Measured
at NAV ( j)
December 31, 2024
Equities:
U.S. large cap (a) 	$÷3,873 	$2,714 	$÷÷÷— 	$— 	$1,159
U.S. mid and small cap (b) 	918 	909 	— 	1 	8
International (c) 	2,827 	518 	— 	— 	2,309
Fixed income securities:
U.S. government securities (d) 	441 	7 	420 	— 	14
Corporate debt instruments (e) 	1,558 	120 	1,032 	— 	406
Non-U.S. government securities (f ) 	627 	43 	2 	— 	582
Other (g) 	916 	335 	175 	— 	406
Absolute return funds (h) 	1,814 	283 	— 	— 	1,531
Cash and Cash Equivalents 	314 	16 	— 	— 	298
Other (i) 	1,132 	7 	— 	— 	1,125
$14,420 	$4,952 	$1,629 	$«1 	$7,838
December 31, 2023
Equities:
U.S. large cap (a) 	$÷3,425 	$2,305 	$÷÷÷— 	$— 	$1,120
U.S. mid and small cap (b) 	814 	807 	— 	1 	6
International (c) 	2,725 	493 	— 	— 	2,232
Fixed income securities:
U.S. government securities (d) 	391 	5 	371 	— 	15
Corporate debt instruments (e) 	1,519 	125 	1,055 	— 	339
Non-U.S. government securities (f ) 	586 	36 	3 	— 	547
Other (g) 	863 	322 	106 	— 	435
Absolute return funds (h) 	1,669 	270 	— 	— 	1,399
Cash and Cash Equivalents 	276 	16 	— 	— 	260
Other (i) 	1,105 	5 	— 	— 	1,100
$13,373 	$4,384 	$1,535 	$«1 	$7,453
(a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices.
(b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid and small cap indices.
(c) A mix of index funds and actively managed pooled investment funds that are benchmarked to various non-U.S. equity indices in both developed and emerging markets.
(d) A mix of index funds and actively managed accounts that are benchmarked to various U.S. government bond indices.
(e) A mix of index funds and actively managed accounts that are benchmarked to various corporate bond indices.
(f ) Primarily United Kingdom, Canada, Japan and Eurozone government bonds.
(g) Primarily asset backed securities, bank loans, interest rate swap positions and diversified fixed income vehicles benchmarked to SOFR, Sterling Overnight Interbank Average (SONIA)
or EURIBOR.
(h) Primarily hedge funds and funds invested by managers that have a global mandate with the flexibility to allocate capital broadly across a wide range of asset classes and strategies including,
but not limited to equities, fixed income, commodities, interest rate futures, currencies and other securities to outperform an agreed upon benchmark with specific return and volatility targets.
(i) Primarily investments in private funds, such as private equity, private credit, private real estate and private energy funds.
( j) Investments measured at fair value using the net asset value (NAV) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are
intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet.

-- 58 of 86 --

57
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
Equities that are valued using quoted prices are valued at the
published market prices. Equities in a common collective trust or
a registered investment company are valued at the NAV provided
by the fund administrator. The NAV is based on the value of the
underlying assets owned by the fund minus its liabilities. For
approximately half of these funds, investments may be redeemed
once per week or month, with a required 2 to 30 day notice period.
For the remaining funds, daily redemption of an investment is
allowed. Fixed income securities that are valued using significant
other observable inputs are valued at prices obtained from inde-
pendent financial service industry recognized vendors. Abbott
did not have any unfunded commitments related to fixed income
funds at December 31, 2024 and 2023. Fixed income securities in
a common collective trust or a registered investment company
are valued at the NAV provided by the fund administrator. For
the majority of these funds, investments may be redeemed either
weekly or monthly, with a required 2 to 60 day notice period.
For the remaining funds, investments may be generally
redeemed daily.
Absolute return funds are valued at the NAV provided by the fund
administrator. Abbott did not have any unfunded commitments
related to absolute return funds at December 31, 2024 and 2023.
Investments in these funds may be generally redeemed monthly or
quarterly with required notice periods ranging from 5 to 90 days.
For approximately $300 million of the absolute return funds,
redemptions are subject to a 25 percent gate and $60 million is
subject to a lock until 2025. All private funds are valued at the
NAV provided by the fund on a one-quarter lag adjusted for
known cash flows and significant events through the reporting
date. Investments in the private funds cannot be redeemed but the
funds will make distributions through liquidation. The estimate
of the liquidation period for each fund ranges from 2025 to 2034.
Abbott’s unfunded commitment in these funds was $540 million
and $555 million as of December 31, 2024 and 2023, respectively.
The investment mix of equity securities, fixed income and other
asset allocation strategies is based upon achieving a desired
return, as well as balancing higher return, more volatile equity
securities with lower return, less volatile fixed income securities.
Investment allocations are made across a range of markets,
industry sectors, capitalization sizes, and in the case of fixed
income securities, maturities and credit quality. The plans do
not directly hold any securities of Abbott. There are no known
significant concentrations of risk in the plans’ assets. Abbott’s
medical and dental plans’ assets are invested in a similar mix as
the pension plan assets. The actual asset allocation percentages
at year end are consistent with the company’s targeted asset
allocation percentages.
The plans’ expected return on assets, as shown above, is based on
management’s expectations of long-term average rates of return to
be achieved by the underlying investment portfolios. In establishing
this assumption, management considers historical and expected
returns for the asset classes in which the plans are invested, as
well as current economic and capital market conditions.
Abbott funds its domestic pension plans according to U.S. Internal
Revenue Service (IRS) funding limitations. International pension
plans are funded according to similar regulations. Abbott funded
$349 million in 2024 and 2023 to defined pension plans. Abbott
expects to contribute approximately $302 million to its pension
plans in 2025.
Total benefit payments expected to be paid to participants, which
includes payments funded from company assets, as well as paid
from the plans, are as follows:
(in millions)
Defined
Benefit Plans
Medical and
Dental Plans
2025 	$÷«412 	$÷64
2026 	431 	69
2027 	453 	73
2028 	475 	78
2029 	500 	82
2030 to 2034 	2,856 	455
The Abbott Stock Retirement Plan is the principal defined contri-
bution plan. Abbott’s contributions to this plan were $207 million
in 2024, $199 million in 2023 and $190 million in 2022.
NOTE 15 — TAXES ON EARNINGS
Taxes on earnings reflect the annual effective rates, including
charges for interest and penalties. Deferred income taxes reflect the
tax consequences on future years of differences between the tax
bases of assets and liabilities and their financial reporting amounts.
Taxes on earnings include approximately $50 million, $22 million
and $43 million in excess tax benefits associated with share-based
compensation in 2024, 2023 and 2022, respectively. As a result of
the resolution of various tax positions related to prior years, taxes
on earnings in 2024, 2023 and 2022 also include approximately
$25 million, $80 million and $20 million of net tax expense,
respectively. In the fourth quarter of 2024, taxes on earnings
includes $7.5 billion in non-cash valuation allowance adjustments
resulting from the restructuring of certain foreign affiliates and
the confirmation of certain tax filing positions. The restructuring
improved profitability to several of Abbott’s affiliates and manage-
ment concluded that the related preexisting deferred tax assets,
which historically had a full valuation allowance, were more
likely than not to be realizable in future periods. In particular,
Abbott considered the likelihood of sustained ongoing profitability
of the affiliates as a positive factor that outweighed all available
negative evidence considered. Accordingly, Abbott released the
full valuation allowance on such deferred tax assets and recorded
the offset to tax expense.
The TCJA includes a one-time transition tax that is based on
Abbott’s total post-1986 earnings and profits (E&P) that were
previously deferred from U.S. income taxes. The tax computation
also requires the determination of the amount of post-1986
E&P considered held in cash and other specified assets. As of
December 31, 2024, the remaining balance of Abbott’s transition
tax obligation related to the TCJA is approximately $432 million,
which will be paid over the next two years as allowed by the TCJA.
Undistributed foreign earnings remain indefinitely reinvested in
foreign operations. Determining the amount of unrecognized
deferred tax liability related to any remaining undistributed
foreign earnings not subject to the transition tax and additional
outside basis difference in its foreign entities is not practicable.

-- 59 of 86 --

58
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
In the U.S., Abbott’s federal income tax returns through 2016 are
settled. In September 2023, Abbott received a Statutory Notice of
Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS)
for the 2019 Federal tax year in the amount of $417 million. The
primary adjustments proposed in the SNOD relate to the realloca-
tion of income between Abbott’s U.S. entities and its foreign
affiliates. Abbott believes that the income reallocation adjustments
proposed in the SNOD are without merit, in part because certain
adjustments contradict methods that were agreed to with the IRS
in prior audit periods. The SNOD also contains other proposed
adjustments that Abbott believes are erroneous and unsupported.
Abbott filed a petition with the U.S. Tax Court contesting the
SNOD in December 2023.
In June 2024, Abbott received a SNOD from the IRS for the 2017
and 2018 Federal tax years in the amount of $192 million. The
matters proposed in the 2017/2018 SNOD are substantially similar
to the income allocation adjustments included in the 2019 SNOD.
Abbott filed a petition in September 2024 with the U.S. Tax Court
contesting the 2017/2018 SNOD in a manner consistent with its
petition for the 2019 SNOD.
In October 2024, Abbott received a SNOD from the IRS for the
2020 Federal tax year assessing an additional $443 million of
income tax. The primary adjustments proposed in the SNOD
are substantially similar to the income allocation adjustments
included in the 2017/2018 and 2019 SNODs. Abbott believes that
the income reallocation adjustments proposed in the SNOD are
without merit. The SNOD also contains other proposed adjust-
ments and omissions that Abbott believes are erroneous and
unsupported. In addition to the tax assessment for the 2020 tax
year, the 2020 SNOD also contested a deduction for which an
estimated $440 million cash tax benefit would be available in a
different taxable year as allowed under applicable U.S. tax law.
Abbott filed a petition with the U.S. Tax Court contesting the
SNOD in December 2024.
Abbott intends to vigorously defend its filing positions through
ongoing discussions with the IRS, the IRS independent appeals
process and/or through litigation as necessary. Abbott reserves
for uncertain tax positions related to unresolved matters with the
IRS and other taxing authorities. Abbott continues to believe that
its reserves for uncertain tax positions are appropriate.
There are numerous other income tax jurisdictions for which
tax returns are not yet settled, none of which Abbott expects to
be individually significant. Reserves for interest and penalties
are not significant.
The Organization for Economic Cooperation & Development
(OECD) has proposed a two-pillared plan for a revised international
tax system. Pillar 1 proposes to reallocate taxing rights among the
jurisdictions in which in-scope multinational corporations operate.
Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2
proposes to assess a 15 percent minimum tax on the earnings of
in-scope multinational corporations on a country-by-country basis.
Numerous countries have enacted legislation to adopt the Pillar 2
model rules. The enactment of current Pillar 2 model rules did
not and is not projected to have a material impact to Abbott’s
consolidated financial statements.
Earnings before taxes, and the related provisions for taxes on
earnings, were as follows:
(in millions) 	2024 	2023 	2022
Earnings Before Taxes:
Domestic 	$÷÷947 	$1,192 	$3,732
Foreign 	6,066 	5,472 	4,574
Total 	$«7,013 	$6,664 	$8,306
(in millions) 	2024 	2023 	2022
Taxes on Earnings:
Current:
Domestic 	$÷÷497 	$÷«528 	$1,309
Foreign 	1,075 	874 	723
Total current 	1,572 	1,402 	2,032
Deferred:
Domestic 	(459) 	(382) 	(610)
Foreign 	(7,502) 	(79) 	(49)
Total deferred 	(7,961) 	(461) 	(659)
Total 	$(6,389) 	$÷«941 	$1,373
Differences between the effective income tax rate and the U.S.
statutory tax rate were as follows:
2024 	2023 	2022
Statutory tax rate on earnings 	21.0%« 	21.0% 	21.0%
Impact of foreign operations 	(1.8)÷÷ 	(3.6)÷« 	(2.5)÷«
Foreign-derived intangible
income benefit 	(2.3)÷÷ 	(2.2)÷« 	(2.0)÷«
Valuation allowance adjustments 	(107.1)÷÷ 	—÷« 	—÷«
Excess tax benefits related to
stock compensation 	(0.7)÷÷ 	(0.3)÷« 	(0.5)÷«
Research tax credit 	(1.0)÷÷ 	(1.1)÷« 	(0.9)÷«
Resolution of certain tax positions
pertaining to prior years 	0.4÷÷ 	1.2÷« 	0.2÷«
Intercompany restructurings
and integration 	0.2÷÷ 	(1.4)÷« 	—÷«
State taxes, net of federal benefit 	0.3÷÷ 	0.5÷« 	0.7÷«
All other, net 	(0.1)÷÷ 	—÷« 	0.5÷«
Effective tax rate on earnings 	(91.1)«% 	14.1% 	16.5%
Impact of foreign operations is primarily derived from operations
in Puerto Rico, Switzerland, Ireland, the Netherlands, Costa Rica,
Singapore, Malta and Malaysia.

-- 60 of 86 --

59
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The tax effect of the differences that give rise to deferred tax
assets and liabilities were as follows:
(in millions) 	2024 	2023
Deferred tax assets:
Compensation and employee benefits 	$÷÷÷÷— 	$÷÷÷«89
Trade receivable reserves 	230 	221
Research and development costs 	773 	568
Inventory reserves 	168 	198
Lease liabilities 	265 	272
Deferred intercompany profit 	284 	283
NOLs, reserves not currently deductible,
credit carryforwards and other 	10,353 	9,922
Total deferred tax assets before valuation
allowance 	12,073 	11,553
Valuation allowance 	(1,664) 	(8,690)
Total deferred tax assets 	10,409 	2,863
Deferred tax liabilities:
Compensation and employee benefits 	(276) 	—
Depreciation 	(408) 	(414)
Right of Use lease assets 	(249) 	(258)
Other, primarily the excess of book basis over
tax basis of intangible assets 	(1,365) 	(1,777)
Total deferred tax liabilities 	(2,298) 	(2,449)
Total net deferred tax assets (liabilities) 	$÷8,111 	$÷÷«414
The following table summarizes the gross amounts of unrecog-
nized tax benefits without regard to reduction in tax liabilities or
additions to deferred tax assets and liabilities if such unrecognized
tax benefits were settled:
(in millions) 	2024 	2023
January 1 	$3,323 	$2,036
Increase due to current year tax positions 	167 	225
Increase due to prior year tax positions 	174 	1,338
Decrease due to prior year tax positions 	(50) 	(89)
Settlements 	(13) 	(144)
Lapse of statute 	(33) 	(43)
December 31 	$3,568 	$3,323
Abbott’s unrecognized tax benefits table includes amounts related
to tax positions for which a deferred tax asset has not been recog-
nized because the recognition of the future benefit is not expected.
The total amount of unrecognized tax benefits that, if recognized,
would impact the effective tax rate is approximately $2.6 billion.
Abbott believes that it is reasonably possible that the recorded
amount of gross unrecognized tax benefits may decrease approxi-
mately $90 million, including cash adjustments, within the next
twelve months as a result of concluding various domestic and
international tax matters.
NOTE 16 — SEGMENT AND GEOGRAPHIC AREA INFORMATION
Abbott’s principal business is the discovery, development, manu-
facture and sale of a broad line of health care products. Abbott’s
products are generally sold directly to retailers, wholesalers,
hospitals, health care facilities, laboratories, physicians’ offices
and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products—International sales of a
broad line of branded generic pharmaceutical products.
Nutritional Products—Worldwide sales of a broad line of adult
and pediatric nutritional products.
Diagnostic Products—Worldwide sales of diagnostic systems and
tests for blood banks, hospitals, commercial laboratories and
alternate-care testing sites. For segment reporting purposes, the
Core Laboratory Diagnostics, Rapid Diagnostics, Molecular
Diagnostics and Point of Care Diagnostics businesses are aggre-
gated and reported as the Diagnostic Products segment.
Medical Devices—Worldwide sales of rhythm management, elec-
trophysiology, heart failure, vascular, structural heart,
neuromodulation and diabetes care products. For segment report-
ing purposes, the Cardiac Rhythm Management,
Electrophysiology, Heart Failure, Vascular, Structural Heart,
Neuromodulation and Diabetes Care divisions are aggregated and
reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal
entity basis for government and public reporting requirements.
Segment disclosures are on a performance basis consistent with
internal management reporting. The chief operating decision
maker (CODM) at Abbott is the Chief Executive Officer (CEO).
The CODM primarily considers sales and operating margin to
assess the performance of segments and to allocate resources,
where segment operating margin profitability includes cost of
products sold and operating expenses. The cost of some corpo-
rate functions and the cost of certain employee benefits are
charged to segments at predetermined rates that approximate
cost. Remaining costs, if any, are not allocated to segments. In
addition, intangible asset amortization is not allocated to operat-
ing segments, and intangible assets and goodwill are not included
in the measure of each segment’s assets.

-- 61 of 86 --

60
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above,
and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
(in millions)
Net Sales to External
Customers (a)
Cost of
Products Sold
Research and
Development
Selling, General and
Administrative
Operating
Earnings (a)
2024 	2023 	2022 	2024 	2023 	2022 	2024 	2023 	2022 	2024 	2023 	2022 	2024 	2023 	2022
Established
Pharmaceuticals 	$÷5,194 $÷5,066 $÷4,912 $÷(2,444) $÷(2,357) $÷(2,305) 	$÷«(176) $÷«(173) $÷«(186) $÷«(1,341) $(1,330) $(1,372) 	$÷1,233 $÷1,206 $÷1,049
Nutritionals 	8,413 	8,154 	7,459 	(4,532) 	(4,495) 	(4,314) 	(209) 	(204) 	(191) 	(2,167) 	(2,122) 	(2,248) 	1,505 	1,333 	706
Diagnostics (b) 	9,341 	9,988 	16,469 	(4,995) 	(5,264) 	(7,287) 	(656) 	(698) 	(777) 	(1,617) 	(1,593) 	(1,765) 	2,073 	2,433 	6,640
Medical Devices (b) 	18,986 	16,887 	14,802 	(6,408) 	(5,803) 	(4,968) 	(1,546) 	(1,362) 	(1,328) 	(4,879) 	(4,416) 	(4,070) 	6,153 	5,306 	4,436
Total 	$41,934 $40,095 $43,642 $(18,379) $(17,919) $(18,874) 	$(2,587) $(2,437) $(2,482) $(10,004) $(9,461) $(9,456) 	$10,964 $10,278 $12,831
Other 	16 	14 	11
Net sales 	$41,950 $40,109 $43,653
Corporate functions
and plan benefit costs 	(422) 	(308) 	(509)
Net interest expense 	(215) 	(252) 	(375)
Share-based
compensation 	(673) 	(644) 	(685)
Amortization of
Intangible assets 	(1,878) 	(1,966) 	(2,013)
Other, net (c) 	(763) 	(444) 	(943)
Earnings before Taxes 	$÷7,013 $÷6,664 $÷8,306
(a) In 2024, 2023 and 2022, foreign exchange unfavorably impacted net sales and operating earnings.
(b) 2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health
business from Diagnostic Products to Medical Devices on January 1, 2023.
(c) Other, net includes costs directly related to integrating acquired businesses and restructuring charges in 2024, 2023, and 2022. Charges and expenses for restructuring actions and other cost
reduction initiatives were approximately $185 million in 2024, $122 million in 2023, and $265 million in 2022. Other, net also includes: in 2024, a $143 million loss on the divestiture of a
non-core business, as well as intangible and IRP&D asset impairments; in 2023, charges of $100 million related to intangible asset impairments, partially offset by income arising from fair value
changes in contingent consideration related to previous business acquisitions; and in 2022, charges of $176 million related to a voluntary recall within the Nutritional products segment and
charges of $111 million related to the impairment of IPR&D intangible assets.
(in millions)
Depreciation
Additions to
Property and Equipment 	Total Assets
2024 	2023 	2022 	2024 	2023 	2022 	2024 	2023 	2022
Established Pharmaceuticals 	$÷÷«96 	$÷«104 	$÷÷«97 	$÷«183 	$÷«185 	$÷«175 	$÷3,087 	$÷3,118 	$÷2,883
Nutritionals 	159 	155 	155 	382 	457 	251 	4,404 	4,270 	3,625
Diagnostics 	521 	499 	494 	758 	750 	832 	7,678 	7,767 	7,985
Medical Devices 	343 	315 	311 	630 	604 	335 	9,472 	9,029 	7,844
Total Reportable Segments 	1,119 	1,073 	1,057 	1,953 	1,996 	1,593 	$24,641 	$24,184 	$22,337
Other 	221 	204 	197 	292 	213 	182
Total 	$1,340 	$1,277 	$1,254 	$2,245 	$2,209 	$1,775
(in millions) 	2024 	2023
Total Reportable Segment Assets 	$24,641 	$24,184
Cash and investments 	8,853 	8,078
Goodwill and intangible assets 	29,755 	32,494
All other (e) 	18,165 	8,458
Total Assets 	$81,414 	$73,214
(d) Amounts exclude property, plant and equipment acquired through business acquisitions.
(e) All other includes the long-term assets associated with the defined benefit plans of $5.7 billion in 2024 and $4.2 billion in 2023. In 2024, all other also includes $7.5 billion deferred tax assets
for which full valuation allowances were adjusted in 2024.

-- 62 of 86 --

61
A B B O T T 2 0 2 4 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
(in millions)
Net Sales to External Customers (f )
2024 	2023 	2022
United States 	$16,323 	$15,452 	$18,142
Germany 	2,539 	2,345 	2,340
China 	2,113 	2,253 	2,133
India 	1,817 	1,750 	1,649
Switzerland 	1,747 	1,638 	1,336
Japan 	1,441 	1,513 	1,932
Netherlands 	1,124 	1,074 	1,111
All Other Countries 	14,846 	14,084 	15,010
Consolidated 	$41,950 	$40,109 	$43,653
(f ) Sales by country are based on the country that sold the product..
Long-lived assets on a geographic basis primarily include property
and equipment. It excludes goodwill, intangible assets, deferred
tax assets, and financial instruments. At December 31, 2024 and
2023, long-lived assets totaled $18.5 billion and $16.2 billion,
respectively, and in the United States such assets totaled
$10.3 billion and $8.9 billion, respectively. Long-lived asset
balances associated with other countries were not material
on an individual country basis in either of the two years.

-- 63 of 86 --

62
A B B O T T 2 0 2 4 A N N U A L R E P O R T
M A N A G E M E N T R E P O R T O N I N T E R N A L
C O N T R O L O V E R F I N A N C I A L R E P O R T I N G
R E P O R T O F I N D E P E N D E N T R E G I S T E R E D
P U B L I C A C C O U N T I N G F I R M
The management of Abbott Laboratories is responsible for estab-
lishing and maintaining adequate internal control over financial
reporting. Abbott’s internal control system was designed to pro-
vide reasonable assurance to the company’s management and
board of directors regarding the preparation and fair presentation
of published financial statements.
All internal control systems, no matter how well designed, have
inherent limitations. Therefore, even those systems determined
to be effective can provide only reasonable assurance with respect
to financial statement preparation and presentation.
Abbott’s management assessed the effectiveness of the company’s
internal control over financial reporting as of December 31, 2024.
In making this assessment, it used the criteria set forth in Internal
Control — Integrated Framework (2013) issued by the Committee
of Sponsoring Organizations of the Treadway Commission. Based
on our assessment, we believe that, as of December 31, 2024, the
company’s internal control over financial reporting was effective
based on those criteria.
Abbott’s independent registered public accounting firm has
issued an audit report on their assessment of the effectiveness
of the company’s internal control over financial reporting.
This report appears on page 79.
Robert B. Ford
Chairman of the Board and Chief Executive Officer
Philip P. Boudreau
Executive Vice President, Finance and Chief Financial Officer
John A. McCoy, Jr.
Vice President, Finance and Controller
February 21, 2025
To the Shareholders and the Board of Directors of Abbott
Laboratories
OPINION ON THE FINANCIAL STATEMENTS
We have audited the accompanying consolidated balance sheets
of Abbott Laboratories and subsidiaries (the Company) as of
December 31, 2024 and 2023, the related consolidated statements
of earnings, comprehensive income, shareholders’ investment
and cash flows for each of the three years in the period ended
December 31, 2024, and the related notes (collectively referred
to as the “consolidated financial statements”). In our opinion, the
consolidated financial statements present fairly, in all material
respects, the financial position of the Company at December 31,
2024 and 2023, and the results of its operations and its cash flows
for each of the three years in the period ended December 31, 2024,
in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States)
(PCAOB), the Company’s internal control over financial reporting
as of December 31, 2024, based on criteria established in Internal
Control—Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (2013
framework), and our report dated February 21, 2025 expressed
an unqualified opinion thereon.
BASIS FOR OPINION
These financial statements are the responsibility of the
Company’s management. Our responsibility is to express an
opinion on the Company’s financial statements based on our
audits. We are a public accounting firm registered with the
PCAOB and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws
and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error
or fraud. Our audits included performing procedures to assess the
risks of material misstatement of the financial statements, whether
due to error or fraud, and performing procedures that respond to
those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis
for our opinion.

-- 64 of 86 --

63
A B B O T T 2 0 2 4 A N N U A L R E P O R T
CRITICAL AUDIT MATTER
The critical audit matter communicated below is a matter arising
from the current period audit of the financial statements that
was communicated or required to be communicated to the audit
committee and that: (1) relates to accounts or disclosures that are
material to the financial statements and (2) involved our especially
challenging, subjective or complex judgments. The communication
of the critical audit matter does not alter in any way our opinion
on the consolidated financial statements, taken as a whole, and
we are not, by communicating the critical audit matter below,
providing a separate opinion on the critical audit matter or on
the accounts or disclosures to which it relates.
Income taxes – Unrecognized tax benefits
Description of the Matter
As described in Note 15 to the consolidated financial statements,
unrecognized tax benefits were approximately $3.6 billion at
December 31, 2024. Unrecognized tax benefits are assessed by
management quarterly for identification and measurement, or
more frequently if there are any indicators suggesting a change
in unrecognized tax benefits. Assessing tax positions involves
judgment including interpreting tax laws of multiple jurisdictions
and assumptions relevant to the measurement of an unrecognized
tax benefit, including the estimated amount of tax liability that
may be incurred should the tax position not be sustained upon
inspection by a tax authority. These judgments and assumptions
can significantly affect unrecognized tax benefits.
How We Addressed the Matter in our Audit
We obtained an understanding, evaluated the design and tested
the operating effectiveness of controls over the Company’s
identification and measurement of unrecognized tax benefits, as
well as its process for the assessment of events that may indicate
a change in unrecognized tax benefits is warranted. For example,
we tested controls over management’s review of the completeness
of identified unrecognized tax benefits, as well as controls over
management’s review of significant assumptions used within the
measurement of unrecognized tax benefits.
With the support of our tax professionals, among other audit
procedures performed, we evaluated the reasonableness of
management’s judgment with respect to the interpretation of tax
laws of multiple jurisdictions by reading and evaluating manage-
ment’s documentation, including relevant accounting policies,
and by considering how tax laws, including statutes, regulations,
and case law, affected management’s judgments. We tested the
completeness of management’s assessment of the identification
of unrecognized tax benefits including evaluation of the technical
merits of the unrecognized tax benefits. We also tested the
appropriateness and consistency of management’s methods and
significant assumptions associated with the measurement of
unrecognized tax benefits, including assessing the estimated
amount of tax liability that may be incurred should the tax
position not be sustained upon inspection by a tax authority.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2013.
Chicago, Illinois
February 21, 2025

-- 65 of 86 --

64
A B B O T T 2 0 2 4 A N N U A L R E P O R T
DEFINITION AND LIMITATIONS OF INTERNAL CONTROL
OVER FINANCIAL REPORTING
A company’s internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted
accounting principles. A company’s internal control over financial
reporting includes those policies and procedures that (1) pertain
to the maintenance of records that, in reasonable detail, accurately
and fairly reflect the transactions and dispositions of the assets of
the company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company are
being made only in accordance with authorizations of manage-
ment and directors of the company; and (3) provide reasonable
assurance regarding prevention or timely detection of unautho-
rized acquisition, use, or disposition of the company’s assets that
could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projec-
tions of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with
the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Chicago, Illinois
February 21, 2025
R E P O R T O F I N D E P E N D E N T R E G I S T E R E D
P U B L I C A C C O U N T I N G F I R M
To the Shareholders and the Board of Directors of Abbott Laboratories
OPINION ON INTERNAL CONTROL
OVER FINANCIAL REPORTING
We have audited Abbott Laboratories and subsidiaries’ internal
control over financial reporting as of December 31, 2024, based on
criteria established in Internal Control—Integrated Framework
issued by the Committee of Sponsoring Organizations of the
Treadway Commission (2013 framework) (the COSO criteria). In our
opinion, Abbott Laboratories and subsidiaries (the Company) main-
tained, in all material respects, effective internal control over financial
reporting as of December 31, 2024, based on the COSO criteria.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States)
(PCAOB), the consolidated balance sheets of the Company as of
December 31, 2024 and 2023, the related consolidated statements
of earnings, comprehensive income, shareholders’ investment
and cash flows for each of the three years in the period ended
December 31, 2024, and the related notes and our report dated
February 21, 2025 expressed an unqualified opinion thereon.
BASIS FOR OPINION
The Company’s management is responsible for maintaining
effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial
reporting included in the accompanying Management Report on
Internal Control Over Financial Reporting. Our responsibility is
to express an opinion on the Company’s internal control over
financial reporting based on our audit. We are a public accounting
firm registered with the PCAOB and are required to be independent
with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether effective
internal control over financial reporting was maintained in all
material respects.
Our audit included obtaining an understanding of internal
control over financial reporting, assessing the risk that a material
weakness exists, testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk, and
performing such other procedures as we considered necessary in
the circumstances. We believe that our audit provides a reasonable
basis for our opinion.

-- 66 of 86 --

65
A B B O T T 2 0 2 4 A N N U A L R E P O R T
F I N A N C I A L I N S T R U M E N T S A N D R I S K M A N A G E M E N T
MARKET PRICE SENSITIVE INVESTMENTS
The fair value of equity securities held by Abbott with a readily
determinable fair value was approximately $10 million and
$12 million as of December 31, 2024 and 2023, respectively.
These equity securities are subject to potential changes in fair
value. A hypothetical 20 percent decrease in the share prices of
these investments would decrease their fair value at December 31,
2024 by approximately $2 million. Changes in the fair value of
these securities are recorded in earnings. The fair value of
investments in mutual funds that are held in a rabbi trust for
the purpose of paying benefits under a deferred compensation
plan was approximately $313 million and $314 million as of
December 31, 2024 and 2023, respectively. Changes in the fair
value of these investments, as well as an offsetting change in
the benefit obligation, are recorded in earnings.
NON-PUBLICLY TRADED EQUIT Y SECURITIES
Abbott holds equity securities that are not traded on public
stock exchanges. The carrying value of these investments was
$91 million and $88 million as of December 31, 2024 and 2023,
respectively. No individual investment is recorded at a value in
excess of $20 million. Abbott measures these investments at cost
minus impairment, if any, plus or minus changes resulting from
observable price changes in orderly transactions for the identical
or a similar investment of the same issuer.
INTEREST RATE SENSITIVE FINANCIAL INSTRUMENTS
At December 31, 2024 and 2023, Abbott had interest rate hedge
contracts with notional values totaling $2.2 billion to manage its
exposure to changes in the fair value of debt. The effect of these
hedges is to change the fixed interest rate to a variable rate for the
portion of the debt that is hedged. Abbott does not use derivative
financial instruments, such as interest rate swaps, to manage its
exposure to changes in interest rates for its investment securities.
The fair value of long-term debt at December 31, 2024 and 2023
amounted to $13.7 billion and $14.8 billion, respectively (average
interest rates of 3.8% and 3.6% as of December 31, 2024 and 2023,
respectively) with maturities through 2046. At December 31, 2024
and 2023, the fair value of current and long-term investment
securities amounted to approximately $1.2 billion. A hypothetical
100-basis point change in the interest rates would not have a
material effect on cash flows, income or fair values.
FOREIGN CURRENCY SENSITIVE FINANCIAL INSTRUMENTS
Certain Abbott foreign subsidiaries enter into foreign currency
forward exchange contracts to manage exposures to changes in
foreign exchange rates for anticipated intercompany purchases
by those subsidiaries whose functional currencies are not the
U.S. dollar. These contracts are designated as cash flow hedges of
the variability of the cash flows due to changes in foreign currency
exchange rates and are marked-to-market with the resulting gains
or losses reflected in Accumulated other comprehensive income
(loss). Gains or losses will be included in Cost of products sold at
the time the products are sold, generally within the next twelve
to eighteen months. At December 31, 2024 and 2023, Abbott held
$7.0 billion and $7.3 billion of notional values, respectively, of
such contracts. Contracts held at December 31, 2024 will mature
in 2025 or 2026 depending on the contract. Contracts held at
December 31, 2023 matured in 2024 or will mature in 2025
depending upon the contract.
Abbott enters into foreign currency forward exchange contracts
to manage its exposure to foreign currency denominated inter-
company loans and trade payables and third-party trade payables
and receivables. The contracts are marked-to-market, and resulting
gains or losses are reflected in income and are generally offset by
losses or gains on the foreign currency exposure being managed.
At December 31, 2024 and 2023, Abbott held $16.2 billion and
$13.8 billion of notional values, respectively, of such contracts,
which mature within 13 months.
Abbott has designated a yen-denominated, 5-year term loan of
approximately $583 million and $419 million as of December 31,
2024 and December 31, 2023, respectively, as a hedge of the net
investment in certain foreign subsidiaries. The change in the value
of the debt is due to net incremental borrowing of $201 million,
discussed in Note 10 — Debt and Lines of Credit, as well as
changes in foreign exchange rates, recorded in Accumulated
other comprehensive income (loss), net of tax.
The following table reflects the total foreign currency forward exchange contracts outstanding at December 31, 2024 and 2023:
(dollars in millions)
2024 	2023
Contract
Amount
Weighted
Average
Exchange
Rate
Fair and
Carrying
Value
Receivable/
(Payable)
Contract
Amount
Weighted
Average
Exchange
Rate
Fair and
Carrying
Value
Receivable/
(Payable)
Primarily U.S. dollars to be exchanged for
the following currencies:
Euro 	$10,954 	1.0848 	$136 	$÷9,221 	1.0865 	$(35)
Chinese Yuan 	1,926 	7.1132 	22 	2,115 	7.0785 	3
Japanese Yen 	1,479 	149.1298 	51 	1,635 	138.2288 	24
All other currencies 	8,832 	n/a 	50 	8,189 	n/a 	(54)
Total 	$23,191 	$259 	$21,160 	$(62)

-- 67 of 86 --

F I N A N C I A L R E V I E W
66
A B B O T T 2 0 2 4 A N N U A L R E P O R T
Abbott’s revenues are derived primarily from the sale of a broad
line of health care products, which include medical devices,
diagnostic testing products, nutritional products and branded
generic pharmaceuticals. These products are sold under short-
term receivable arrangements. Patent protection and licenses,
technological and performance features, and inclusion of Abbott’s
products under a contract most impact which products are sold;
price controls, competition and rebates most impact the net selling
prices of products; and the measurement of net sales and costs is
impacted by foreign currency translation. Sales in international
markets comprise 61 percent of consolidated net sales.
Abbott’s sales growth in 2024 was primarily driven by the
Medical Devices, Established Pharmaceutical and Nutritional
businesses. The growth is the result of a productive research and
development (R&D) pipeline and a combination of the introduc-
tion of new products and indication expansions across various
businesses. Sales growth was negatively impacted by continued
year-over-year decline in COVID-19 testing-related sales, as the
COVID-19 pandemic shifted to an endemic state. In 2024, 2023
and 2022, Abbott’s COVID-19 testing related sales total
$747 million, $1.6 billion and $8.4 billion, respectively. Sales in
emerging markets, which represent approximately 37 percent of
total company sales, increased 8.2 percent in 2024 and 5.4 percent
in 2023, excluding the impact of foreign exchange. (Emerging
markets include all countries, except the United States, Japan,
Canada, Australia, New Zealand, the United Kingdom and
Western European countries.)
Abbott’s operating margin profile increased in 2024 to 16.3 percent
from 16.2 percent in 2023. The increase in 2024 reflects the favorable
impact of margin improvement initiatives, partially offset by foreign
exchange and inflation. In 2022, operating margin as a percentage of
sales was 19.2 percent. The decrease in 2023 from 2022 reflects the
unfavorable effects of lower COVID-19 testing-related sales, foreign
exchange, and higher costs for various manufacturing inputs. In
2023, these unfavorable effects were partially offset by the favorable
impact of margin improvement initiatives.
With respect to the performance of each reportable segment
over the last three years, sales in the Medical Devices segment,
excluding the impact of foreign exchange, increased 13.7 percent
in 2024 and 15.1 percent in 2023. In Medical Devices, sales in 2024
and 2023 increased across all businesses, with double-digit growth
in Diabetes Care, Structural Heart, Electrophysiology, and Heart
Failure. In 2023, Neuromodulation sales also increased double
digits. Growth was led by Diabetes Care where sales of Abbott’s
continuous glucose monitoring (CGM) systems continued to
increase and totaled $6.4 billion in 2024 and $5.3 billion in 2023.
In 2024, key product approvals in the Medical Devices
segment included:
• U.S. Food and Drug Administration (FDA) clearance for two
new over-the-counter CGM systems, Lingo® and Libre Rio™,
which are based on Abbott’s FreeStyle Libre® CGM technology,
• FDA approval of the Esprit™ below-the-knee (BTK) system,
which is designed to keep arteries open in people living with
peripheral artery disease and deliver a drug to support vessel
healing prior to completely dissolving,
• FDA approval of TriClip®, which provides a minimally invasive
treatment option for patients with tricuspid regurgitation, or a
leaky tricuspid heart valve,
• CE Mark for the Aveir® dual chamber (DR) leadless pacemaker
system, which is the world’s first dual chamber leadless pace-
maker system that treats people with abnormal or slow heart
rhythms, and
• FDA clearance for Advisor® HD Grid X Mapping Catheter,
Sensor Enabled™, which will further support mapping of
both pulsed field ablation (PFA) and radiofrequency (RF)
ablation cases.
Operating earnings for the Medical Devices segment increased
16.0 percent in 2024 and 19.6 percent in 2023. The operating
margin profile for the Medical Devices segment increased from
30.0 percent in 2022 to 31.4 percent in 2023 and then increased
to 32.4 percent in 2024. The increase in 2024 from 2022 reflects
the impact of higher sales volumes across the Medical Devices
businesses.
In Abbott’s Diagnostics segment, sales decreased 3.9 percent in
2024 and 38.2 percent in 2023, excluding the impact of foreign
exchange. The 2024 and 2023 sales decreases were driven by
continued lower demand for the company’s portfolio of COVID-19
tests, partially offset by higher volume of routine diagnostic tests
in the Rapid Diagnostics and Core Laboratory businesses and the
continued deployment of Abbott’s Alinity® testing platform.
Abbott continues to build out its test menu for the Alinity testing
platform. In the first quarter of 2024, Abbott received FDA clear-
ance of its i-STAT™ traumatic brain injury (TBI) cartridge for use
with the i-STAT Alinity instrument, a whole blood point-of-care
test to help assess mild TBI. In the fourth quarter of 2023, Abbott
received FDA approval of its new laboratory automation system,
GLP systems Track™, to help laboratories optimize lab perfor-
mance by consolidating multiple analytical instruments into a
unified workflow.
In 2024, operating earnings for the Diagnostics segment
decreased 14.8 percent. The operating margin profile decreased
from 40.3 percent in 2022 to 22.2 percent in 2024 primarily due
to lower demand for Abbott’s COVID-19 tests.

-- 68 of 86 --

F I N A N C I A L R E V I E W
67
A B B O T T 2 0 2 4 A N N U A L R E P O R T
In Abbott’s Nutritional Products segment, total pediatric nutri-
tion sales, excluding the impact of foreign exchange, increased
3.7 percent in 2024 and 14.8 percent in 2023, which includes
market share recovery in the U.S. infant formula business follow-
ing the voluntary recall of certain products in 2022, as discussed
below, and the continued favorable impact of price increase ini-
tiatives. Excluding the impact of foreign exchange, total adult
nutrition sales increased 8.0 percent in 2024 and 8.8 percent in
2023, led by the continued growth of Abbott’s Ensure® and
Glucerna® products. U.S. Adult Nutritionals sales were partially
offset by the discontinuation of the ZonePerfect® product line.
In 2024, operating earnings for the Nutritional Products segment
increased 12.9 percent compared to 2023. Operating margin profile
for this segment increased from 9.5 percent in 2022 to 16.4 percent
in 2023 and then increased to 17.9 percent in 2024. The increase in
2024 reflects the favorable effects of higher sales, the favorable
impact of price increases and a continued focus on margin
improvement initiatives. The increase in 2023 reflects the
favorable effects of higher sales and a continued focus on margin
improvement initiatives, partially offset by higher commodity
and other costs.
In February 2022, Abbott’s U.S. Pediatric Nutrition business was
impacted by a voluntary recall of certain infant powder formula
products manufactured at its facility in Sturgis, Michigan, at
which time the company temporarily stopped operations at that
facility. Abbott took various actions to mitigate the impact of the
recall on the supply of formula in the U.S. Abbott resumed opera-
tions later in 2022 and made significant progress through 2023
to increase production of infant formula in the U.S and recover
market share. Beginning in the fourth quarter of 2023 and through
2024, Abbott has regained and maintained its market-leading
position in the U.S., as measured on a volume basis.
The Established Pharmaceutical Products segment focuses on
the sale of its products in emerging markets. Excluding the impact
of foreign exchange, Established Pharmaceutical sales increased
9.2 percent in 2024 and 10.9 percent in 2023. The sales increase
in 2024 was led by higher revenue in several countries in Latin
America, Southeast Asia and the Middle East and across several
therapeutic areas, including respiratory, gastroenterology, cardio-
metabolic and central nervous system/pain management. The
sales increase in 2023 reflects higher sales in several geographies
including India, Vietnam, and Brazil. In 2024, operating earnings
for the Established Pharmaceutical Products segment increased
2.2 percent. Operating margin profile increased from 21.4 percent
in 2022 to 23.7 percent in 2024 primarily due to the impact of
margin improvement initiatives and higher sales, partially offset
by inflation on various product inputs.
With respect to Abbott’s financial position, at December 31, 2024
and 2023, Abbott’s cash and cash equivalents and short-term invest-
ments total approximately $8.0 billion and $7.3 billion, respectively.
Abbott’s long-term debt totals $14.1 billion and $14.7 billion at
December 31, 2024 and 2023, respectively.
Abbott declared dividends of $2.24 per share in 2024 and
$2.08 per share in 2023, an increase of 7.7 percent. Dividends paid
totaled $3.8 billion in 2024 compared to $3.6 billion in 2023. The
year-over-year change in the amount of dividends paid reflects the
increase in the dividend rate. In December 2024, Abbott increased
the company’s quarterly dividend by 7.3 percent to $0.59 per share
from $0.55 per share, effective with the dividend paid in February
2025. In December 2023, Abbott increased the company’s quarterly
dividend by 7.8 percent to $0.55 per share from $0.51 per share,
effective with the dividend paid in February 2024.
On September 22, 2023, Abbott completed the acquisition of
Bigfoot Biomedical, Inc. (Bigfoot), which furthers Abbott’s efforts
to develop connected solutions for making diabetes management
more personal and precise. On April 27, 2023, Abbott completed
the acquisition of Cardiovascular Systems, Inc. (CSI). CSI’s
atherectomy system, which is used in treating peripheral and
coronary artery disease, adds complementary technologies to
Abbott’s portfolio of vascular device offerings.
In 2025, Abbott will focus on continuing to invest in product
development areas that provide the opportunity for strong
sustainable growth over the next several years. In its diagnostics
business, Abbott’s focus will include driving sales growth from
its Alinity suite of diagnostics instruments along with GLP track
integration and its portfolio of rapid diagnostic testing systems.
In the medical devices business, Abbott will focus on growing
recently launched new products and expanding its market
position across the various businesses. In its nutritional business,
Abbott will continue to focus on driving growth globally and
further enhancing its portfolio with the introduction of science-
based products and line extensions. In the established
pharmaceuticals business, Abbott will continue to focus on
growing its business with the depth and breadth of its portfolio
in emerging markets.
CRITICAL ACCOUNTING POLICIES
Sales Rebates — In 2024, 48 percent of Abbott’s consolidated
gross revenues were subject to various forms of rebates and
allowances that Abbott recorded as reductions of revenues at
the time of sale. Most of these rebates and allowances in 2024 are
in the Nutritional Products and Diabetes Care businesses. Abbott
provides rebates to state agencies that administer the Special
Supplemental Nutrition Program for Women, Infants, and
Children (WIC), wholesalers, group purchasing organizations, and
other government agencies and private entities. Rebate amounts
are usually based upon the volume of purchases using contractual
or statutory prices for a product. Factors used in the rebate calcu-
lations include the identification of which products have been sold
subject to a rebate, which customer or government agency price
terms apply, and the estimated lag time between sale and payment
of a rebate. Using historical trends, adjusted for current changes,
Abbott estimates the amount of the rebate that will be paid, and

-- 69 of 86 --

F I N A N C I A L R E V I E W
68
A B B O T T 2 0 2 4 A N N U A L R E P O R T
records the liability as a reduction of gross sales when Abbott
records its sale of the product. Settlement of the rebate generally
occurs from one to six months after sale. Abbott regularly analyzes
the historical rebate trends and makes adjustments to reserves for
changes in trends and terms of rebate programs. Rebates and
chargebacks charged against gross sales in 2024, 2023, and 2022
amounted to $4.4 billion in 2024 and $3.9 billion in 2023 and
2022, or 18.6 percent, 17.4 percent, and 17.6 percent of gross sales,
respectively, based on gross sales of approximately $23.5 billion,
$22.7 billion, and $22.4 billion, respectively, subject to rebate.
A one-percentage point increase in the percentage of rebates to
related gross sales would decrease net sales by approximately
$235 million in 2024. Abbott considers a one-percentage point
increase to be a reasonably likely increase in the percentage of
rebates to related gross sales. Other allowances charged against
gross sales were approximately $319 million, $263 million, and
$280 million for cash discounts in 2024, 2023, and 2022, respec-
tively, and $211 million, $169 million, and $379 million for returns
in 2024, 2023, and 2022, respectively. Cash discounts are known
within 15 to 30 days of sale, and therefore can be reliably estimated.
Returns can be reliably estimated because Abbott’s historical
returns are low, and because sales returns terms and other sales
terms have remained relatively unchanged for several periods.
Management analyzes the adequacy of ending rebate accrual
balances each quarter. In the domestic nutritional business,
management uses both internal and external data available to
estimate the accruals. In the WIC business, estimates are required
for the amount of WIC sales within each state where Abbott holds
the WIC contract. The state where the sale is made, which is the
determining factor for the applicable rebated price, is reliably
determinable. Rebated prices are based on contractually obligated
agreements generally lasting a period of two to four years. Except
for a change in contract price or a transition period before or after
a change in the supplier for the WIC business in a state, accruals
are based on historical redemption rates and data from the U.S.
Department of Agriculture (USDA) and the states submitting
rebate claims. The USDA, which administers the WIC program,
has been making its data available for many years. Management
also estimates the states’ processing lag time based on sales and
claims data. Management has access to several large customers’
inventory management data, which allows management to make
reliable estimates of inventory in the retail distribution channel.
At December 31, 2024, Abbott had WIC business in 42 states.
Historically, adjustments to prior years’ rebate accruals have not
been material to net earnings. Abbott employs various techniques
to verify the accuracy of claims submitted to it, and where possible,
works with the organizations submitting claims to gain insight
into changes that might affect the rebate amounts. For government
agency programs, the calculation of a rebate involves interpreta-
tions of relevant regulations, which are subject to challenge or
change in interpretation.
Income Taxes — Abbott operates in numerous countries where its
income tax returns are subject to audits and adjustments. Because
Abbott operates globally, the nature of the audit items is often very
complex, and the objectives of the government auditors can result
in a tax on the same income in more than one country. Abbott
employs internal and external tax professionals to minimize audit
adjustment amounts where possible. In accordance with the
accounting rules relating to the measurement of tax contingencies,
in order to recognize an uncertain tax benefit, the taxpayer must
be more likely than not of sustaining the position, and the measure-
ment of the benefit is calculated as the largest amount that is more
than 50 percent likely to be realized upon resolution of the benefit.
Application of these rules requires a significant amount of judgment.
In the U.S., Abbott’s federal income tax returns through 2016 were
settled as of December 31, 2024. Undistributed foreign earnings
remain indefinitely reinvested in foreign operations. Determining
the amount of unrecognized deferred tax liability related to any
remaining undistributed foreign earnings not subject to the transi-
tion tax and additional outside basis difference in its foreign
entities is not practicable.
Pension and Post-Employment Benefits — Abbott offers pension
benefits and post-employment health care to many of its employees.
Abbott engages outside actuaries to assist in the determination
of the obligations and costs under these programs. Abbott must
develop long-term assumptions, the most significant of which are
the health care cost trend rates, discount rates and the expected
return on plan assets. The discount rates used to measure liabilities
were determined based on high-quality fixed income securities
that match the duration of the expected retiree benefits. The
health care cost trend rates represent Abbott’s expected annual
rates of change in the cost of health care benefits and are a forward
projection of health care costs as of the measurement date. A
difference between the assumed rates and the actual rates, which
will not be known for years, can be significant in relation to the
obligations and the annual cost recorded for these programs. The
net actuarial gains for these plans in 2024 reflect the impact of
actual asset returns during the year in excess of expected returns
and the impact of higher discount rates on the measurement of
plan liabilities. At December 31, 2024, pretax net actuarial losses
and prior service costs and (credits) recognized in Accumulated
other comprehensive income (loss) were net losses of $777 million
for Abbott’s defined benefit plans and net losses of $21 million for
Abbott’s medical and dental plans. Actuarial losses and gains are
amortized over the remaining service attribution periods of the
employees under the corridor method, in accordance with the
rules for accounting for post-employment benefits. Differences
between the expected long-term return on plan assets and the
actual annual return are amortized over a five-year period.

-- 70 of 86 --

F I N A N C I A L R E V I E W
69
A B B O T T 2 0 2 4 A N N U A L R E P O R T
Valuation of Intangible Assets — Abbott has acquired and contin-
ues to acquire significant intangible assets that Abbott records
at fair value at the acquisition date. Transactions involving the
purchase or sale of intangible assets occur with some frequency
between companies in the health care field and valuations are
usually based on a discounted cash flow analysis. The discounted
cash flow model requires assumptions about the timing and
amount of future net cash flows, risk, cost of capital, terminal
values and market participants. Each of these factors can signifi-
cantly affect the value of the intangible asset. Abbott engages
independent valuation experts who review Abbott’s critical
assumptions and calculations for acquisitions of significant
intangibles. Abbott reviews definite-lived intangible assets for
impairment each quarter. An undiscounted net cash flows
approach is used to test for impairment. If the undiscounted cash
flows of an intangible asset are less than the carrying value of an
intangible asset, the intangible asset is written down to its fair
value, which is usually the discounted cash flow amount. Where
cash flows cannot be identified for an individual asset, the review
is applied at the lowest group level for which cash flows are identi-
fiable. Goodwill and indefinite-lived intangible assets, which relate
to in-process research and development acquired in a business
combination, are reviewed for impairment annually or when an
event that could result in an impairment occurs. At December 31,
2024, goodwill amounted to $23.1 billion and net intangibles
amounted to $6.6 billion. Amortization expense for intangible
assets amounted to $1.9 billion in 2024 and $2.0 billion per year
in 2023 and 2022. There was no reduction of goodwill relating to
impairments in 2024, 2023, and 2022.
Litigation — Abbott accounts for litigation losses in accordance
with Financial Accounting Standards Board (FASB) Accounting
Standards Codification (ASC) No. 450, “Contingencies.” Under
ASC No. 450, loss contingency provisions are recorded for probable
losses at management’s best estimate of a loss, or when a best
estimate cannot be made, a minimum loss contingency amount is
recorded. These estimates are often initially developed substan-
tially earlier than the ultimate loss is known, and the estimates are
refined each accounting period as additional information becomes
known. Accordingly, Abbott is often initially unable to develop a
best estimate of loss, and therefore the minimum amount, which
could be zero, is recorded. As information becomes known, either
the minimum loss amount is increased, resulting in additional
loss provisions, or a best estimate can be made, also resulting in
additional loss provisions. Occasionally, a best estimate amount is
changed to a lower amount when events result in an expectation
of a more favorable outcome than previously expected. Abbott
estimates the range of possible loss to be from approximately
$25 million to $35 million for its legal proceedings and environ-
mental exposures. Accruals of approximately $30 million have
been recorded at December 31, 2024 for these proceedings and
exposures. These accruals represent management’s best estimate
of probable loss, as defined by FASB ASC No. 450, “Contingencies.”
RESULTS OF OPERATIONS
SALES
The following table details the components of sales growth by
reportable segment for the last two years:
Total %
Change
Components of % Change
Price 	Volume 	Exchange
Total Net Sales
2024 vs. 2023 	4.6 	3.5 	3.7 	(2.6)
2023 vs. 2022 	(8.1) 	2.6 	(8.7) 	(2.0)
Total U.S.
2024 vs. 2023 	5.6 	1.9 	3.7 	—
2023 vs. 2022 	(14.8) 	1.1 	(15.9) 	—
Total International
2024 vs. 2023 	3.9 	4.6 	3.5 	(4.2)
2023 vs. 2022 	(3.3) 	3.7 	(3.5) 	(3.5)
Established Pharmaceutical Products Segment
2024 vs. 2023 	2.5 	8.2 	1.0 	(6.7)
2023 vs. 2022 	3.1 	6.0 	4.9 	(7.8)
Nutritional Products Segment
2024 vs. 2023 	3.2 	7.7 	(1.7) 	(2.8)
2023 vs. 2022 	9.3 	11.4 	0.2 	(2.3)
Diagnostic Products Segment
2024 vs. 2023 	(6.5) 	1.4 	(5.3) 	(2.6)
2023 vs. 2022 	(39.4) 	(0.9) 	(37.3) 	(1.2)
Medical Devices Segment
2024 vs. 2023 	12.4 	1.4 	12.3 	(1.3)
2023 vs. 2022 	14.1 	1.0 	14.1 	(1.0)
The increase in total net sales in 2024, excluding the impact of
foreign exchange, primarily reflects higher sales in the Medical
Devices, Established Pharmaceutical Products and Nutritional
Products segments, partially offset by a decrease in demand for
Abbott’s rapid diagnostic tests to detect COVID-19. Abbott’s
COVID-19 testing-related sales totaled $747 million in 2024,
$1.6 billion in 2023 and $8.4 billion in 2022. Excluding the impact
of COVID-19 testing-related sales, Abbott’s total net sales
increased 7.0 percent in 2024. Excluding the impacts of COVID-19
testing-related sales and foreign exchange, Abbott’s total net sales
increased 9.6 percent. Abbott’s net sales in 2024 were unfavorably
impacted by changes in foreign exchange rates as the relatively
stronger U.S. dollar decreased total international sales by
4.2 percent and total sales by 2.6 percent.

-- 71 of 86 --

F I N A N C I A L R E V I E W
70
A B B O T T 2 0 2 4 A N N U A L R E P O R T
The decrease in total net sales in 2023 reflects the decline in
demand for Abbott’s rapid diagnostic tests to detect COVID-19,
partially offset by higher sales in the Medical Devices, Established
Pharmaceutical Products and Nutritional Products segments.
Excluding the impact of COVID-19 testing-related sales, Abbott’s
total net sales increased 9.2 percent in 2023. Excluding the impacts
of COVID-19 testing-related sales and foreign exchange, Abbott’s
total net sales increased 11.7 percent. Abbott’s net sales in 2023
were unfavorably impacted by changes in foreign exchange rates
as the relatively stronger U.S. dollar decreased total international
sales by 3.5 percent and total sales by 2.0 percent.
The table below provides detail by sales category for the years
ended December 31. Percent changes are versus the prior year
and are based on unrounded numbers.
(dollars in millions) 	2024 	2023
Total
Change
Impact of
Exchange
Total
Change
Excl.
Exchange
Established
Pharmaceutical
Products—
Key Emerging
Markets 	$3,858 	$3,807 	1.3% 	(8.2)«% 	9.5%
Other 	1,336 	1,259 	6.1÷« 	(2.3)÷÷ 	8.4÷«
Nutritional Products —
International
Pediatric
Nutritionals 	1,815 	1,957 	(7.3)÷« 	(3.0)÷÷ 	(4.3)÷«
U.S. Pediatric
Nutritionals 	2,208 	1,977 	11.7÷« 	—÷÷ 	11.7÷«
International Adult
Nutritionals 	2,909 	2,784 	4.5÷« 	(6.0) ÷« 	10.5÷«
U.S. Adult
Nutritionals 	1,481 	1,436 	3.2÷« 	—÷÷ 	3.2÷«
Diagnostic Products —
Core Laboratory 	5,235 	5,159 	1.5÷« 	(4.1)÷÷ 	5.6÷«
Molecular 	521 	574 	(9.2)÷« 	(0.7)÷÷ 	(8.5)÷«
Point of Care 	588 	565 	4.1÷« 	—÷÷ 	4.1÷«
Rapid Diagnostics 	2,997 	3,690 	(18.8)÷« 	(1.0)÷÷ 	(17.8)÷«
Medical Devices —
Rhythm
Management 	2,390 	2,255 	6.0÷« 	(0.9)÷÷ 	6.9÷«
Electrophysiology 	2,467 	2,195 	12.3÷« 	(2.1)÷÷ 	14.4÷«
Heart Failure 	1,279 	1,161 	10.2÷« 	(0.1)÷÷ 	10.3÷«
Vascular 	2,837 	2,681 	5.8÷« 	(0.9)÷÷ 	6.7÷«
Structural Heart 	2,246 	1,944 	15.5÷« 	(1.5)÷÷ 	17.0÷«
Neuromodulation 	962 	890 	8.2÷« 	(1.3)÷÷ 	9.5÷«
Diabetes Care 	6,805 	5,761 	18.1÷« 	(1.6)÷÷ 	19.7÷«
(dollars in millions) 	2023 	2022
Total
Change
Impact of
Exchange
Total
Change
Excl.
Exchange
Established
Pharmaceutical
Products —
Key Emerging
Markets 	$3,807 	$3,766 	1.1% 	(9.2)«% 	10.3%
Other 	1,259 	1,146 	9.8÷« 	(3.0)÷÷ 	12.8÷«
Nutritional Products —
International
Pediatric
Nutritionals 	1,957 	1,919 	2.0÷« 	(3.2)÷÷ 	5.2÷«
U.S. Pediatric
Nutritionals 	1,977 	1,562 	26.6÷« 	—÷÷ 	26.6÷«
International Adult
Nutritionals 	2,784 	2,621 	6.2÷« 	(4.2)÷÷ 	10.4÷«
U.S. Adult
Nutritionals 	1,436 	1,357 	5.8÷« 	—÷÷ 	5.8÷«
Diagnostic Products —
Core Laboratory 	5,159 	4,888 	5.5÷« 	(2.9)÷÷ 	8.4÷«
Molecular 	574 	995 	(42.3)÷« 	(0.7)÷÷ 	(41.6)÷«
Point of Care 	565 	525 	7.5÷« 	(0.2)÷÷ 	7.7÷«
Rapid Diagnostics 	3,690 	10,061 	(63.3)÷« 	(0.4)÷÷ 	(62.9)÷«
Medical Devices —
Rhythm
Management 	2,255 	2,119 	6.5÷« 	(1.0)÷÷ 	7.5÷«
Electrophysiology 	2,195 	1,927 	13.9÷« 	(2.0)÷÷ 	15.9÷«
Heart Failure 	1,161 	1,035 	12.1÷« 	0.1÷÷ 	12.0÷«
Vascular 	2,681 	2,483 	8.0÷« 	(1.3)÷÷ 	9.3÷«
Structural Heart 	1,944 	1,712 	13.6÷« 	(0.7)÷÷ 	14.3÷«
Neuromodulation 	890 	770 	15.5÷« 	(0.9)÷÷ 	16.4÷«
Diabetes Care 	5,761 	4,756 	21.1÷« 	(0.8)÷÷ 	21.9÷«
Notes:
The Acelis Connected Health business was internally transferred from Diagnostic Products to
Medical Devices on January 1, 2023. As a result, $115 million of sales in 2022 were moved from
Diagnostic Products to Medical Devices.
In order to compute results excluding the impact of exchange rates, current year U.S. dollar
sales are multiplied or divided, as appropriate, by the current year average foreign exchange
rates and then those amounts are multiplied or divided, as appropriate, by the prior year
average foreign exchange rates.
Established Pharmaceutical Products sales increased 9.2 percent
in 2024 and 10.9 percent in 2023, excluding the unfavorable impact
of foreign exchange. Excluding the effect of foreign exchange, sales
in Key Emerging Markets for Established Pharmaceutical Products
increased 9.5 percent in 2024 and 10.3 percent in 2023, led by
higher revenue in several countries and across several therapeutic
areas, including respiratory, gastroenterology, cardiometabolic
and central nervous system/pain management. Other Emerging
Markets, excluding the effect of foreign exchange, increased by
8.4 percent in 2024 and 12.8 percent in 2023.

-- 72 of 86 --

F I N A N C I A L R E V I E W
71
A B B O T T 2 0 2 4 A N N U A L R E P O R T
Excluding the impact of foreign exchange, total Nutritional
Products sales increased 5.9 percent in 2024 and 11.6 percent in
2023. In U.S. Pediatric Nutritional sales, the 11.7 percent increase
in 2024 reflects infant formula market share gains and the
continued favorable impact of price increases, partially offset by
a decrease in PediaSure® and Pedialyte® product sales. In 2023,
U.S. Pediatric Nutritional sales increased 26.6 percent as a result
of market share recovery related to the voluntary recall of certain
infant formula products in the first quarter of 2022, partially
offset by a decrease in 2023 Pedialyte sales.
Excluding the effect of foreign exchange, the 4.3 percent decrease
in International Pediatric Nutritional sales in 2024 reflects a
decrease in sales in the Asia Pacific and Latin America regions,
partially offset by increased sales in Canada and the Europe/
Middle East regions. Excluding the effect of foreign exchange,
the 5.2 percent increase in International Pediatric Nutritional
sales in 2023 reflects higher sales in Latin America and Canada,
partially offset by the impact of exiting the pediatric nutrition
business in China.
In 2024 and 2023, U.S. and International Adult Nutritional sales
increased due to higher Ensure® and Glucerna® product sales. In
2024 and 2023, U.S. Adult Nutritional sales increased 3.2 percent
and 5.8 percent, respectively, and International Adult Nutritional
sales, excluding the effect of foreign exchange, increased
10.5 percent and 10.4 percent, respectively. In 2024, U.S. Adult
Nutritional sales were partially offset by the discontinuation of
the ZonePerfect® product line.
Excluding the effect of foreign exchange, Diagnostic Products
segment sales decreased 3.9 percent in 2024 and 38.2 percent
in 2023, driven by lower demand for COVID-19 tests. Rapid
Diagnostics sales decreased 17.8 percent in 2024 and 62.9 percent
in 2023, excluding the effect of foreign exchange. The decrease
reflects lower demand for COVID-19 tests. Rapid Diagnostics
COVID-19 testing-related sales were $725 million in 2024,
$1.5 billion in 2023 and $7.9 billion in 2022.
Rapid Diagnostics sales, excluding COVID-19 testing-related sales,
increased 4.8 percent in 2024 and remained unchanged in 2023.
In 2024, Rapid Diagnostics sales increased 6.0 percent, excluding
the impact of foreign exchange and COVID-19 testing-related sales,
due to strong demand for respiratory disease tests used to diagnose
influenza, strep throat and RSV. In 2023, Rapid Diagnostics sales
increased 1.3 percent, excluding the impact of foreign exchange
and COVID-19 testing-related sales. Growth in various Rapid
Diagnostics products in 2023 was partially offset by the unfavor-
able effects of an early 2022 flu season and a later start of the 2023
flu season.
In Core Laboratory, sales increased 5.6 percent in 2024 and
8.4 percent in 2023, excluding the effect of foreign exchange. The
increase in 2024 was due to the continued deployment of Abbott’s
Alinity® testing platform and higher volume of routine diagnostic
testing performed in hospitals and other laboratories along with
price increases, partially offset by lower sales in China. The
increase in 2023 was due to higher year-over-year volume of
routine diagnostic testing performed in hospitals and other
laboratories, partially offset by lower test sales for the detection of
COVID-19 IgG and IgM antibodies. Core Laboratory COVID-19
testing-related sales on Abbott’s ARCHITECT® and Alinity i
platforms were $10 million in 2024, $20 million in 2023, and
$62 million in 2022. Excluding COVID-19 testing-related sales,
Core Laboratory sales increased 1.7 percent in 2024 and
6.5 percent in 2023. Excluding the impact of foreign exchange
and COVID-19 testing-related sales, Core Laboratory sales
increased 5.8 percent in 2024 and 9.4 percent in 2023.
Excluding the effect of foreign exchange, total Medical Devices
sales grew 13.7 percent in 2024 and 15.1 percent in 2023, led by
double-digit growth in 2024 in Diabetes Care, Structural Heart,
Electrophysiology and Heart Failure. Higher Diabetes Care sales
were driven by continued growth in Abbott’s CGM systems, in
the U.S. and internationally. CGM sales totaled $6.4 billion in 2024,
which reflected a 21.8 percent increase, excluding the effect of
foreign exchange, over 2023 when CGM sales totaled $5.3 billion.
Procedure volumes continued to increase across the cardiovascular
and neuromodulation businesses in 2024. In Structural Heart,
excluding the effect of foreign exchange, the 17.0 percent and
14.3 percent sales increases in 2024 and 2023, respectively, reflect
continued growth of the Navitor® and TriClip® products, as well
as growth in surgical valves, structural interventions and other
transcatheter repair sales.
Electrophysiology sales, excluding the effect of foreign exchange,
increased 14.4 percent in 2024 and 15.9 percent in 2023 which
primarily reflects higher procedure volumes and increased
demand for catheters and cardiac mapping products across
all regions.
In Heart Failure, the 10.3 percent increase in sales in 2024,
excluding the effect of foreign exchange, primarily reflects
growth in heart assist devices, which offer treatment for chronic
and temporary conditions. In 2023, Heart Failure sales increased
12.0 percent, excluding the effect of foreign exchange, as proce-
dure volumes and staffing challenges, which occurred during the
COVID-19 pandemic, began to recover.

-- 73 of 86 --

F I N A N C I A L R E V I E W
72
A B B O T T 2 0 2 4 A N N U A L R E P O R T
In Rhythm Management, the 6.9 percent increase in 2024,
excluding the impact of foreign exchange, was primarily due to
growth in Aveir® leadless pacemaker and Assert IQ® implantable
cardiac monitor sales. In 2023, the 7.5 percent increase, excluding
the impact of foreign exchange, was due to growth across the
portfolio of low and high voltage pacemakers, led by the Aveir
leadless pacemaker that launched in 2022.
In Vascular, the 6.7 percent increase in 2024, excluding the impact
of foreign exchange, was primarily due to higher vessel closure
sales. In 2023, the 9.3 percent increase, excluding the impact of
foreign exchange, was primarily due to the acquisition of CSI in
April 2023.
Abbott’s operations in Russia and Ukraine represent approxi-
mately 2 percent of Abbott’s total revenues and net assets, and to
date the financial impact of Russia’s invasion of Ukraine has not
been material to Abbott’s operations or financial condition. Future
implications are difficult to predict, but at present Abbott does not
anticipate that the Russia-Ukraine conflict will have a material
impact on its operations or financial condition. A more detailed
discussion of the risks associated with the Russia-Ukraine conflict
is contained in Item 1A. Risk Factors.
The expiration of licenses and patent protection can affect the
future revenues and operating income of Abbott. There are no
significant patent or license expirations in the next three years
that are expected to materially affect Abbott.
OPERATING EARNINGS
Gross profit margins were 50.9 percent of net sales in 2024,
50.3 percent of net sales in 2023, and 51.5 percent of net sales
in 2022. The increase in 2024 reflects the favorable impacts of
margin improvement initiatives, partially offset by the unfavor-
able effect of foreign exchange. The decrease in 2023 reflects
the unfavorable effects of lower sales of COVID-19 tests, foreign
exchange, and higher costs for various manufacturing inputs,
partially offset by the nonrecurrence of the negative impact in
2022 of the voluntary product recall in the nutritional business
and the impact in 2023 of margin improvement initiatives.
Research and development (R&D) expenses were $2.8 billion in
2024, $2.7 billion in 2023, and $2.9 billion in 2022. The increase in
R&D expense in 2024 was primarily driven by higher spending
on various projects, partially offset by lower 2024 charges for
the impairment of in-process R&D (IPR&D) assets acquired in
previous business combinations. In 2023, the decrease in R&D
expense was primarily driven by lower restructuring charges,
lower impairment charges related to IPR&D acquired in previous
business combinations, and other cost reductions.
Selling, general and administrative (SG&A) expenses were
$11.7 billion in 2024, $10.9 billion in 2023 and $11.2 billion in 2022.
In 2024, higher selling and marketing spending to drive growth
across various businesses was partially offset by the favorable
impact of foreign exchange. The 2023 decrease in SG&A expenses
reflects the favorable impact of foreign exchange and lower
restructuring charges in 2023, as well as the non-recurrence of
2022 expenses related to the voluntary product recall in the
Nutritional Products segment.
RESTRUCTURINGS
In 2024, Abbott management approved plans to streamline cer-
tain operations in order to reduce costs and improve efficiencies
in its Diagnostic, Medical Devices, Established Pharmaceutical
and Nutritional businesses, including the discontinuation of its
ZonePerfect® product line. Abbott recorded employee related
severance and other charges of $129 million, of which $62 million
was recorded in Cost of products sold, $21 million was recorded in
Research and development, and $46 million was recorded in
Selling, general and administrative expenses. Payments related
to these actions totaled $32 million in 2024 and the remaining
liability totaled $97 million at December 31, 2024. In addition,
Abbott recognized inventory related charges of $34 million and
fixed asset impairment charges of $12 million related to these
restructuring plans.
In 2023, Abbott management approved plans to restructure
various operations in order to reduce costs in its Medical Devices,
Diagnostic, and Established Pharmaceutical businesses. Abbott
recorded employee related severance and other charges of
$144 million of which approximately $56 million was recorded in
Cost of products sold, $22 million was recorded in Research and
development and $66 million was recorded in Selling, general and
administrative expenses. In addition, Abbott recognized fixed
asset impairment and inventory related charges of $31 million
related to these restructuring plans.
In 2022, Abbott management approved plans to streamline
operations in order to reduce costs and improve efficiencies in
its Medical Devices, Nutritional, Diagnostic, and Established
Pharmaceutical businesses. Abbott recorded employee related
severance and other charges of $234 million of which $59 million
was recorded in Cost of products sold, $36 million was recorded
in Research and development and $139 million was recorded in
Selling, general and administrative expenses. In addition, Abbott
recognized inventory related charges of $23 million and fixed
asset impairment charges of $4 million related to these restruc-
turing plans.
INTEREST EXPENSE AND INTEREST (INCOME)
Interest expense, net decreased from $252 million in 2023 to
$215 million in 2024. Interest expense decreased in 2024 due to
the repayment of approximately $2.25 billion of long-term debt in
September and November of 2023, partially offset by a reduction
in interest income due to lower average cash and short-term
investment balances versus the prior year. Interest expense, net
decreased $123 million in 2023 due to the favorable impact of
higher interest rates on interest income, partially offset by the
negative impact of interest rate hedge contracts related to certain
fixed-rate debt.

-- 74 of 86 --

F I N A N C I A L R E V I E W
73
A B B O T T 2 0 2 4 A N N U A L R E P O R T
OTHER (INCOME) EXPENSE, NET
Other income, net was $376 million of income in 2024,
$479 million of income in 2023 and $321 million of income in
2022. Other income, net includes income of approximately
$542 million, $498 million, and $406 million in 2024, 2023, and
2022, respectively, related to the non-service cost components of
the net periodic benefit costs associated with the pension and
post-retirement medical plans. The decrease in 2024 reflects the
recognition of a $143 million loss on the sale of a non-core business
related to the Established Pharmaceutical Products segment.
The decrease in 2024 was partially offset by an increase in income
associated with the non-service cost components of net pension
and post-retirement medical benefit costs. In 2023, Other income,
net included equity investment impairments that totaled approxi-
mately $39 million, as well as income from a $42 million reduction
in the fair value of contingent consideration related to previous
business acquisitions.
TAXES ON EARNINGS
Taxes on earnings reflect the annual effective rates, including
charges for interest and penalties. Deferred income taxes reflect
the tax consequences on future years of differences between the
tax bases of assets and liabilities and their financial report-
ing amounts.
Taxes on earnings include approximately $50 million, $22 million
and $43 million in excess tax benefits associated with share-based
compensation in 2024, 2023 and 2022, respectively. As a result of
the resolution of various tax positions related to prior years, taxes
on earnings in 2024, 2023 and 2022 also include approximately
$25 million, $80 million and $20 million of net tax expense,
respectively. In the fourth quarter of 2024, taxes on earnings
includes $7.5 billion in non-cash valuation allowance adjustments
resulting from the restructuring of certain foreign affiliates and
the confirmation of certain tax filing positions. The restructuring
improved profitability to several of Abbott’s affiliates and manage-
ment concluded that the related preexisting deferred tax assets,
which historically had a full valuation allowance, were more likely
than not to be realizable in future periods. In particular, Abbott
considered the likelihood of sustained ongoing profitability of the
affiliates as a positive factor that outweighed all available negative
evidence considered. Accordingly, Abbott released the full valua-
tion allowance on such deferred tax assets and recorded the
offset to tax expense.
The U.S. Tax Cuts and Jobs Act (TCJA) includes a one-time
transition tax that is based on Abbott’s total post-1986 earnings
and profits (E&P) that were previously deferred from U.S. income
taxes. The tax computation also requires the determination of
the amount of post-1986 E&P considered held in cash and other
specified assets. As of December 31, 2024, the remaining balance
of Abbott’s transition tax obligation related to the TCJA is approx-
imately $432 million, which will be paid over the next two years
as allowed by the TCJA. Undistributed foreign earnings remain
indefinitely reinvested in foreign operations. Determining the
amount of unrecognized deferred tax liability related to any
remaining undistributed foreign earnings not subject to the
transition tax and additional outside basis difference in its foreign
entities is not practicable.
In the U.S., Abbott’s federal income tax returns through 2016 are
settled. In September 2023, Abbott received a Statutory Notice of
Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS)
for the 2019 Federal tax year in the amount of $417 million.
The primary adjustments proposed in the SNOD relate to the
reallocation of income between Abbott’s U.S. entities and its
foreign affiliates. Abbott believes that the income reallocation
adjustments proposed in the SNOD are without merit, in part
because certain adjustments contradict methods that were agreed
to with the IRS in prior audit periods. The SNOD also contains
other proposed adjustments that Abbott believes are erroneous
and unsupported. Abbott filed a petition with the U.S. Tax Court
contesting the SNOD in December 2023.
In June 2024, Abbott received a SNOD from the IRS for the 2017
and 2018 Federal tax years in the amount of $192 million. The
matters proposed in the 2017/2018 SNOD are substantially similar
to the income allocation adjustments included in the 2019 SNOD.
Abbott filed a petition in September 2024 with the U.S. Tax Court
contesting the 2017/2018 SNOD in a manner consistent with its
petition for the 2019 SNOD.
In October 2024, Abbott received a SNOD from the IRS for the
2020 Federal tax year assessing an additional $443 million of
income tax. The primary adjustments proposed in the SNOD
are substantially similar to the income allocation adjustments
included in the 2017/2018 and 2019 SNODs. Abbott believes that
the income reallocation adjustments proposed in the SNOD are
without merit. The SNOD also contains other proposed adjust-
ments and omissions that Abbott believes are erroneous and
unsupported. In addition to the tax assessment for the 2020 tax
year, the 2020 SNOD also contested a deduction for which an
estimated $440 million cash tax benefit would be available in a
different taxable year as allowed under applicable U.S. tax law.
Abbott filed a petition with the U.S. Tax Court contesting the
SNOD in December 2024.
Abbott intends to vigorously defend its filing positions through
ongoing discussions with the IRS, the IRS independent appeals
process and/or through litigation as necessary. Abbott reserves
for uncertain tax positions related to unresolved matters with the
IRS and other taxing authorities. Abbott continues to believe that
its reserves for uncertain tax positions are appropriate.
There are numerous other income tax jurisdictions for which
tax returns are not yet settled, none of which Abbott expects to
be individually significant. Reserves for interest and penalties
are not significant.

-- 75 of 86 --

F I N A N C I A L R E V I E W
74
A B B O T T 2 0 2 4 A N N U A L R E P O R T
The Organization for Economic Cooperation & Development
(OECD) has proposed a two-pillared plan for a revised international
tax system. Pillar 1 proposes to reallocate taxing rights among the
jurisdictions in which in-scope multinational corporations operate.
Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2
proposes to assess a 15 percent minimum tax on the earnings of
in-scope multinational corporations on a country-by-country basis.
Numerous countries have enacted legislation to adopt the Pillar 2
model rules. The enactment of current Pillar 2 model rules did
not and is not projected to have a material impact to Abbott’s
consolidated financial statements.
See Note 15 — Taxes on Earnings to the consolidated financial
statements for a full reconciliation of the effective tax rate to the
U.S. federal statutory rate.
RESEARCH AND DEVELOPMENT PROGRAMS
Abbott currently has numerous pharmaceutical, medical device,
diagnostic and nutritional products in development.
RESEARCH AND DEVELOPMENT PROCESS
In the Established Pharmaceutical Products segment, the develop-
ment process focuses on the geographic expansion and continuous
improvement of the segment’s existing products to provide benefits
to patients and customers. As Established Pharmaceutical Products
does not actively pursue primary research, development usually
begins with work on existing products or after the completion of
an acquisition or licensing agreement.
Depending upon the product, the phases of development
may include:
• Drug product development.
• Phase I bioequivalence studies to compare a future Established
Pharmaceutical’s brand with an already marketed compound
with the same active pharmaceutical ingredient (API).
• Phase II studies to test the efficacy of benefits in a small group
of patients.
• Phase III studies to broaden the testing to a wider population
that reflects the actual medical use.
• Phase IV and other post-marketing studies to obtain new clinical
use data on existing products within approved indications.
The specific requirements (e.g., scope of clinical trials) for
obtaining regulatory approval vary across different countries and
geographic regions. The process may range from one year for a
bioequivalence study project to six or more years for complex
formulations, new indications, or geographic expansion in
specific countries.
In the Diagnostic Products segment, the phases of the research
and development process include:
• Discovery, which focuses on identification of a product that
will address a specific therapeutic area, platform, or unmet
clinical need.
• Concept/Feasibility, during which the materials and
manufacturing processes are evaluated; testing may include
product characterization and analysis is performed to confirm
clinical utility.
• Development, during which extensive testing is performed
to demonstrate that the product meets specified design
requirements and that the design specifications conform to
user needs and intended uses.
The regulatory requirements for diagnostic products vary across
different countries and geographic regions. In the U.S., the FDA
classifies diagnostic products into classes (I, II, or III) and the
classification determines the regulatory process for approval.
While the Diagnostics segment has products in all three classes,
the vast majority of its products are categorized as Class I or
Class II. Submission of a separate regulatory filing is not required
for Class I products. Class II products typically require premarket
notification to the FDA through a regulatory filing known as a
510(k) submission. Most Class III products are subject to the
FDA’s Premarket Approval (PMA) requirements. Other Class III
products, such as those used to screen blood, require the submis-
sion and approval of a Biological License Application (BLA).
In the European Union (EU), diagnostic products are also catego-
rized into different categories and the regulatory process, which
had been governed by the European In Vitro Diagnostic Medical
Device Directive, depends upon the category. Certain product
categories requiring review and approval by an independent
company, known as a Notified Body, before the manufacturer
can affix a CE mark to the product to declare conformity to the
Directive. Other products only require a self-certification process.
In 2017, the EU adopted the new In Vitro Diagnostic Regulation
(IVDR) which replaced the existing directive in the EU for
in vitro diagnostic products and imposed additional premarket
and post-market regulatory requirements on manufacturers of
such products. In July 2024, the IVDR was amended to extend
the transition timeline period for dates of compliance as long as
December 2029, depending on the diagnostic device classification.
The diagnostic device must meet additional specific conditions
set out in the amended regulations. However, the amendment did
not delay the date of application of the IVDR itself which took
effect on May 26, 2022.

-- 76 of 86 --

F I N A N C I A L R E V I E W
75
A B B O T T 2 0 2 4 A N N U A L R E P O R T
In the Medical Devices segment, the research and development
process begins with research on a specific technology that is
evaluated for feasibility and commercial viability. If the research
program passes that hurdle, it moves forward into development.
The development process includes evaluation, selection and
qualification of a product design, completion of applicable clinical
trials to test the product’s safety and efficacy, and validation of the
manufacturing process to demonstrate its repeatability and ability
to consistently meet pre-determined specifications.
Similar to the diagnostic products discussed above, in the U.S.,
medical devices are classified as Class I, II, or III. Most of Abbott’s
medical device products are classified as Class II devices that
follow the 510(k) regulatory process or Class III devices that are
subject to the PMA process.
In the EU, medical devices are also categorized into different
classes and the regulatory process, which had been governed by the
European Medical Device Directive and the Active Implantable
Medical Device Directive, varies by class. In the second quarter of
2017, the EU adopted the new Medical Devices Regulation (MDR)
which replaced the existing directives in the EU for medical
devices and imposes additional premarket and post-market regula-
tory requirements on manufacturers of such products. The MDR
applies to manufacturers as of May 26, 2021 with extended transi-
tion periods lasting as long as December 31, 2028 depending on
the risk classification of the device in the regulation. Each product
must bear a CE mark to show compliance with the MDR.
Some products require submission of a design dossier to the
appropriate regulatory authority for review and approval prior to
CE marking of the device. For other products, the company is
required to prepare a technical file which includes testing results
and clinical evaluations but can self-certify its ability to apply the
CE mark to the product. Outside the U.S. and the EU, the regulatory
requirements vary across different countries and regions.
After approval and commercial launch of some medical devices,
post-market trials may be conducted either due to a conditional
requirement of the regulatory market approval or with the objective
of proving product superiority.
In the Nutritional Products segment, the research and develop-
ment process generally focuses on identifying and developing
ingredients and products that address the nutritional needs of
particular populations (e.g., infants and adults) or patients
(e.g., people with diabetes). Depending upon the country and/or
region, if claims regarding a product’s efficacy will be made,
clinical studies typically must be conducted.
In the U.S., the FDA requires that it be notified of proposed new
formulations and formulation or packaging changes related to
infant formula products. Prior to the launch of an infant formula
or product packaging change, the company is required to obtain
the FDA’s confirmation that it has no objections to the proposed
product or packaging. For other nutritional products, notification
or pre-approval from the FDA is not required unless the product
includes a new food additive. In some countries, regulatory
approval may be required for certain nutritional products,
including infant formula and medical nutritional products.
AREAS OF FOCUS
In 2025 and beyond, Abbott expects to focus on the follow-
ing areas:
Established Pharmaceuticals — Abbott focuses on building
country-specific portfolios made up of high-quality medicines
that meet the needs of people in emerging markets. Over the next
several years, Abbott plans to expand its product portfolio in key
therapeutic areas and biosimilars with the aim of addressing the
health needs of more people in emerging markets and being
among the first to launch new off-patent and differentiated medi-
cines. In addition, Abbott continues to expand existing brands
into new markets, implement product enhancements that provide
value to patients and acquire strategic products and technology
through licensing activities. Abbott is also actively working on
the further development of several key brands such as Creon™,
Duphaston™, Femoston™ and Influvac™. Depending on the
product, the activities focus on development of new data,
markets, formulations, delivery systems, or indications.
Medical Devices — Abbott’s research and development programs
focus on:
• Cardiac Rhythm Management – Development of next-generation
rhythm management technologies, including advanced commu-
nication capabilities and leadless pacing therapies.
• Heart Failure – Continued enhancements to Abbott’s mechani-
cal circulatory support and pulmonary artery pressure systems,
including enhanced clinical performance and usability.
• Electrophysiology – Development of next-generation
technologies in the areas of ablation, diagnostic, mapping,
and visualization and recording.
• Vascular – Development of next-generation technologies for
use in coronary and peripheral vascular procedures.
• Structural Heart – Development of transcatheter and surgical
devices for the repair and replacement of heart valves, and
occlusion therapies for congenital heart defects and stroke-risk
reduction.
• Neuromodulation – Development of clinical evidence and next-
generation technologies leveraging digital health to support
improved patient clinical outcomes, physician engagement, and
expanded indications in the treatment of chronic pain, move-
ment disorders and other indications.
• Diabetes Care – Develop enhancements and additional indications
for continuous monitoring products to help patients improve
their ability to manage diabetes and for use beyond diabetes.
Nutritionals — Abbott is focusing its research and development
spend on platforms that span the pediatric and adult nutrition
areas: gastrointestinal/immunity health, brain health, mobility
and metabolism, and user experience platforms. Numerous new
products that build on advances in these platforms are currently
under development, including clinical outcome testing, and are
expected to be launched over the coming years.

-- 77 of 86 --

F I N A N C I A L R E V I E W
76
A B B O T T 2 0 2 4 A N N U A L R E P O R T
Core Laboratory Diagnostics — Abbott continues to commercial-
ize its next-generation blood and plasma screening, immunoassay,
clinical chemistry and hematology systems, along with assays,
including a focus on unmet medical needs, in various areas includ-
ing infectious disease, cardiac care, metabolics, oncology, and
neurologic assays as well as informatics solutions to help optimize
diagnostics laboratory performance and automation solutions to
increase efficiency in laboratories.
Rapid Diagnostics — Abbott’s research and development programs
focus on the development of diagnostic products for infectious
disease, cardiometabolic disease and toxicology.
In addition, the Diagnostic Products segment continues to pursue
the FDA’s customary regulatory process for remaining COVID-19
tests for which Emergency Use Authorizations (EUAs) were
obtained and yet to be cleared.
Given the diversity of Abbott’s business, its intention to remain a
broad-based health care company and the numerous sources for
potential future growth, no individual project is expected to be
material to cash flows or results of operations over the next five
years. Factors considered included research and development
expenses projected to be incurred for the project over the next
year relative to Abbott’s total research and development
expenses, as well as qualitative factors, such as marketplace
perceptions and impact of a new product on Abbott’s overall
market position. There were no delays in Abbott’s 2024 research
and development activities that are expected to have a material
impact on operations.
While the aggregate cost to complete the numerous projects
currently in development is expected to be material, the total cost
to complete will depend upon Abbott’s ability to successfully
finish each project, the rate at which each project advances, and
the ultimate timing for completion. Given the potential for signifi-
cant delays and the risk of failure inherent in the development
of new products and technologies, it is not possible to accurately
estimate the total cost to complete all projects currently in devel-
opment. Abbott plans to manage its portfolio of projects to achieve
research and development spending that will be competitive in
each of the businesses in which it participates, and such spending
is targeted at approximately 7 percent of total Abbott sales in
2025. Abbott does not regularly accumulate or make management
decisions based on the total expenses incurred for a particular
development phase in a given period.
GOODWILL
At December 31, 2024, goodwill recorded as a result of business
combinations totaled $23.1 billion. Goodwill is reviewed for
impairment annually in the third quarter or when an event that
could result in an impairment occurs, using a quantitative assess-
ment to determine whether it is more likely than not that the fair
value of any reporting unit is less than its carrying amount. The
income and market approaches are used to calculate the fair
value of each reporting unit. The results of the last impairment
test indicated that the fair value of each reporting unit was
substantially in excess of its carrying value.
FINANCIAL CONDITION
CASH FLOW
Net cash from operating activities amounted to $8.6 billion,
$7.3 billion, and $9.6 billion in 2024, 2023, and 2022, respectively.
The increase in Net cash from operating activities in 2024 as
compared to 2023 is primarily due to higher segment operating
earnings and improved working capital management, partially
offset by higher cash payments for income taxes. The decrease in
Net cash from operating activities in 2023 compared to 2022 was
primarily due to the decline in operating earnings and increased
payments related to accounts payable and accrued liabilities,
partially offset by lower expenditures for inventory and lower
cash payments for income taxes due to lower earnings.
A substantial portion of Abbott’s cash and cash equivalents at
December 31, 2024, is held by Abbott affiliates outside of the U.S.
If these funds were needed for operations in the U.S., Abbott does
not expect to incur significant additional income taxes in the
future to repatriate these funds.
Abbott funded $349 million in 2024 and 2023, and $413 million
in 2022 to defined benefit pension plans. Abbott expects pension
funding of approximately $302 million in 2025 for its pension
plans. Abbott expects annual cash flow from operating activities
to continue to exceed Abbott’s capital expenditures and cash
dividends.
DEBT AND CAPITAL
At December 31, 2024, Abbott’s long-term debt rating was
AA- by S&P Global Ratings and Aa3 by Moody’s Investors Service.
Abbott expects to maintain an investment grade rating.
Abbott has readily available financial resources, including
unused lines of credit that support commercial paper borrowing
arrangements and provide Abbott with the ability to borrow up
to $5 billion on an unsecured basis. On January 29, 2024, Abbott
terminated its 2020 Five Year Credit Agreement (2020 Agreement)

-- 78 of 86 --

F I N A N C I A L R E V I E W
77
A B B O T T 2 0 2 4 A N N U A L R E P O R T
and entered into a new Five Year Credit Agreement (Revolving
Credit Agreement). There were no outstanding borrowings under
the 2020 Agreement at the time of its termination. Any borrowings
under the Revolving Credit Agreement will mature and be payable
on January 29, 2029 and will bear interest, at Abbott’s option, based
on either a base rate or Secured Overnight Financing Rate (SOFR),
plus an applicable margin based on Abbott’s credit ratings.
As of December 31, 2024, Abbott’s total debt outstanding was
$14.1 billion, of which approximately $1.5 billion will mature
in 2025. On June 26, 2024, Abbott modified its existing, yen-
denominated 5-year term loan scheduled to mature in November
2024. The amended terms include a net increase in principal debt
from ¥59.8 billion to ¥92.0 billion, with a new maturity date in
June 2029. The modified, 5-year term loan bears interest at the
Tokyo Interbank Offered Rate (TIBOR) plus a fixed spread, and
the interest rate is reset quarterly. The net proceeds equated to
approximately $201 million. The ¥92.0 billion loan is designated
as a hedge of Abbott’s net investment in certain foreign
subsidiaries.
On November 19, 2024, Abbott repaid the €590 million outstanding
principal amount of its 0.10% Notes upon maturity. The repayment
equated to approximately $640 million. On November 30, 2023,
Abbott repaid the $1.05 billion outstanding principal amount of its
3.40% Notes upon maturity. On September 27, 2023, Abbott repaid
the €1.14 billion outstanding principal amount of its 0.875% Notes
upon maturity. The repayment equated to approximately $1.2 billion.
In September 2023, Abbott repaid approximately $197 million of
debt assumed as part of a recent business acquisition.
On October 11, 2024, the board of directors authorized the repurchase
of up to $7 billion of Abbott common shares, from time to time (the
“2024 repurchase program”). The 2024 repurchase program is in
addition to the unused portion of the 2021 repurchase program,
which the board of directors approved in December 2021 and
authorized the repurchase of up to $5 billion of Abbott’s common
shares from time to time. As of December 31, 2024, $293 million
remains available for repurchase under the 2021 repurchase pro-
gram. In 2024 and 2023, Abbott repurchased approximately
10.2 million and 9.8 million, respectively, of its common shares
for $1.1 billion and $1.0 billion, respectively, under the 2021 repur-
chase program. In 2022, Abbott repurchased 32.3 million of its
common shares for $3.7 billion which fully utilized the authoriza-
tion remaining under the October 2019 share repurchase program,
and a portion of the 2021 repurchase program.
Abbott declared dividends of $2.24 per share in 2024 compared
to $2.08 per share in 2023, an increase of 7.7 percent. Dividends
paid were $3.8 billion in 2024 compared to $3.6 billion in 2023.
The year-over-year change in dividends paid reflects the impact
of the increase in the dividend rate.
WORKING CAPITAL
Working capital was $9.5 billion at December 31, 2024 and
$8.8 billion at December 31, 2023. The increase in working capital
in 2024 primarily reflects an increase in cash and cash equivalents
and accounts receivable, partially offset by an increase in the
current portion of long-term debt. The increase in cash and cash
equivalents from $6.9 billion at December 31, 2023 to $7.6 billion
at December 31, 2024 primarily reflects the cash generated from
operations and an increase in Abbott’s yen-denominated loan,
partially offset by the payment of dividends and capital
expenditures.
Abbott monitors the credit worthiness of customers and establishes
an allowance that reflects the current estimate of credit losses
expected to be incurred over the life of the financial asset. Abbott
considers various factors in establishing, monitoring, and adjust-
ing its allowance for doubtful accounts, including the aging of the
accounts and aging trends, the historical level of charge-offs, and
specific exposures related to particular customers. Abbott also
monitors other risk factors and forward-looking information, such
as country risk, when determining credit limits for customers and
establishing adequate allowances.
CAPITAL EXPENDITURES
Capital expenditures of $2.2 billion in 2024 and 2023, and
$1.8 billion in 2022 were principally for upgrading and expanding
manufacturing and research and development facilities and equip-
ment in various segments, investments in information technology,
and laboratory instruments placed with customers.
CONTRACTUAL OBLIGATIONS
Abbott believes that its available cash and cash equivalents along
with its ability to generate operating cash flow and continued
access to debt markets are sufficient to fund existing and planned
cash requirements. Abbott’s material cash requirements include
the following contractual obligations:
Debt — Principal payments required on long-term debt outstanding
at December 31, 2024 are $1.5 billion in 2025, $2.9 billion in 2026,
$617 million in 2027, $650 million in 2028, $583 million in 2029 and
$8.0 billion in 2030 and thereafter. Interest payments required on
long-term debt outstanding at December 31, 2024 are projected to
be $512 million in 2025, $478 million in 2026, $396 million in 2027,
$390 million in 2028, $384 million in 2029 and $4.7 billion in 2030
and thereafter.
Operating leases — As of December 31, 2024, estimated contractual
obligations for operating lease payments were $1.3 billion, with
$290 million due within 12 months.
In addition, Abbott enters into purchase commitments in the
normal course of business to meet operational and capital expen-
diture requirements. The majority of outstanding purchase
commitments generally do not extend past one year.

-- 79 of 86 --

F I N A N C I A L R E V I E W
78
A B B O T T 2 0 2 4 A N N U A L R E P O R T
CONTINGENT OBLIGATIONS
Abbott periodically acquires a business or product rights in which
Abbott agrees to pay contingent consideration based on attaining
certain thresholds or based on the occurrence of certain events.
BUSINESS ACQUISITIONS
On September 22, 2023, Abbott completed the acquisition of
Bigfoot, which furthers Abbott’s efforts to develop connected
solutions for making diabetes management more personal and
precise. The purchase price, the final allocation of acquired assets
and liabilities, and the revenue and net income contributed by
Bigfoot since the date of acquisition are not material to Abbott’s
consolidated financial statements.
On April 27, 2023, Abbott completed the acquisition of CSI for
$20 per common share, which equated to a purchase price of
$851 million. The transaction was funded with cash on hand and
accounted for as a business combination. CSI’s atherectomy
system, which is used in treating peripheral and coronary artery
disease, adds complementary technologies to Abbott’s portfolio
of vascular device offerings.
The final allocation of the purchase price of the CSI acquisition
resulted in the recording of two non-deductible developed tech-
nology intangible assets totaling $305 million; a non-deductible
in-process research and development asset of $15 million, which
will be accounted for as an indefinite-lived intangible asset until
regulatory approval or discontinuation; non-deductible goodwill
of $369 million; net deferred tax assets of $46 million and other net
assets of $116 million. The goodwill is identifiable to the Medical
Devices reportable segment and is attributable to expected syner-
gies from combining operations, as well as intangible assets that
do not qualify for separate recognition. Revenues and earnings of
CSI included in Abbott’s consolidated financial statements since
the acquisition date are not material to Abbott’s consolidated
revenue and earnings.
LEGISLATIVE ISSUES
Abbott’s primary markets are highly competitive and subject to
substantial government regulations throughout the world. Abbott
expects debate to continue at all government levels worldwide
over the manufacture, quality assurance requirements, marketing
authorization processes, post-market surveillance requirements,
availability, method of delivery, and payment for health care prod-
ucts and services, as well as data privacy and security. It is not
possible to predict the extent to which Abbott or the health care
industry in general might be adversely affected by these factors in
the future. A more complete discussion of these factors is con-
tained in Item 1, Business, and Item 1A, Risk Factors.
RECENTLY ISSUED ACCOUNTING STANDARDS
RECENTLY ADOPTED ACCOUNTING STANDARDS
In November 2023, the FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment
Disclosures, which expands the breadth and frequency of required
segment disclosures. The guidance is required to be applied retro-
spectively to all periods presented in the financial statements.
Abbott adopted the standard on January 1, 2024. The new stan-
dard did not have an impact on Abbott’s consolidated financial
statements, but required additional disclosures as included in
Note 16 — Segment and Geographic Area Information.
In September 2022, the FASB issued Accounting Standards
Update (ASU) 2022-04, Disclosure of Supplier Finance Program
Obligations, which requires an entity to report information about
its supplier finance program. Abbott adopted the standard on
January 1, 2023. The new standard did not have an impact on
Abbott’s consolidated financial statements.
RECENT ACCOUNTING STANDARDS NOT YET ADOPTED
In November 2024, the FASB issued ASU 2024-03, Income
Statement (Subtopic 220-40): Reporting Comprehensive
Income – Expense Disaggregation Disclosures, which requires
an entity to disclose on an annual and interim basis, disaggre-
gated information about specific income statement expense
categories. The guidance should be applied prospectively with
the option to apply the standard retrospectively. The standard
becomes effective for Abbott for full year 2027 reporting. Abbott
is currently evaluating the impact of this new standard on its
consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes
(Topic 740): Improvements to Income Tax Disclosures, which
requires an entity to disclose annually additional information
related to the company’s income tax rate reconciliation and
income taxes paid during the period. The guidance should be
applied prospectively with the option to apply the standard retro-
spectively. The standard becomes effective for Abbott for full year
2025 reporting. Abbott is currently evaluating the impact of this
new standard on its consolidated financial statements.
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 — A
CAUTION CONCERNING FORWARD-LOOKING STATEMENTS
Under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, Abbott cautions investors that any
forward-looking statements or projections made by Abbott,
including those made in this document, are subject to risks and
uncertainties that may cause actual results to differ materially
from those projected. Economic, competitive, governmental,
technological and other factors that may affect Abbott’s opera-
tions are discussed in Item 1A, Risk Factors.

-- 80 of 86 --

• • •
F I N A N C I A L R E V I E W
79
A B B O T T 2 0 2 4 A N N U A L R E P O R T
P E R F O R M A N C E G R A P H
Assuming $100 invested on December 31, 2019 with dividends reinvested.
Abbott Laboratories
S&P 500 Index
S&P 500 Health Care
2020	2019 	2021 	2022 	2023 	2024
$0
$50
$150
$100
$250
$200
This graph compares the change
in Abbott’s cumulative total shareholder
return on its common shares with the
Standard & Poor’s 500 Index and the
Standard & Poor’s 500 Health Care Index.

-- 81 of 86 --

80
A B B O T T 2 0 2 4 A N N U A L R E P O R T
S U M M A R Y O F S E L E C T E D F I N A N C I A L D ATA
(Dollars in millions except per share data)
Year Ended December 31 	2024 	2023 	2022 	2021 	2020
Summary of Operations:
Net Sales 	$ 	41,950 	40,109 	43,653 	43,075 	34,608
Cost of products sold 	$ 	20,584 	19,941 	21,155 	20,584 	17,135
Research & development 	$ 	2,844 	2,741 	2,888 	2,742 	2,420
Selling, general, and administrative 	$ 	11,697 	10,949 	11,248 	11,324 	9,696
Operating earnings 	$ 	6,825 	6,478 	8,362 	8,425 	5,357
Interest expense 	$ 	559 	637 	558 	533 	546
Interest income 	$ 	(344) 	(385) 	(183) 	(43) 	(46)
Other (income) expense, net (a) 	$ 	(403) 	(438) 	(319) 	(276) 	(111)
Earnings before taxes 	$ 	7,013 	6,664 	8,306 	8,211 	4,968
Taxes on earnings from continuing operations 	$ 	(6,389) 	941 	1,373 	1,140 	497
Earnings from continuing operations 	$ 	13,402 	5,723 	6,933 	7,071 	4,471
Net earnings 	$ 	13,402 	5,723 	6,933 	7,071 	4,495
Basic earnings per common share from continuing operations 	$ 	7.67 	3.28 	3.94 	3.97 	2.51
Basic earnings per common share 	$ 	7.67 	3.28 	3.94 	3.97 	2.52
Diluted earnings per common share from continuing operations 	$ 	7.64 	3.26 	3.91 	3.94 	2.49
Diluted earnings per common share 	$ 	7.64 	3.26 	3.91 	3.94 	2.50
Financial Positions:
Working capital 	$ 	9,499 	8,829 	9,735 	11,134 	8,534
Long-term investment securities 	$ 	886 	799 	766 	816 	821
Net property & equipment 	$ 	10,658 	10,154 	9,162 	8,959 	9,029
Total assets 	$ 	81,414 	73,214 	74,438 	75,196 	72,548
Long-term debt, including current portion 	$ 	14,125 	14,679 	16,773 	18,050 	18,534
Shareholders’ investment 	$ 	47,901 	38,827 	36,905 	36,024 	33,003
Book value per share 	$ 	27.66 	22.39 	21.24 	20.42 	18.63
Other Statistics:
Gross profit margin 	% 	50.9 	50.3 	51.5 	52.2 	50.5
Research and development to net sales 	% 	6.8 	6.8 	6.6 	6.4 	7.0
Net cash from operating activities 	$ 	8,558 	7,261 	9,581 	10,533 	7,901
Capital expenditures 	$ 	2,207 	2,202 	1,777 	1,885 	2,177
Cash dividends declared per common share 	$ 	2.24 	2.08 	1.92 	1.82 	1.530
Common shares outstanding (in thousands) 	1,731,697 	1,734,076 	1,737,795 	1,764,082 	1,771,230
Number of common shareholders 	30,768 	32,449 	34,019 	35,926 	37,450
Market price per share - high 	$ 	121.64 	115.83 	139.83 	142.60 	115.14
Market price per share - low 	$ 	99.71 	89.67 	93.25 	105.36 	61.61
Market price per share - close 	$ 	113.11 	110.07 	109.79 	140.74 	109.49
a) These amounts include debt extinguishment costs and net foreign exchange (gain) loss.

-- 82 of 86 --

81
A B B O T T 2 0 2 4 A N N U A L R E P O R T
*Denotes executive officer
D I R EC TO R S
Robert J. Alpern, M.D.
Ensign Professor of Medicine
and Physiology and Professor
of Internal Medicine and
Cellular and Molecular
Physiology, and Former Dean
of Yale School of Medicine
Claire Babineaux-Fontenot
Chief Executive Officer,
Feeding America
Sally E. Blount, Ph.D.
President and Chief
Executive Officer, Catholic
Charities of the Archdiocese
of Chicago and
Michael L. Nemmers
Professor of Strategy and
Former Dean of the
J.L. Kellogg Graduate School
of Management at
Northwestern University
Robert B. Ford
Chairman of the Board and
Chief Executive Officer,
Abbott Laboratories
Paola Gonzalez
Vice President, Global FP&A,
The Clorox Company
Michelle A. Kumbier
President, Turf &
Consumer Products,
Briggs & Stratton, LLC
Darren W. McDew
Retired General, United
States Air Force, and
Former Commander of U.S.
Transportation Command
Nancy McKinstry
Chief Executive Officer
and Chairman of the
Executive Board,
Wolters Kluwer N.V.
Michael G. O’Grady
Chairman and
Chief Executive Officer,
Northern Trust Corporation
Michael F. Roman
Retired Chairman of the
Board, President and
Chief Executive Officer,
3M Company
Daniel J. Starks
Retired Chairman, President
and Chief Executive Officer,
St. Jude Medical, Inc.
John G. Stratton
Executive Chairman,
Frontier Communications
Parent, Inc.
S E N I O R M A N AG E M E N T
Robert B. Ford*
Chairman of the Board and
Chief Executive Officer
Hubert L. Allen*
Executive Vice President,
General Counsel and
Secretary
Philip B. Boudreau*
Executive Vice President,
Finance and
Chief Financial Officer
Lisa D. Earnhardt*
Executive Vice President
and Group President,
Medical Devices
Joseph Manning
Executive Vice President,
Nutritional Products
Mary K. Moreland*
Executive Vice President,
Human Resources
Louis H. Morrone*
Executive Vice President,
Core Diagnostics
Daniel Salvadori*
Executive Vice President and
Group President, Established
Pharmaceuticals
and Nutritional Products
Christopher J. Scoggins
Executive Vice President,
Diabetes Care
Melissa D. Brotz
Senior Vice President,
Public Affairs and
Corporate Marketing
Christopher J. Calamari
Senior Vice President,
U.S. Nutrition
Elizabeth C. Cushman
Senior Vice President,
Legal
Sabina Ewing
Senior Vice President,
Business and Technology
Services and Chief
Information Officer
Sammy Karam
Senior Vice President,
Established Pharmaceuticals,
Emerging Markets
Scott M. Leinenweber
Senior Vice President,
Licensing, Acquisitions
and Ventures
Sandra Lesenfants
Senior Vice President,
Structural Heart
Fernando Mateus
Senior Vice President,
International Nutrition
Eric Shroff*
Senior Vice President,
Rapid and Molecular
Diagnostics
Julie L. Tyler
Senior Vice President,
Abbott Vascular
Randel W. Woodgrift
Senior Vice President,
Cardiac Rhythm
Management
Uri Yaron
Senior Vice President,
Electrophysiology
CO R P O R AT E V I C E PR E S I D E N T S
Venu Ambati
Vice President, Established
Pharmaceuticals, India
Elizabeth M. Balthrop
Vice President,
Transfusion Medicine
Erica L. Battaglia
Vice President, Chief Ethics
and Compliance Officer
Keith Boettiger
Vice President,
Heart Failure
Badia Boudaiffa
Vice President,
North America
Commercial Operations,
Diabetes Care
Fanny Chen
Vice President,
Core Diagnostics, China
Keith Cienkus
Vice President.
Molecular Diagnostics
Michael A. Comilla
Vice President, Investor
Relations
Alison E. Davies
Vice President, Treasurer
Thomas C. Evers
Vice President,
Government Affairs
Rodrigo Ferreira
Vice President,
EPD Latin America
John S. Frels
Vice President,
Research and Development,
Immunoassay/Clinical
Chemistry
Damian P. Halloran
Vice President,
Infectious Disease,
Rapid Diagnostics
Gary C. Johnson
Vice President, Clinical,
Regulatory and Health
Economics Outcomes
Research, Cardiovascular
and Neuromodulation
Robert R. Kunkler
Vice President,
Toxicology, Cardiometabolic
and Consumer Products
and Services
Brian Lehman
Vice President,
Commercial Operations,
Electrophysiology
Pedro Malha
Vice President,
Neuromodulation
John A. McCoy Jr.*
Vice President,
Finance and Controller
Jana Mihaylova
Vice President,
Nutrition, Asia Pacific
John M. Murphy
Vice President,
Nutrition Supply Chain
Joseph L. Novak
Vice President, Taxes
Michaela Pardubicka-Jenkins
Vice President, Pediatric
Nutrition
Ansgar Resch
Vice President, International
Commercial Operations,
Diabetes Care
Ric A. Schneider
Vice President,
Chief Operations and
Procurement Officer
Thomas R. Stanis
Vice President,
Core Laboratory
Diagnostics, International
Commercial Operations
Marc Taub
Vice President,
Technical Operations,
Diabetes Care
Frank Weitekamper
Vice President,
Abbott Transition
Organization
James R. Wenner
Vice President,
Internal Audit
Monica J. Wilkins
Vice President,
Regulatory, Quality,
and Compliance
D I R E C T O R S A N D C O R P O R AT E O F F I C E R S

-- 83 of 86 --

MIX
Paper I Supporting
FSC responsible forestry
FSC° CO20268
82
A B B O T T 2 0 2 4 A N N U A L R E P O R T
S H A R E H O L D E R A N D C O R P O R AT E I N F O R M AT I O N
S H A R E S L I S T I N G
The ticker symbol for Abbott’s common
shares is ABT. The principal market for
Abbott’s common shares is the New York
Stock Exchange. Shares are also listed on
the Chicago Stock Exchange and traded on
various regional and electronic exchanges.
Outside the United States, Abbott’s shares
are listed on the Swiss Stock Exchange.
Q UA R T E R LY D I V I D E N D DAT E S
Dividends are expected to be declared,
recorded, and paid on the following
schedule in 2025, pending approval by the
Board of Directors:
Quarter 	Declared Recorded Paid
First 	2/21 	4/15 	5/15
Second 	6/13 	7/15 	8/15
Third 	9/18 	10/15 	11/15
Fourth 	12/13 	1/15/26 	2/13/26
TA X INFORM ATION FOR SHAREHOLDERS
Abbott is an Illinois High Impact
Business (HIB) through June 2043 and is
located in a U.S. federal Foreign Trade
Sub-Zone (Sub-Zone 22F). Dividends may
be eligible for a subtraction from base
income for Illinois income-tax purposes.
If you have any questions, please contact
your tax advisor.
D I V I D E N D R E I N V E S TM E N T PL A N
The Abbott Dividend Reinvestment
Plan offers registered shareholders
an opportunity to purchase additional
shares, commission-free, through
automatic dividend reinvestment and/or
optional cash investments. Interested
persons may contact the transfer agent, or
call Abbott’s Investor Newsline, as listed in
the right-hand column.
D I V I D E N D D I R EC T D E P O S IT
Shareholders may have quarterly dividends
deposited directly into a checking or savings
account at any financial institution that
participates in the Automated Clearing
House system. For more information, please
contact the transfer agent, listed at right.
D I R EC T R EG I S T R AT I O N S Y S T E M
In August 2008, Abbott implemented a
Direct Registration System (DRS) for all
registered shareholder transactions.
Shareholders will be sent a statement in
lieu of a physical stock certificate for
Abbott Laboratories common shares.
Please contact the transfer agent with
any questions.
A N N UA L M E E T I N G
The Annual Meeting of Shareholders will
be held virtually at 9 a.m. Central Time on
Friday, April 25, 2025. Questions regarding
the Annual Meeting may be directed to
the Corporate Secretary. A copy of Abbott’s
2024 Form 10-K Annual Report, as filed
with the U.S. Securities and Exchange
Commission, is available on Abbott’s Web
site at www.abbott.com or by calling the
Investor Newsline (above, right).
C EO A N D C FO C E R T I FI C AT I O N S
In 2024, Abbott’s chief executive officer
(CEO) provided to the New York Stock
Exchange the annual CEO certification
regarding Abbott’s compliance with the
New York Stock Exchange’s corporate-
governance listing standards. In addition,
Abbott’s CEO and chief financial officer
(CFO) filed with the U.S. Securities and
Exchange Commission all required
certifications regarding the quality of
Abbott’s public disclosures in its fiscal
2024 reports.
I N V E S TO R N E WS L I N E
224-667-7300
I N V E S TO R R E L AT I O N S
Dept. 362, AP6D2
Abbott
100 Abbott Park Road
Abbott Park, IL 60064-6400 U.S.
224-667-6100
S H A R E H O L D E R S E RV I C E S ,
T R A N S FE R AG E N T A N D R EG I S T R A R
Computershare
P.O. Box 43078
Providence, RI 02940-3078
888-332-2268 (U.S. or Canada)
781-575-3910 (outside U.S. or Canada)
www.computershare.com
CO R P O R AT E S EC R E TA RY
Dept. 364, AP6D2
Abbott
100 Abbott Park Road
Abbott Park, IL 60064-6400 U.S.
224-667-6100
WE B S IT E
www.abbott.com
A B B OT T O N L I N E A N N UA L R E P O R T
www.abbott.com/annualreport
G LO B A L S U S TA I N A B I L IT Y R E P O R T
www.abbott.com/sustainability
S H A R E H O L D E R I N FO RM AT I O N
Shareholders with questions about their
accounts may contact the transfer agent,
listed above.
Individuals who would like to receive
additional information, or have questions
regarding Abbott’s business activities, may
call the Investor Newsline at the number
listed above, write Abbott Investor Relations
at the address above, or visit Abbott’s website,
www.abbott.com.
NEUROMODULATION
NOTES (pp. 10-11)
1) Comparison is limited to the
U.S. market only and is based
on volume measurements of the
following smallest IPG offerings:
Abbott Liberta RC DBS System
(13.6 cc), Boston Scientificǂ
Vercise Genusǂ R16 (20.1 cc), and
Medtronicǂ Perceptǂ RC (13.77 cc).
Sizing for the Liberta RC DBS IPG
is determined using engineering
model measurement(s). Methods
to calculate size may vary among
manufacturers.
2) Abbott. Liberta RC DBS System
Size Comparison Claims Memo
(MAT-2400042). 2024.
3) Upon implant of the Liberta RC
DBS System when programmed
with standard (nominal) stimulation
settings as described in device
instructions for use. Recommended
recharge frequency and duration
for competitor product described
in their respective IFU or clinical
studies, which may involve different
patient populations and other
variables. Not a head-to-head
comparison of stimulation settings
or clinical outcomes.
4) Abbott. Liberta RC DBS System
Recharging Comparison Claims
Memo (MAT-2400043). 2024.
5) Abbott. Liberta RC Deep Brain
Stimulation Implantable Pulse
Generator Clinician’s Manual. 2024.
6) Abbott. First and Only DBS IPGs
with Remote Programming Memo
(MAT-2406193). 2024.
7) U.S. market only. Based off
comparison to volumetric
measurement of the following
smallest rechargeable SCS IPGs in
the U.S. market: Abbott Eterna SCS
System, 13.6 cc; Boston Scientific‡
WaveWriter Alpha‡ 16, 20.1 cc;
Medtronic‡ Inceptiv‡, 13.77 cc;
Nevro‡ Senza‡ Omnia‡, 26 cc;
Saluda‡ Evoke‡, 33 cc; Biotronik‡
Prospera‡, 29 cc. Sizing for Eterna
SCS IPG is determined using
engineering model measurement(s).
Methods to calculate size may vary
among manufacturers.
8) Abbott. Eterna SCS IPG Size
Comparison Claims Memo (MAT-
2210151). 2024.
9) Eterna SCS Implantable Pulse
Generator Clinician’s Manual. 2023.
10) Abbott. Eterna Lowest Recharge
Burden Comparison Memo (MAT-
2210739). 2023
11) Upon implant of the Eterna
SCS System, approximately three
hours five times per year (69 to 74
days between charges) or one hour
per month (25 to 27 days between
charges) at standard (nominal)
settings for BurstDR programming:
30/90 dosing when programmed
with amplitude of 0.6mA and all
other BurstDR stimulation settings
are left at default.
12) Abbott. Eterna IPG Battery
Recharge Characterization Report
(90903492); 2022.
13) Abbott. Eterna IPG Elect Design
Verification Report: Current Draw
(90860050). 2022
VASCULAR NOTES (pp. 16-17)
1) Data on File. Excluding platinum
markers
2) Brian G. DeRubertis et al., Two-
Year Outcomes of the LIFE-BTK
Randomized Controlled Trial
Evaluating the Esprit BTK Drug-
eluting Resorbable Scaffold for
Treatment of Infrapopliteal Lesions,
VIVA 2024.
DIABETES CARE
NOTES (pp. 22-23)
1) Data on file. Abbott Diabetes
Care.
2) Data based on the number of
users worldwide for the FreeStyle
Libre family of personal CGMs
compared to the number of users
for other leading personal CGM
brands and based on CGM sales
dollars compared to other leading
personal CGM brands.
3) Study was performed with
the outside-U.S. version of the
FreeStyle Libre 14 day system. Data
is applicable to FreeStyle Libre 2 and
3 systems, as feature sets are similar
to FreeStyle Libre 14 day system,
excluding alarms.
4) Fokkert, Marion, et al. “Improved
well-being and decreased disease
burden after 1-year use of flash
glucose monitoring (FLARE-
NL4).” BMJ Open Diabetes
Research and Care 7 (2019):
e000809. https://doi.org/10.1136/
bmjdrc-2019-000809
5) Evans, Mark, et al. “Reductions
in HbA1c with flash glucose
monitoring are sustained for up
to 24 months: a meta analysis
of 75 real-world observational
studies.” Diabetes Therapy (April
2022). https://doi.org/10.1007/
s13300-022-01253-9
6) Among patient-applied sensors.
Abbott trademarks and products
in-licensed by Abbott are shown in
italics in the text of this report.
© 2025 Abbott Laboratories
Some statements in this annual
report may be forward-looking
statements for purposes of the
Private Securities Litigation
Reform Act of 1995. Abbott
cautions that these forward-looking
statements are subject to risks and
uncertainties that may cause actual
results to differ materially from
those indicated in the forward-
looking statements.
Economic, competitive,
governmental, technological
and other factors that may affect
Abbott’s operations are discussed
in Item 1A, “Risk Factors,” in
our Securities and Exchange
Commission 2024 Form 10-K and
are incorporated by reference.
We undertake no obligation to
release publicly any revisions to
forward-looking statements as
the result of subsequent events or
developments, except as required
by law.
The Abbott 2024 Annual Report
cover and text are printed on
recycled paper that contains a
minimum of 10% post-consumer
fiber and the financial pages on 30%
post-consumer fiber.

-- 84 of 86 --

BACK COVER:
Whether conditioning to climb the highest
peak on each continent or row across an ocean,
professional adventurer Nick Hollis relies on
Ensure NutriVigor to get his body ready for his
next quest.
Nick Hollis
MARLOW, BUCKINGHAMSHIRE, ENGLAND
ENSURE NUTRIVIGOR

-- 85 of 86 --

it
life. to thefullest:
t Abbott

-- 86 of 86 --